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Duchenne muscular dystrophy (DMD) is an X-linked recessive muscle wasting 
disease caused by mutations in the DMD gene, which encodes the large 
cytoskeletal protein dystrophin. Alongside severe muscle pathology, one-third of 
DMD patients exhibit cognitive problems ranging from reduced verbal 
intelligence to severe autism. There is conclusive evidence that the muscle 
pathology exhibited by DMD patients is progressive, yet it remains unknown 
whether the cognitive impairments in DMD are also progressive. Previous 
studies have highlighted a cognitive impairment in the mdx mouse model of 
DMD, but no studies have investigated if this cognitive impairment worsens with 
age. We assessed the consequences of dystrophin deficiency on brain 
morphology and cognitive function in two dystrophin-deficient mouse models 
(mdx and Cmah-/-mdx mice). The overall project aim was to identify outcome 
measures to monitor central nervous system (CNS) pathology non-invasively in 
DMD mice.  
 
Magnetic resonance imaging (MRI) identified a total brain volume increase in 
DMD mice, alongside morphological changes in brain ventricles. Behavioural 
testing revealed a deficit in hippocampal spatial learning and memory, 
particularly long-term memory, in mdx mice, which appears to progressively 
worsen with age. Immunoblotting identified a progressive reduction of 
aquaporin-4 (AQP4) expression, the major water channel of the CNS, in DMD 
mice. Moreover, contrast enhancing MRI and Evans blue extravasation 
demonstrated a progressive impairment in blood-brain barrier (BBB) integrity in 
mdx mice. Proteomic profiling of the mdx cerebellum identified changes in 
expression of mitochondrial subunit complexes, suggestive of changes in 
mitochondrial function. Additionally, elevated levels of inflammatory markers 
were identified and confirmed in the mdx cerebellum.  
 
Our studies suggest that dystrophin deficiency causes a progressive cognitive 
impairment in mdx mice. We also present evidence showing that changes in 
osmotic equilibrium may be involved in the pathogenesis of DMD, with 
reductions in AQP4 expression and BBB disruptions. We speculate that some 
of the changes in the mdx cerebellar proteome, in comparison to wild type mice, 
 iii 
serve as compensatory mechanisms whilst others may contribute directly to 
cognitive dysfunction in DMD. These results support a role for dystrophin in 
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Chapter 1. Introduction 
1.1  Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD) is an X-linked recessive disease, 
occurring at an incidence of 1 in 3,600-10,000 live male births (Emery, 1991; 
Mah et al., 2014). Although rare it remains the commonest of all muscular 
dystrophies. The less severe allelic form, Becker muscular dystrophy (BMD) 
occurs less frequently (1 in 10,000) and the clinical course is milder (Emery, 
1991) (Bushby et al., 1991). DMD is characterised by a severe pathology of the 
skeletal musculature causing progressive loss of muscle, with premature death 
frequently occurring in the third decade of life as a result of cardiac and 
respiratory complications (Wallace and McNally, 2009). This fatal disease arises 
from mutations in the DMD gene; the largest gene in the human genome, with 
79 exons spanning 2.4 Mb (Davies et al., 1988), and coding for a 427 kDa 
intracellular protein named dystrophin (Monaco et al., 1986; Hoffman et al., 
1987a; Hoffman et al., 1992; Roberts et al., 1993). The extremely large size of 
the DMD gene contributes to a complex mutational spectrum, with more than 
7000 mutations identified and a high spontaneous mutation rate is associated 
with this gene (Bladen et al., 2015). Approximately one-third of DMD cases are 
as a result of spontaneous mutations whereas the other two-thirds occur 
through maternal inheritance (Aartsma-Rus et al., 2006). Dystrophin forms part 
of a membrane spanning protein complex, the dystrophin-glycoprotein complex 
(DGC; Figure 1.1), which plays a pivotal role in anchoring the intracellular 
cytoskeleton to the extracellular matrix, stabilising the sarcolemma during 
muscle contraction (Hoffman et al., 1987b; Campbell and Kahl, 1989; Ahn and 
Kunkel, 1993; Brown, 1997). Absence of dystrophin disrupts the DGC causing 
increased muscle membrane fragility. A cascade of events including influx of 
calcium into the sarcoplasm, activation of proteases and pro-inflammatory 
cytokines, and mitochondrial dysfunction, cumulate in progressive muscle 
degeneration (Blake et al., 2002; Allen et al., 2010; Gumerson and Michele, 
2011). The severe phenotype associated with DMD is most often associated 
with out-of-frame mutations (Monaco et al., 1988; Koenig et al., 1989), causing 
complete loss of functional dystrophin protein. Whereas in-frame mutations 
allow for the synthesis of an internally truncated but partially functional 
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dystrophin protein product and are found in BMD patients, although exceptions 
to the reading frame hypothesis occur in <10% of all DMD mutations (Aartsma-
Rus et al., 2006). Although dystrophin is most abundantly expressed in muscle 
tissues, it is also expressed in the central nervous system (CNS) with the brain 
harbouring high amounts of dystrophin and its various isoforms. Considerable 
research has been devoted to understanding the role of dystrophin in muscle 
cells, its role in the brain has received less attention.  
1.1.1 Clinical phenotype  
DMD was first detailed in 1852 by an English physician: Edward Meryon 
(Meryon, 1852), the clinical manifestations of eight boys from three families 
were described, which highlighted progressive muscle wasting and weakening 
confined to muscles, leaving the nervous system unaffected (Meryon, 1852). 
This disorder was later named after Guillaume Benjamin Amand Duchenne who 
was indeed the first to study patient biopsies (Duchenne, 1868).  
 
Progressive muscle wasting and weakness is the major hallmark of DMD, 
where patient muscle fibres are vulnerable to contraction induced damage, yet 
despite efforts of muscle to regenerate, muscle mass is gradually lost. DMD 
usually presents within the first few years of life, between the ages of two and 
five years old, and is characterised by calf muscle hypertrophy and a delay in 
motor milestones e.g. slow to begin walking, difficulties running and climbing 
stairs (Bushby et al., 1999). The Gowers manoeuvre becomes evident when 
patients have difficulties rising from the ground and begin using their arms to 
climb up their body (Gowers, 1879). By the second decade of life patients are 
usually wheelchair dependent due to loss of strength in their lower limb 
muscles. Loss of function of all extremities occurs in the later stages of the 
disease due to progressive weakness of the shoulder girdle and arm muscles 
(Blake et al., 2002). 
 
Cardiac involvement is also a major characteristic of DMD with 90% of patients 
exhibiting cardiac dysfunction including 25% of patients under the age of 6 
years old (Finsterer and Stollberger, 2003). Common cardiac complications in 
DMD include myocardial ischemia (leading to necrosis), conduction defects, 
and/or arrhythmias (Eagle et al., 2002). One of the leading causes of death is 
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cardiomyopathy, where the heart chambers are dilated and ventricles have poor 
contractility causing a decreased ejection fraction (Finsterer and Stollberger, 
2003). In the heart, degeneration of cardiomyocytes leads to fibrosis. Initially, 
this phenomenon affects particularly the posterobasal segment of the left 
ventricle (Goodwin and Muntoni, 2005). Loss of cardiomyocytes in DMD leads 
to an increase wall stress and the myocardium has an increased vulnerability to 
pressure overload in vivo compared to normal (Kamogawa et al., 2001). 
Progressively, systolic left ventricle function decreases and myocardial oxygen 
consumption increases, eventually leading to left ventricular dilation and left 
ventricular dysfunction (Fayssoil et al., 2010; Spurney, 2011). 
 
In addition, patients often suffer from spinal deformities such as thoracolumbar 
kyphosis and scoliosis, resultant of asymmetric weakening of the muscles 
supporting the spine (Yamashita et al., 2001; Eagle et al., 2007). Furthermore, 
respiratory involvement is evident in later stages of the disease with assisted 
ventilation sought initially at night but progressing to a more permanent state 
(Lo Mauro et al., 2010). A low bone mineral density, lower lean tissue and 
higher fat mass compared to healthy age matched controls results from DMD 
patients’ immobility and one study found that by the age of 13 years old 47% of 
patients were obese and 34% were underweight primarily as a consequence of 
swallowing difficulties (Martigne et al., 2011).  
1.1.2 Current care strategies for DMD  
There is currently no cure for DMD and treatment strategies aim to alleviate 
symptoms in addition to reducing muscle necrosis (Guglieri and Bushby, 2010). 
Strategies focus on optimising growth and development, promoting a well-
balance diet, participating in physical and recreational activity, and delaying the 
onset of secondary complications through ongoing medical and psychosocial 
support (Zamani et al., 2016; Wong et al., 2017).  
Supportive interventions include timely administration of corticosteroids. 
Corticosteroids are a group of steroid hormones produced naturally by the body 
and are involved in a wide variety of physiological processes such as the 
immune response, stress response, and regulation of inflammation (Greaves, 
1976). Corticosteroids are an important treatment option in DMD as they have 
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anti-inflammatory, immunosuppressive, anti-proliferative, and vasoconstrictive 
effects, to slow the progression of inflammatory damage. Historically, 
corticosteroids have offered benefit to DMD patients through the stabilisation of 
muscle strength and function, delaying progression of scoliosis, prolonging 
independent ambulation and delaying onset of cardiomyopathy (Mendell et al., 
1989; Griggs et al., 1991; Moxley et al., 2005; Kinali et al., 2007; Markham et 
al., 2008). Other treatment options include respiratory care, where supportive 
strategies such as non-invasive positive pressure ventilation, assisted airway 
clearance, and mechanical cough assistance, can help some DMD patients live 
beyond their third decade of life (Lo Mauro et al., 2010). Preventative cardiac 
care is also available through the early use of angiotensin-converting enzyme 
(ACE) inhibitors or beta-blockers to delay the progression of cardiomyopathy 
(Bushby et al., 2010). Additionally, there are currently multiple therapeutic trials 
looking to restore, repair, and/or prevent further damage to muscle and it is 
hoped that in the future life expectancy and quality of life will improve further for 
DMD patients (Mendell et al., 2013; Mah, 2016; Robinson-Hamm and 
Gersbach, 2016).  
1.2 The dystrophin-glycoprotein complex (DGC) 
1.2.1 DGC in muscle 
In skeletal muscle, the DGC is comprised of three sub-complexes and their 
constituent proteins: the dystroglycan complex, the transmembrane 
sarcoglycan-sarcospan complex, and the cytoplasmic complex of dystrophin, 
dystrobrevins, and syntrophins (Ervasti and Campbell, 1991; Yoshida et al., 
1994). The dystroglycan complex consists of both α and β subunits (Allikian and 
McNally, 2007). The extracellular protein laminin-α2 binds directly to α-
dystroglycan, which in turn binds to β-dystroglycan, thus providing the initial link 
in the DGC to the extracellular milieu (Ervasti and Campbell, 1991). The 
cytoplasmic proteins of the DGC include α-dystrobrevin, α- and β-syntrophin, 
and dystrophin. α-dystrobrevin directly interacts with cytoplasmic dystrophin and 
β1-and β2- syntrophin (Lapidos et al., 2004). α-syntrophin interact directly with 
dystrophin at its C-terminal as well as with α-dystrobrevin (Blake et al., 2002). A 
more recently identified cytoplasmic DGC member, dysbindin, resides in 
muscle, where it associates with α-dystrobrevin (Benson et al., 2001). In 
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skeletal muscle, neuronal nitric oxide synthase (nNO) interactions with the DGC 
are primarily through α-syntrophin (Adams et al., 2001). In the absence of 
dystrophin, nNOS detaches from the sarcolemma, attenuating nitric oxide (NO) 
production. This leads to functional ischemia, in skeletal muscle, due to 
impaired vascular relaxation and in the heart decreased NO production is 
known to contribute to the development of a myopathy (Kanai et al., 2001). 
Through syntrophin, the DGC is thought to anchor a variety of signalling 
molecules including: nNOS, kinases, and transporters in the muscle membrane, 
which are hypothesised to contribute to the secondary disease features such as 
inflammation and alteration of muscle regeneration (Kameya et al., 1999; Inoue 
et al., 2002). In addition, syntrophin interacts with aquaporin-4 (AQP4), a water 
channel, via a PDZ-binding domain (see Figure 1.1). 
 
Dystrophin is the best characterised component of the complex (Koenig et al., 
1988; Ervasti and Campbell, 1993) and is organised into four (general) 
functional domains. First is the N-terminal actin-binding domain (ABD), 
containing two calponin homology motifs. The second is the triple-helical rod 
domain which is characterised by 24 spectrin- like repeats in three sub-regions 
separated by 4 proline rich hinges and contains a second ABD (able to bind 
actin primarily by electrostatic interaction (Amann et al., 1998)) and the binding 
site for nNOS. The third is a cysteine-rich region responsible for binding to β-
dystroglycan (composed of a WW domain, two EF hands EF1 & EF2, 
and a zinc-finger domain). Finally, the C-terminal end binds to α- and β-
syntrophin and dystrobrevin (Koenig et al., 1988). A change in dystrophin 
expression levels has a disproportionately large effect on the integrity of the 
DGC in muscle relative to other DGC components (Ervasti et al., 1990).  
 
Utrophin (a product of the UTRN gene) is an autosomal homologue of 
dystrophin. Similar to dystrophin, utrophin contains an N-terminal actin-binding 
domain and a C-terminal dystroglycan-binding domain (Tinsley et al., 1992). 
Utrophin is expressed ubiquitously in many fetal and adult tissues, including 
liver, spleen, skeletal muscle and testes (Love et al., 1991). Utrophin localises in 
the neuromuscular junction of adult skeletal muscles, where it is focused at the 
sarcolemma in regenerating muscle fibers (Tinsley et al., 1992). Utrophin 




Figure 1.1: A schematic representation of the components of the muscle 
dystrophin-glycoprotein complex (DGC).  This complex protein network is 
known as the dystrophin-glycoprotein complex (DGC) and has multiple 
interactions with other proteins. The DGC is critical in connecting the 
cytoskeleton of muscle fibres to the surrounding extracellular matrix by 
spanning the cell membrane. Dystrophin interacts with sarcomeric F-actin at its 
N-terminus (NH2) and transmembrane protein β-dystroglycan at a cysteine-rich 
domain (Cys) close to its C-terminus (COOH), where dystrophin is associated 
with nNOS. β-dystroglycan interacts with the sarcoglycan complex as well as α-
dystroglycan on the extracellular side of the sarcolemma. Aquaporin-4 (AQP4) 
is a major water channel enriched at the sarcolemma of skeletal muscle and is 
theorised to have a role in accommodating the rapid changes in cell volume and 
hydrostatic forces that may occur during muscle contraction to prevent 
sarcolemma damage (Crosbie et al., 2002). Figure from:(Khurana and Davies, 
2003; Nichols et al., 2015). 
1.2.2 The DGC in brain  
Within the CNS dystrophin is expressed in a specific population of neurons 
responsible for higher order functions, including learning and memory. 
Dystrophin is localised to cerebellar Purkinje cells (PCs), hippocampal neurons, 
and pyramidal neurons of the cerebral cortex of the human brain (Lidov et al., 
1990). Dystrophin expression is greatest in the cerebellum where it is localised 
as discrete puncta along the somatic and dendritic membranes of PCs in both 
mice (Lidov et al., 1990; Lidov et al., 1993) and humans (Uchino et al., 1994). 
Dystrophin has is also been identified to extensively colocalise within a subset 
of γ-aminobutyric acid type A (GABAA) receptor clusters found in the 




In addition to dystrophin expression in the brain, other DGC components have 
also been found to be expressed within the CNS. Both α- and β-dystroglycan 
are found in pyramidal neurons of the cortex (Zaccaria et al., 2001). Cerebellar 
Purkinje cell (PC) dendrites and soma reportedly express α-dystroglycan in a 
punctate distribution similar to that seen for dystrophin (Zaccaria et al., 2001). 
More recently, sarcoglycans have been detected within the CNS; ε-sarcoglycan 
has been localised to PC soma and dendrites identified by immunofluorescence 
imaging (Chan et al., 2005). Syntrophins, one of the cytoplasmic proteins of the 
DGC, has been observed in the granule cells of the cerebellum in both isoforms 
α1 and β2 (Gorecki et al., 1997). In contrast to the DGC of muscle fibres, the 
transmembrane protein sarcospan has not been identified in the CNS and is not 
believed to be a member of the neuronal DGC (Pilgram et al., 2010). 
Furthermore, the brain DGC contains proteins that are not expressed in the 
muscle DGC, including β-dystrobrevin and γ-syntrophin (Piluso et al., 2000).  
 
Unlike muscle tissue, there are multiple DGC-like complexes present in the 
brain (Blake et al., 1999). Discrepancies regarding the precise localisation of 
dystrophin and various DGC components in the CNS are perhaps due to 
variation in the quality of immune-detection methods (i.e. staining and protein 
analysis). For example, dystrophin localisation in the cerebellum has yielded 
inconsistent results; some studies report abundant cytoplasmic staining of full-
length dystrophin in mouse cerebellum (Lidov et al., 1990), whereas others 
report negligible cytoplasmic labelling (Huard and Tremblay, 1992).  
 
1.3 The DMD gene and dystrophin 
 
The DMD gene has 7 promoters resulting in various sized dystrophin protein 
products (Figure 1.2). The promoters located in the proximal region of the gene 
give rise to three full-length dystrophin isoforms: Dp427b (brain), Dp427m 
(muscle) and Dp427p (Purkinje), which have the same number of exons, but 
differ in terms of their respective promoter and unique first exon (Holder et al., 
1996). The brain promoter drives expression predominantly in the hippocampal 
cortical neurons, the Purkinje promoter in PCs, and the muscle promoter in both 
skeletal muscle and cardiomyocytes (Muntoni et al., 2003). As a consequence 
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of splicing events and alternative transcripts, four shorter dystrophin isoforms 
are created (via promotors located in introns) producing protein products Dp260 
in retina, Dp140 in brain, retina and kidney, Dp116 in Schwann cells, and Dp71 
with ubiquitous expression in most non-muscle tissues (Byers et al., 1993; 
D'Souza et al., 1995). Full length dystrophin (Dp427), absent from patients with 
DMD, is found in neurons which are specifically involved in cognitive functions, 
including memory formation and learning: cerebellar PCs, and the pyramidal 
neurons of the cerebral cortex and hippocampus (Mehler, 2000). The shortest 
dystrophin isoform, Dp40, is produced by alternative splicing of the Dp71 
transcript and little is known about its function, but it is theorised to have a role 
in presynaptic function via interactions with synaptic vesicles (forming a novel 
complex) in the mouse brain and is therefore implicated in cognitive functioning 





















Figure 1.2: Genomic organisation of the DMD gene and dystrophin protein 
isoforms. A. Shows the location of the DMD locus at Xp21. The black arrows 
indicate the various promoters: the brain promoter (B), the muscle promoter 
(M), and Purkinje promoter (P) which give rise to full-length dystrophin (Dp427b, 
Dp427m, and Dp427p respectively). Another brain promoter (B3) also gives rise 
to the shorter Dp140 isoform implicated in cerebral dysfunction (Moizard et al., 
1998), which alongside with the Dp71 isoform, controlled under a general (G) 
promoter, is associated with cognitive impairment in DMD patients (Moizard et 
al., 1998). Dp260 is predominantly expressed in the retina. B. i. Structure of the 
full-length 427 kDa isoform of dystrophin, which consists of an N-terminal actin 
binding domain, a rod domain of 24 spectrin-like repeats, a cysteine rich region, 
a carboxy-terminal domain (COOH) and also possesses 4 hinge regions. ii. 
Summarises the Dp140 shorter isoform structure which has only 6 spectrin-like 
repeats and 3 hinge regions in the rod domain. iii. The short isoform Dp71, 
expressed in most tissues, lacks any of the central rod domain repeats and 
possesses only 1 hinge region. The shortest isoform of dystrophin, Dp40, is 
thought to lack all or most spectrin- like repeats in addition to the COOH 
terminal region. Figure adapted from: (Blake et al., 1995; Muntoni et al., 2003; 
Nichols et al., 2015). 
 
 
1.4 Cognitive functioning in DMD  
Intellectual impairment has long been recognised as a disease symptom in 
DMD. Indeed, even in the earliest reports of the disease, De l’electrisation 








1868). Developmental delay has also been detailed by clinicians to be amongst 
the first signs at disease presentation. However, prior to 1960 the cause of 
cognitive disability in DMD patients was attributed to functional disabilities and 
social environment (Morrow and Cohen, 1954) and until recently relatively few 
studies had addressed this disease parameter.  
 
It is generally acknowledged that the average IQ of DMD patients is 85, one 
standard deviation below the norm (Cotton et al., 2001; Cotton et al., 2005) and 
the frequency of mental retardation is also higher in DMD; 20.9% versus 3% in 
the general population (Cohen et al., 1968) (based upon IQ scores). 
Approximately one-third of patients with DMD have some degree of cognitive 
deficit frequently manifesting itself in memory impairment, but ranging from 
reduced verbal intelligence (Cotton et al., 2001; Hendriksen and Vles, 2006) to 
severe autism (Wu et al., 2005). Literature documenting cognitive impairments 
in DMD remains inconclusive regarding the severity of verbal intelligence 
affected (Cotton et al., 2001). Compliance data for 32 studies from 1960-1999 
were examined to determine the relationship between verbal intelligence 
quotation (VIQ) and performance intelligence quotation (PIQ) (Cotton et al., 
2005). The results from the analysis of 1224 children and young adults with 
DMD (aged between 2-27 years old) with variable cognitive impairment 
revealed that VIQ and PIQ were one standard deviation below the population 
mean, with at least one-third of DMD patients in the study producing scores 
indicative of mental retardation (Cotton et al., 2005). Overall this study 
demonstrated and confirmed a decreased general cognitive functioning in DMD 
and illustrated a decreased verbal relative to non-verbal cognitive ability, but not 
to a high extent (Cotton et al., 2005). The potential association between VIQ, 
full-scale intelligence quotation (FSIQ) and PIQ in DMD was examined and 
revealed that age and disease severity were indeed related with more advanced 
IQ impairments exhibited in older DMD patients. However, there was no 
difference in age groups with respect to PIQ, FSIQ or VIQ (Cotton et al., 2001).  
 
Memory deficits in DMD patients compared to age matched controls have also 
been reported (Anderson et al., 1988). During a task boys were asked to recall 
the position of a series of pictures from the Peabody Picture vocabulary test 
(Dunn 1959). DMD patients had severe difficulties in the serial positioning 
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memory task in comparison to relative controls (Anderson et al., 1988). More 
specifically, DMD patients had significant impairments in remembering the first 
four pictures presented in a series of eight. These studies are indicative of 
impairments in both verbal and visual memory of DMD patients (Anderson et 
al., 1988). 
 
There is conclusive evidence that the muscle pathology exhibited by DMD is 
progressive, yet it remains unknown whether the cognitive impairments in DMD 
are also progressive in nature. One study found no significant difference 
between FSIQ scores within a group of 29 DMD patients upon serial 
administration of the Wechsler Intelligence Scale for Children (WISC) two to six 
years after initial testing (Prosser et al., 1969). However, VIQ appeared to 
increase with age whereas PIQ remained static. Conversely, a significant 
negative correlation between age and VIQ among DMD patients has been 
reported, suggestive of an intellectual decline in verbal domains with increasing 
age (Black, 1973). However, no correlation analysis between PIQ and VIQ was 
performed in these DMD patients. Other studies have yielded equally 
inconsistent results, DMD patients aged younger than 9 years old showed no 
difference on FSIQ, VIQ, or PIQ in comparison to DMD patients aged 10 years 
and over (Dorman et al., 1988). In contrast other reports have noted that 
defects in verbal abilities were more prominent in younger versus older DMD 
patients (Miller et al., 1985).  
Although numerous studies define the cognitive deficit observed in DMD 
patients to be non-progressive in nature (Billard et al., 1992), this proposition 
remains conjectural due to the lack of concrete long-term studies investigating 
this disease parameter. Additionally, these previous studies do no correlate 
intellectual abilities with morphological brain changes in DMD patients. 
 
More recently investigators are highlighting a potentially progressive nature of 
cognitive aspects in older DMD patients. Recent studies have established that 
dystrophin colocalises with GABAA receptor (GABAA-R) clusters at the 
postsynaptic membrane (Kueh et al., 2011). The GABAergic system plays a key 
role in a variety of distinct neuronal processes, including regulation of neuronal 
excitability, synchronicity of local networks, and neuronal plasticity (Macdonald 
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and Olsen, 1994; Varju et al., 2001). Additionally, the impact of the GABAA-R on 
cognitive function has been emphasised in neurological disorders, including 
schizophrenia, trauma, and autism (Rudolph and Mohler, 2014). Moreover, 
there is recent evidence to suggest a significant decline in GABAA-R within the 
prefrontal cortices of DMD patients (Suzuki et al., 2017). Remarkably, the 
observed decline was more pronounced in older adult DMD patients, indicating 
that the observed decline in GABAA-R was likely part of the disease process. 
Furthermore, investigators detected cognitive dysfunction in the Wisconsin Card 
Sorting Test (WCST), although IQ and global memory were virtually unaffected 
(Suzuki et al., 2017). Likewise, age-related differences in WCST scores in the 
DMD group suggested that cognitive dysfunction would be progressive, as 
younger DMD patients out performed older DMD patients (18-37 years old) 
(Suzuki et al., 2017).  
1.4.1 Variable protein expression in DMD 
There is a variable degree of cognitive deficits within the DMD population, 
possibly due to different mutations in the DMD gene. The probable link between 
the loss of dystrophin and brain abnormalities remains elusive with no concrete 
genotype-phenotype profile existing. Mutations in all parts of the DMD gene can 
be associated with cognitive impairment (Bushby et al., 1995). However, 
mutations in the distal region of the DMD gene are more highly associated with 
cognitive abnormalities, as mutations encompass Dp140 and Dp71, compared 
to proximal gene mutations (Bushby, 1992; Lenk et al., 1993; Daoud et al., 
2009; Taylor et al., 2010). An apparent association of mental retardation and 
specific deletions has also been observed, with approximately 70% of patients 
with a deletion in exon 52 of the DMD gene exhibiting cognitive impairments 
(Rapaport et al., 1991). Most recently, an association between the degree of 
cognitive impairment and the presence of mutation in the Dp71 isoform has 
been reported (Daoud et al., 2009). Dp71 is the major product of the DMD gene 
in the brain but the precise function of this shortened DMD isoform remains 
unknown. High levels of Dp71 have been noted in neonatal and in adult brains, 
particularly in the hippocampus and in some layers of cerebral cortex (Sarig et 
al., 1999). Subcellular distribution analysis has identified a gradual increase in 
brain expression from embryo to adult and Dp71 is mainly found in synaptic 
membranes, microsomes, and to a lesser extent synaptic vesicles and 
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mitochondria (Haenggi et al., 2004). There is now substantial evidence that 
despite their rarity, all patients with mutations involving the Dp71 isoform have 
severe intellectual disability (Lenk et al., 1993). Recent reports have identified 
multiple Dp71 transcripts, generated by several alternative splicing events, in 
the mouse brain and retina suggesting that these Dp71 isoforms are 
differentially regulated in tissues (Aragon et al., 2017) and may have different 
functional roles. 
 
With increasing amounts of research focusing upon the cognitive dysfunction 
observed in DMD, more evidence is emerging of a link between increased 
severity of cognitive impairment and loss of Dp140 and Dp71 isoforms. Other 
researchers have looked at the role of mutations affecting Dp140 in DMD, and 
concluded that mild mental retardation is significantly more frequent with 
mutations affecting Dp140 (Daoud et al., 2009; Doorenweerd et al., 2014). 
Additionally, there is increasing evidence detailing a significant effect of grouped 
isoform involvement on FSIQ which is clearly identifiable when the data are 
categorised into 5 groups: Dp427, Dp260+Dp140utr (mutations located in the 
extended 5′UTR of the Dp140 isoform, which leave the Dp140 promoter intact), 
Dp140pc (indicate mutations that affect the promoter and/or coding region of 
the Dp140 isoform), Dp116, and Dp71 (Figure 1.3). The data presented in the 
study identified that assignment of mutations to isoform groups provided a 
better explanation for the greater percentages of the variance in FSIQ 
compared to the consideration of the effects of mutations purely by location 






Figure 1.3: Effect of cumulative loss of dystrophin isoforms on full scale 
intelligence quotient (FSIQ) (adapted from (Taylor et al., 2010)). A boxplot 
representation of patient full-scale intelligence quotient (FSIQ) data classified by 
the most 3′ dystrophin isoform affected by a mutation (each open circle 
represents a patient). There is a significant effect of grouped isoform 
involvement on FSIQ identified when the data were categorised into 5 groups: 
Dp427, Dp260+Dp140utr, Dp140pc, Dp116 and Dp71. 
  
 
1.5 Potential role of dystrophin in the CNS 
The understanding of dystrophin isoform expression and function within the 
brain remains to be fully elucidated. There are many types of cells within the 
nervous system which can be broadly split into two categories: neurons and glia 
(Figure 1.4). Within these categories there are many types of cells that differ in 
their structure, chemistry, and function. Neurons are the most important cells for 
the unique functions of the brain, it is neurons which can sense changes, 
communicate these changes to other neurons and command the bodies’ 
response to these sensations. On the other hand, glia are thought to contribute 
to brain function mainly by insulating, supporting, and nourishing neighboring 
neurons (Mark F. Bear, 2007). 
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Neurons can be classified based on their number of neurites (axons and 
dendrites that extend from the soma), dendrites (branching projection of the 
neurons; in the cerebral cortex pyramidal cells are an abundant dendritic cell 
type), connections (neurons which only communicate with other neurons are 
known as interneurons), axon length (Golgi type I, II and III neurons based on 
their extend of projection from one part of the brain to the other), and 
neurotransmitter (amino acids, peptides, monoamines) (Mark F. Bear, 2007).  
The most numerous glia in the brain are astrocytes, cells filling spaces between 
neurons. Astrocytes have multiple functions in the brain such as regulating the 
chemical content of the extracellular space and modulation of the blood-brain 
barrier (BBB) (Abbott et al., 2010). Myelinating glia includes oligodendroglia and 
Schwann cells. Oligodendrocytes wrap around the neuronal axons for faster 
electrical signal transduction (Mark F. Bear, 2007) (Figure 1.4).  
Other non-neuronal cells include ependymal cells and microglia. Ependymal 
cells provide the lining of fluid filled ventricles within the brain and also 
contribute to directing cell migration during brain development (Jiménez et al., 
2014). Microglia’s function as phagocytes to remove debris left by dead or 
degenerating neurons or glia and present the main form of active immune 
defense (Kreutzberg, 1996). 
 
Figure 1.4: A schematic representation of the main cell types in the brain. 
Adapted from: (Abeysinghe et al., 2016). Astrocytes are the most numerous 
brain glia and participate in many brain functions including ion homeostasis. 
Microglia, resident macrophage cells, acts as the first and main form of active 
immune defence in the central nervous system (CNS). The CNS houses 
oligodendrocytes for myelin synthesis, as neurons in the CNS are covered by a 
myelin sheath, providing electrical insulation. 
42 
 
Many investigators have postulated roles for the DGC in the CNS, but 
unambiguous evidence has yet to emerge. Current literature suggests that 
neuronal DGC composition is complex, with numerous isoforms expressed in 
different tissues and neuron specific localisation (Lidov et al., 1993; Hendriksen 
et al., 2015a). It has been suggested that the DGC may be acting as an adaptor 
between the actin cytoskeleton and membrane bound receptors acting to 
anchor molecules which are critical for neuronal functioning (Yoshihara et al., 
2003). The DGC may also participate in the formation and maintenance of 
macromolecular signalling complexes (Tokarz et al., 1998). Furthermore, it is 
hypothesised that dystrophin may play a role in stabilising the postsynaptic 
apparatus during brain maturation in order to maintain a certain network status 
critical for synaptic plasticity (Brunig et al., 2002). Dp427, for example, has been 
found to colocalise with GABAA receptors (Figure 1.5). It is hypothesised that 
following GABAA receptor insertion into the neural membrane, dystrophin is 
essential for their anchoring and clustering, which in turn is necessary for 
correct signal transduction. As a consequence, lateral diffusion of these 
receptors may be inhibited, hence contributing to their stabilisation (Craig and 
Kang, 2007; Hendriksen et al., 2015a) (Figure 1.5). Other dystrophin isoforms 
appear to be expressed in a cell-specific manner: Dp140 appears to be 
associated with microvascular glia cells (Blake and Kroger, 2000), Dp116 is 
most abundantly found in Schwann cells of peripheral nerves, and Dp71 is the 
most highly expressed dystrophin in the brain (under control of the general 
promotor (G-dystrophin)) and is expressed in both neurons and glia (Austin et 
al., 2000).  
 
Overall the theory is that DGC components have a higher preference to localise 
at the post-synaptic membrane of neurons in brain regions that are critical for 
memory and learning abilities (the hippocampus, cerebral cortex, and 
cerebellum) which suggests that there is an extensive colocalisation with 
proteins involved in excitatory/inhibitory synapses (Lidov et al., 1990; Brunig et 
al., 2002; Levi et al., 2002). Thus, it appears that the neural DGC plays a role in 
maintenance of receptors and ion channels.  
 
Hypotheses regarding the variable expression of the cognitive deficits exhibited 
in DMD have highlighted the role of the cerebellum as paramount (Snow et al., 
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2013). Numerous members of the DGC are distinctively localised in cerebellar 
PCs and their strong presence suggests that DGC members are essential for 
normal cerebellar functioning. The distinctly dense localisation of numerous 
members of the DGC in cerebellar PCs, and the comprehensive presence of 
dystrophin particularly in these neurons, is suggestive that DGC members, 
including dystrophin, play pivotal physiological roles in these neurons, and 
therefore contribute to proper cerebellar functioning (Grady et al., 2006; Snow 


















Figure 1.5: Models of how the DGC and components may function within 
brain tissue Adapted from (Waite et al., 2012). A. Schematic representation of 
how the DGC may function within neurons. Neurexin-neuroligin trans-synaptic 
adhesion complexes drive the post-synaptic recruitment of scaffolding 
molecules where GABAA-receptors (GABAA-Rs) are anchored (Luscher et al., 
2011a). Gephyrin, a scaffold protein, is critical for GABAA-R clustering. NL2 
(neuroligin-2)-mediated activation of GEF (guanine nucleotide exchange factor) 
collybistin recruits Gephyrin to the postsynaptic membrane (Luscher et al., 
2011b). In the cerebellum and hippocampus it is theorised that DGC-like 
complexes participate in Gephyrin –independent clustering of GABAA-Rs 
(Brunig et al., 2002). It is hypothesised that the DGC is recruited to the 
postsynaptic membrane through a different neurexin-dystroglycan interaction 
and an indirect interaction with NL2 via the synaptic scaffold protein S-SCAM 
(synaptic scaffolding molecules) (Sumita et al., 2007). SynArfGEF (ADP 
ribosylation factor), a GEF that shows preferential localisation to the inhibitory 
postsynaptic specialisations, associated with S-SCAM/NL2/DGC complexes and 
could induce local actin cytoskeletal remodelling at inhibitory post-synaptic sites 
through activation of Arf6 and therefore regulate lateral diffusion and 
stabilisation of GABAA-Rs (Fukaya et al., 2011). B. Hypothetical schematic 
representation of an astrocyte where the DGC-like complexes comprising Dp71, 
dystroglycan and the syntrophins are found at the specialised end-feet 
processes of perivascular astrocytes, where they cluster and co-purify with 
AQP4 channels. This interaction is theroised to involve PDZ (PSD-95/Discs 
large/Zona occludens 1) domain of α-syntrophin and a PDZ binding motif in the 
C-terminal tail of AQP4 (Amiry-Moghaddam et al., 2003; Nicchia et al., 2004b). 
 
1.6 The Cerebellum and dystrophin 
The cerebellum has a predominant role in controlling motor coordination 
(Glickstein and Doron, 2008) and more recent studies confirm the importance of 
A. Neuron                                                                         B. Astrocyte  
45 
 
the cerebellum in non-motor functions including cognitive processing 
(Akshoomoff and Courchesne, 1992). The cerebellum contains almost half of 
the neurons within the brain (Andersen et al., 1992) with multiple input and 
output projections, to both motor areas and non-motor areas of the cerebral 
cortex. The major anatomical subdivisions of the cerebellum include the 
flocculonodular lobe, which receives information on balance and equilibrium 
(Dow, 1961), and the lateral and vermal hemispheres (Figure 1.6). It has been 
widely documented that damage to the vermal hemisphere results in impaired 
motor behaviour, affecting equilibrium (Joyal et al., 1996). Damage to the lateral 
hemisphere, which has received less attention, indicates this as being the 
cerebellar region involved in cognition. In addition, studies have documented 
activation of inferior-lateral hemispheres, particularly the activation of the M1 
region in humans, whilst performing cognitive tasks e.g. mental imagery (Ryding 
et al., 1993). Cognition is less easily definable in rodents but can be addressed 
through processes underlying abilities deemed to be ‘cognitive’ (e.g. spatial 
learning). To illustrate, lesions to the lateral cerebellar hemispheres hamper 
spatial learning abilities but have no effect on motor capabilities (Lalonde and 
Strazielle, 2003), however lesions to the vermal cerebellum cause impaired 
visual guidance to target platforms (Joyal et al., 1996). Granted, cognitive 
abilities differ between the species, and any extrapolation of cognitive function 
from rodents to man must be treated with caution, but what is evident is that 
there is clear localisation of motor and mental functioning within sub-regions of 






Figure 1.6: A schematic representation of the anatomical and functional 
division of the cerebellum.  (Figure adapted from (Lai, 2010; Haines and 
Dietrichs, 2012)). The main body of the cerebellum is divided by the primary 
fissure into anterior and posterior lobes. The posterolateral fissure separates 
the flocculonodular lobe. Shallower fissures divide the anterior and posterior 
lobes into nine lobules (Lai, 2010). The vermal cerebellum lies along the midline 
of the cerebellum, receiving information via spinocerebellar tracts regarding 
multimodal sensory input which in turn controls proximal and trunk muscle 
movement (Dow, 1961). The projections of the vermal cerebellum enter the 
brainstem and cortical areas via the fastigial deep cerebellar nuclei, which 
control the proximal movement of the body. The vermal hemisphere is 
separated from the lateral hemisphere by the intermediate zone, which receives 
distinct somatosensory input via spinocerebellar tracts concerning distal muscle 
movement (Dow, 1961). This zone projects to the interposed deep cerebellar 
nuclei. The ‘Spinocerebellum’ thus consists of vermal and intermediate zones. 
In contrast the lateral hemisphere, lying bilaterally of the vermal zone, receives 
information solely from the cerebral cortex (Dow, 1961). Phylogenetically this is 
deemed the newest portion of the cerebellum and is thus termed the 
‘Cerebrocerebellum’ and is associated with cognitive functioning.  
 
Cerebellar circuitry is complex with three cellular layers comprised of five 
neuronal subtypes. The granular cell layer (GCL) houses a vast number of 
granule cells, Golgi interneurons, and mossy fibres. The Purkinje layer (PL), is a 
monolayer of PC bodies (Mark F. Bear, 2007) (Figure 1.7). The final, outermost 
layer is the molecular layer (ML), comprised of the dendrites of PCs, basket and 
satellite cells, and granule cell axons. P-dystrophin, the third full length DMD 
gene product, is expressed in the PCs, which are the neurons that receive the 
highest synaptic input in the brain (Mark F. Bear, 2007). Synapses between the 
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PCs and parallel fibres are involved in synaptic plasticity and are subject to 
modification of their strength, dependent upon their successive summation, 




Figure 1.7: A schematic representation of cerebellar internal circuitry. ‘+’= 
excitatory synapse, ‘-’= inhibitory synapse. This rich interconnected sub-
circuit and cortical neuronal arrangement is preserved across the subdivisions 
of the cerebellum (i.e. flocculonodular lobe, vermal and lateral regions). The 
only difference between the regions is the source of the mossy fibre (MF) input 
as well as the deep cerebellar nuclei (DCN) through which the processed signal 
ultimately leaves the cerebellum (Ito, 2006) Figure adapted from: (Purves D, 
2001 ).  
 
In addition to the expression of dystrophin in cerebellar PCs, other DGC 
components have also been identified (Smalheiser and Kim, 1995; Zaccaria et 
al., 2001; Alessi et al., 2006; Grady et al., 2006). Within the cerebellum, α-
dystroglycan is reported in membranes of PC dendrites and somata in a 
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punctate distribution similar to that reported for dystrophin (Smalheiser and Kim, 
1995). Moreover, electron microscopy studies show preferential localisation of 
α-dystroglycan to postsynaptic specialisations in PCs (Zaccaria et al., 2001). β-
dystroglycan was recently identified in PCs and follows a similar punctate 
distribution as dystrophin in these cells. In PCs, both α-dystrobrevin and β-
dystrobrevin have been identified (Grady et al., 2006). Dystrobrevins appear in 
PCs and show a close colocalisation with dystrophin, gephyrin, and GABAA-R 
clusters. This distribution indicates the presence of dystrobrevins at 
postsynaptic receptor sites (Grady et al., 2006). Another component of the 
DGC; syntrophin, has been reported in brain tissue, including observation of 
both α1- and β2- isoforms of syntrophin within granule cells of the cerebellum 
(Gorecki et al., 1997). Alternate γ1- and γ2-syntrophin isoforms are present in 
PCs (Alessi et al., 2006). The γ-isoforms do not appear to form a strong 
association with dystrophin as is the case with α- and β-syntrophin isoforms. 
Syntrophins, however, have been shown to form a complex with Na+ channel 
proteins in studies of membrane extracts from brain tissue (Gee et al., 1998), 
but this relationship has not been examined in cerebellar tissue specifically. 
Syntrophin also interacts with inward rectifying K+ channels from cerebellar 
tissue, as illustrated using protein purification techniques (Leonoudakis et al., 
2004). It is clearly evident that the DGC and its components have numerous 
and complex functions within the cerebellum. It is therefore widely accepted that 
loss of dystrophin from the DGC has a pivotal and complex impact on PC 
functioning by disrupting the DGC.  
 
There are various claims that cognitive impairment seen in DMD is the result of 
a cerebellar disorder. Based on a cumulating research, it is proposed that the 
deficits in immediate verbal memory, or “limited verbal span”, seen in those with 
DMD, are cerebellar-mediated and arise from aberrations within the 
cerebrocerebellar loops emanating from the lateral cerebellum (Cyrulnik and 
Hinton, 2008). Authors hypothesise that an absence of dystrophin within the 
cerebellum impairs the maintenance and development of phonological memory 
stores and information rehearsal through cerebrocerebellar loops, likely due to 
impaired synaptic transmission (Cyrulnik and Hinton, 2008). A positron emission 
topography (PET) study showed that glucose metabolism is reduced in DMD, in 
areas that typically contain dystrophin, including the cerebellum (Lee et al., 
49 
 
2002). Additionally, post-mortem studies have documented a decreased 
number of cerebellar PCs, consistent with the theory that the cognitive 
impairment observed in DMD is due to cerebellar dysfunction (Jagadha and 
Becker, 1988).  
 
1.7 The hippocampus and dystrophin  
The hippocampus has been identified as a key component in the consolidation 
of information particularly that pertaining to attention and memory (Mark F. 
Bear, 2007). The hippocampus is linked to a variety of memory systems 
including:  
 
 Declarative memory; the long-term storage of facts.  
 Procedural memory; the memory of skills, habit or behaviour.  
 Working memory; the temporary storage and manipulation of 
information which is a necessity for the performance of complex 
cognitive tasks (i.e. reasoning and learning).  
 
Hebb (1948) defined the hippocampus as an extension of the cerebral cortex 
and a complex structure consisting of multiple components. The hippocampal 
formation is comprised of four Cornu Ammonis areas, CA4 through to CA1, 
which are densely packed with pyramidal cells, the dentate gyrus (DG), the 
parahippocampal gyrus (PG), which includes the subicular complex (SC), and 
the entorhinal cortex (EC) (Figure 1.8). The small sub-regions of the 
hippocampus belie the fact that each region is in itself an intricate network of 
neurons which are postulated to each have unique functions within memory 
(Masser et al., 2014). The pyramidal cells in the CA1 region of mdx mice have 
been shown to have an increased susceptibility to hypoxia induced damage, 
resulting in a synaptic transmission loss (Mehler et al., 1992). This data 
suggests that DMD patients may exhibit increased susceptibility of neuronal 
populations to cumulative hypoxic insults contributing to the development of 




The hippocampus is also one of the major sites of neurogenesis; the process 
where new neurons are generated from neural stem cells and progenitor cells, 
within the brain. The phenomenon of adult neurogenesis has been found to 
occur within the DG of the hippocampus (Gould and Gross, 2002).  
Given our current understanding of the cellular basis of memory, adult 
neurogenesis may be a mechanism by which synaptic plasticity and associated 
memory are enhanced in the hippocampus. Neuronal progenitor cells from the 
sub-granular zone of the DG migrate into the granule cell layer, where they 
differentiate into neuronal or glial cells (Becker, 2005). Newly generated 
neuronal cells can then extend their axons into the CA3 region of the 
hippocampus shortly following their mitosis; axons from these cells can then 
form adjacent synapses (van Praag et al., 1999). Younger granular cells appear 
to be more ‘plastic’ i.e. they have an enhanced long-term potentiation (LTP) 
inducible by a lower threshold induction (Schmidt-Hieber et al., 2004), which is 
not inhibited by GABA (Wang et al., 2000). It is therefore reasonable to 
presume that new cells form synaptic connections more rapidly.  
 
However, increased proliferation of neurons in the DG may also disrupt 
information processing within the hippocampus. Thus, abnormally high or low 
levels of neurogenesis and the resulting abnormal patterns of synaptic 
connectivity or neural activity may contribute to cognitive impairments reported 
in DMD. Although the full functional relevance of adult neurogenesis remains 
unclear, it is theorised that hippocampal adult neurogenesis is important for 
learning. The proposed mechanisms behind the relationship between improved 
learning abilities and increased neurogenesis include: computational theories 
that new neurons increase memory capacity (Becker, 2005) and that new 
neurons help the DG to avoid the problem of catastrophic interference when 
adapting to new environments (Wiskott et al., 2006).  
 
Adult neurogenesis is subject to various regulatory factors including growth 
hormones and corticosteroids (Gould and Gross, 2002). Systemic 
administration of NOS inhibitors into adult mice increases cell proliferation in 
neurogenic regions of the brain, but decreases neuronal differentiation, 
indicating that nitric oxide (NO) can play an important role in regulating 
neurogenesis (Cheng et al., 2003). Loss of nNOS expression and activity in 
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muscle is a pathologically important consequence of dystrophin deficiency and 
dystrophin mutation may in turn disrupt adult neurogenesis by promoting cell 
proliferation in the DG, suppressing neuronal differentiation. Thus loss of 




Figure 1.8: A schematic representation of the organisation of the 
anatomical and functional division of the mouse hippocampus. A. Diagram 
of a mouse brain showing the position of the hippocampus and a sagittal 
hippocampal slice. B. Circuitry and anatomical sub-regions within a 
hippocampal slice. C. Circuitry of the Entorhinal cortex (EC) linking with the 
subdivisions of the hippocampus. The EC provides the majority of external input 
to the hippocampus via axons of the perforant path. Projections from the CA1 
region form a distinct pathway to the medial layer V of the EC known as the 
temporoammonic path. Figure adapted from: (Neves et al., 2008) 
 
1.8 Fluid movement within the brain  
1.8.1 The blood-brain barrier (BBB) 
BBB separates the parenchyma of the CNS from the blood. Formation of the 
BBB consists of endothelial cells, which line brain capillaries and are sealed by 
tight junctions unique to the brain microvasculature (Abbott and Friedman, 
2012). The endothelium of the BBB provides both structural and functional 
support through interactions with several cellular and non-cellular components 
including: astrocytes, microglial cells, pericytes, and basement membranes 
(Obermeier et al., 2013). This is known as an interactive cellular complex: 
neurovascular unit (Obermeier et al., 2013) (Figure 1.9). The main role of the 
A B C 
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BBB it to restrict the diffusion of substances, that are potentially neurotoxic, 
whilst still allowing the passage of essential molecules i.e. glucose.  It is well 
documented that disruption of the BBB can contribute to numerous brain 
pathologies including Alzheimer’s disease (Abbott and Friedman, 2012).  
 
Aquaporins are a family of proteins that function as water channels in the brain. 
There are two main aquaporins in the CNS: AQP1 and AQP4. AQP1 is 
localised at the apical membrane of the choroid plexus (CP) whereas AQP4 is 
located in the astrocyte foot processes that surround capillaries in the CNS and 
the basolateral membrane of the ventricular ependymal cells (Nicchia et al., 
2004b). AQP1 has previously been implicated in choroidal CSF secretion, 
driven mainly by carbonic anhydrase and Na+/K+ ATPase (Owler et al., 2010).  
AQP4 has been found in astrocytic endfeet, external and internal glial limiting 
membranes and the basolateral membrane of ependymal cells. The DGC is 
essential for the localisation of AQP4 to the endfeet of astrocytes, where its 
primary role is regulating the distribution of water through the brain. AQP4 also 
colocalises with the inwardly facing potassium channel- Kir4.1, which is crucial 
for the spatial buffering of potassium and thus neuronal excitability (Iacovetta et 
al., 2012). 
 
Mice deficient for AQP4 have increased seizure threshold in comparison to wild 
type (Binder et al., 2006). Interestingly there is a higher incidence of seizures 
and epilepsy reported in the DMD population (Hendriksen et al., 2015b), 
indicating a possible role for dystrophin and AQP4 in regulating neuronal 
excitability. However, there are discrepancies regarding the importance of 
AQP4 in maintaining the integrity of the BBB (Nicchia et al., 2004a). Astrocytes 
at the BBB interface of the mdx brain show an age-related reduction in AQP4 
expression, and AQP4 reduction was associated with swollen astrocyte 
processes (Frigeri et al., 2004). AQP4 deficiency was associated with BBB 
breakdown, with consequent vasogenic oedema, and the presence of swollen 
perivascular astrocytes, indicating a close relationship between BBB integrity 
and control of the water flux by astroglial cells (Nicchia et al., 2004b). Similarly, 
skeletal muscle fibres from mdx mice exhibited an age-dependent reduction in 
AQP4 expression with levels of the protein being 90% lower in 12 months old 
mutant mice as compared with age-matched control mice (Frigeri et al., 2004). 
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These studies strongly implicate an essential role of AQP4 both in muscle and 
brain in maintaining the osmotic potential of tissues rich in dystrophin.  
1.8.2 The blood-cerebral spinal fluid barrier (BCSFB) 
The blood-cerebrospinal fluid barrier (BCSFB) functions together with the BBB 
and the meninges, to control the internal environment of the brain. However, the 
BCSFB displays fundamentally different properties to the BBB. 
 
The production and circulation of CSF is carried out by four cavities (ventricles) 
located within the brain. The brain choroid plexus (CP) consists of epithelial 
tissue masses highly vascularised with fenestrated blood vessels of which there 
are four within the brain located in each ventricle (left and right lateral ventricles, 
third ventricle and fourth ventricle) and in turn produce two thirds of the CSF in 
the brain (Garton and Piatt, 2004; Liddelow, 2015). The remaining third of CSF 
is thought to be produced by the surface of the ventricles and the lining of the 
subarachnoid space (Liddelow, 2015). This fluid circulates in the ventricular 
system, subarachnoid spaces and spinal canal, where the plexuses are 
essential for controlling the homeostasis of CSF composition through regulation 
of movement of essential ions and molecules into, and metabolites out of the 
fluid (Liddelow, 2015). The BCSFB barrier is compromised predominately of the 
CP with other contributions from the arachnoid and arachnoid villi on the outer 
surface of the brain. Within the CP the basolateral membrane utrophin A and 
colocalised dystrophin impart structural stability, transmembrane signalling, and 
ion/water homeostasis (Johanson et al., 2011). 
 
The blood-brain barrier (BBB) and the blood cerebral spinal fluid barrier 
(BCSFB) provide protective restriction barriers, formed by bands of tight 
junctions between adjacent cells, which impede the movement of molecules into 
the CNS. When either is compromised, the brain is subjected to defects in fluid 
handling, impacting upon the brain’s osmotic equilibrium which in turn could 




Figure 1.9: Schematic representation of the neurovascular unit (NVU) in 
the brain. The NVU is important in maintaining optimal brain function. Pericytes 
and astrocytes are important in barrier induction and maintenance. Within the 
brain dystrophin and other members of the DGC are diversely expressed, 
where they have essential roles in various protein complexes that anchor 
receptors to specialised membrane sites. Notably AQP4, which is the main 
water channel of the CNS, contributing to brain water homeostasis, is observed 
in the subpial membrane domains of astrocytes, where it is most abundant. 
AQP4 is theorised to interact with dystrophin and other members of the DGC, 
including β-dystroglycan (Waite et al., 2012). Figure adapted from: (Dubois et 
al., 2014). 
 
1.9 Alteration of brain structure in DMD patients  
Although macroscopic brain alterations like ventricular enlargement and cortical 
atrophy have been indicated in some DMD patients, imaging studies and brain 
autopsies have yielded ambiguous findings. One study concluded that no gross 
or histological brain abnormalities were found in DMD patients (Dubowitz and 
Crome, 1969b) after assessing 21 DMD boys on autopsy and found only one 
case of abnormal brain weight and two cases where there were ‘striking 
histological abnormalities’. Similarly, an MRI study in DMD boys found no focal 
or generalised brain changes, but the sample was very small (n=4) (Bresolin et 
al., 1994). In another study of 15 DMD boys and 15 age‐matched controls, no 
significant difference between these two groups in relative ventricular size was 
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found, but the boys participating in the study were still young (<13 years old) 
(Rae et al., 1998). Cortical atrophy has also been identified in DMD but was 
found to be higher in patients older than 10 years (Yoshioka et al., 1980), the 
patients in this study did however show slight ventricular dilation.    
 
In contrast, a number of other studies have reported a broad range of brain 
abnormalities in DMD. The abnormalities identified include neuronal loss, 
heterotopia, gliosis, neurofibrillary tangles, Purkinje cell loss, dendritic 
abnormalities (length, branching and intersections), disordered architecture, 
astrocytosis, and perinuclear vacuolation (Rosman and Kakulas, 1966; 
Rosman, 1970; Jagadha and Becker, 1988; Itoh et al., 1999; Anderson et al., 
2002). One study reported that macroglossia was associated with a lower IQ in 
DMD but the sample size was only small (Bresolin et al., 1994).  
 
Most recently it has been reported that both grey and white matter is affected in 
boys with DMD at a whole brain level (Doorenweerd et al., 2014). Thirty DMD 
patients were examined and it was shown that they had a smaller total brain 
volume, smaller grey matter volume, lower white matter fractional anisotropy, 
and higher white matter mean and radial diffusivity than healthy controls 
(Doorenweerd et al., 2014). The study also investigated the effect of expression 
of the dystrophin isoform Dp140, which has previously been implicated in 
cognitive ability (Felisari et al., 2000). DMD patients also performed worse on 
neuropsychological examination also, with the subgroup that was null for Dp140 
showing the highest grey matter volume differences and performing worse on 
information processing (Doorenweerd et al., 2014). These findings thus suggest 
that there is an important role for the Dp140 dystrophin isoform in cerebral 
development. 
1.10 The use of corticosteroids in DMD 
In animals, hippocampal injury has been shown to be caused by over exposure 
to corticosteroids causing both reversible and irreversible changes in 
hippocampal structure and cognition (McEwen, 1997). In humans, chronic use 
of steroids can have both physiological and psychological side effects, including 
increased appetite, osteoporosis (altered bone remodelling), rapid mood 
swings, anxiety and depression (Brown and Chandler, 2001). In addition, 
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steroid treatment can affect brain morphology, studies of steroid treatment in 
asthmatic patients or patients suffering from rheumatic diseases demonstrated 
a reduced hippocampal and amygdala volume (Brown et al., 2008). Since the 
majority of patients with DMD are currently receiving corticosteroids, the results 
pertaining to changes identified in the brain (Doorenweerd et al., 2014; 
Doorenweerd et al., 2017a), may be confounded as steroid treatment could 
have an effect on brain morphology. This highlights the importance of preclinical 
research; the effect of dystrophin deficiency can be studied in treatment and 
treatment naïve conditions without surpassing ethical boundaries. 
1.11 Mouse models for DMD  
Animal models are a fundamental component of preclinical research. It is 
essential that animal models are well characterised and accurately mirror the 
disease severity and progression in patients, in addition to providing a reliable 
prediction of treatment effect (Varga et al., 2010). In order for an animal model 
to be deemed ‘good’, it must meet a number of criteria: a similar genetic basis 
as the human patient; key hallmarks of the disease; readily available; easy to 
maintain; a well characterised disease progression; a robust phenotype and a 
reproducible disease course. Mice are commonly used as animal models 
because they are cost-effective to house, easy to genetically manipulate, and 
relatively close to humans (Varga et al., 2010). 
1.11.1 The mdx mouse model of DMD 
Currently the best characterised and gold standard mouse model of DMD is the 
mdx mouse. This naturally occurring dystrophin deficient mouse model has a 
premature stop codon in exon 23 of the Dmd gene, a null allele for dystrophin 
protein expression (Bulfield et al., 1984), and was discovered in 1984 in a 
C57BL/10 wild type colony. This genetically appropriate murine homologue of 
DMD, lacking full length dystrophin expression, but retaining the shorter 
isoforms including Dp71 and Dp140 implicated in cognitive functioning (Moizard 
et al., 1998), also exhibits deficits in cognitive ability expressed in terms of 
memory retardation paradigms (Muntoni et al., 1991), and passive avoidance 
tests such as impaired retention in the T-maze (Vaillend et al., 1995). The mdx 
mice were shown to forget newly learned information much faster than control 
mice (Vaillend et al., 1995). Discrepancies regarding the validity of the mdx 
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mouse as a model for DMD result from the reduced disease severity these mice 
portray. Loss of ambulation, cardiac and respiratory related muscle weakness 
and reduced lifespan are all hallmarks of DMD, but these pathological effects 
are less pronounced in the mdx mouse (Stedman et al., 1991; Connolly et al., 
2001). With the exception of the diaphragm, no other tissues exhibit fibrosis 
extensive enough to cause muscle loss which is comparable enough to that of 
DMD patients (Chamberlain, 2010). A number of approaches have been 
employed to increase the disease severity of the mdx mouse but the 
discrepancies regarding the phenotype still remain (Willmann et al., 2009). The 
lack of knowledge regarding the function of dystrophin within the brain calls into 
question whether the mdx mouse models the human brain phenotype, 
especially considering the mild muscular phenotype of the mdx mouse.  
1.11.2 The Cmah-/-mdx mouse model of DMD 
To circumvent the issue regarding the mild disease phenotype expressed by the 
mdx mouse a double mutant mouse, the Cmah-/-mdx, carrying a homozygous 
human-like mutation in the mouse Cmah gene, has been generated 
(Chandrasekharan et al., 2010). This model has thus far demonstrated a more 
severe pathology, exhibiting a muscle phenotype that more closely resembles 
that of DMD patients (Chandrasekharan et al., 2010). 
 
Cytidine monophospho-N-acetyl neuraminic acid hydroxylase (CMAH) gene is 
known to have been deleted in humans approximately 3 million years ago, prior 
to brain expansion during evolution (Chou et al., 2002). However, it is present in 
nearly all other mammals (Hedlund et al., 2007). It encodes for CMAH, an 
enzyme found in the cytosol that catalyses the generation of N- 
glycolylneuraminic acid (Neu5Gc) from N-acetylneuraminic acid (Neu5Ac) 
(Figure 1.10).  
 
All vertebrae cells express a dense glycan layer often terminated with sialic 
acids, which have multiple functions due to their location and diverse 
modifications. Sialic acids are a large group of more than 50 naturally occurring 
acidic, nine-carbon backbone monosaccharides. Neu5Gc and Neu5Ac are the 
most commonly found sialic acid in mammals and have been found to play a 
role in cell-to-cell adhesion, in inflammatory processes, as well as in immune 
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response (Diaz et al., 2009). Contrasting with other organs that express various 
ratios of Neu5Ac and Neu5Gc dependent upon the variable expression of 
CMAH, Neu5Gc expression in the brain is very low in all vertebrates, 
suggesting that neural expression is detrimental to animals (Naito-Matsui et al., 
2017). In addition there is the theory that low levels of residual brain Neu5Gc in 
other mammals somehow limited brain expansion and that the human CMAH 
mutation released our ancestors from such a constraint (Chou et al., 2002).  
 
Due to the deletion, humans lack Neu5Gc and no alternate de novo pathway 
has been found (Bergfeld and Varki, 2014). However, several studies have 
shown Neu5Gc to be sparsely expressed in human tumours and neural 
precursor embryonic stem cells (Malykh et al., 2001). Furthermore, a low level 
of Neu5Gc has been found in normal human tissues as a consequence of 
incorporation from diet, particularly those rich in red meat and milk, that 
accumulates throughout life (Diaz et al., 2009). Several studies have 
established that mice homozygously deleted for Cmah have an increased 
susceptibility to certain pathogens, disturbed hearing and inner ear morphology, 
defective wound healing, and increased glucose intolerance (Kavaler et al., 
2011). 
 
Recently, the incorporation of this deletion into the mdx mouse aimed to create 
a mouse model that has a more similar phenotype to that of the DMD patient in 
addition to a more homologous genetic background. Currently, there is only one 
study which describes the effect of the Cmah deletion in mouse skeletal muscle, 
demonstrating increased disease severity and significantly reduced lifespan 
(Chandrasekharan et al., 2010). It is theorised that this particular change in 
sialylation capacity is a major contributor to the mild phenotype exhibited by the 
mdx mouse, given that the CMAH gene is absent in DMD patients, who show a 
more severe phenotype. This is possibly due to two unrelated mechanisms, 
firstly reduced strength and expression of the DGC and secondly increased 
activation of the complement system (Chandrasekharan et al., 2010). The first 
involves both weakened expression and function of the DGC, including reduced 
ECM binding to α-dystroglycan and reduced expression of utrophin, with a 
similar homology to dystrophin, that when overexpressed can ameliorate 
disease, as well as reduced expression of other DGC members (Deconinck et 
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al., 1997). Additionally, loss of DGC expression or strength would contribute to 
the weakening of the sarcolemmal membrane and the integrity in muscle fibres 
(Bardor et al., 2005). Secondly, the metabolic accumulation of dietary Neu5Gc, 
generation of Neu5Gc-specific antibodies and the deposition of activated (C5b-
9) complement on muscle fibres (Nguyen et al., 2005). Because Cmah-deficient 
mdx myofibers, like DMD myofibers, appear to preferentially take up Neu5Gc 
from diet, they may better mimic the role of dietary Neu5Gc in priming immune 
responses to regenerating muscle, a process that would seed the destruction of 
the very cells needed to overcome dystrophic muscle damage 
(Chandrasekharan et al., 2010). This could potentially speed up skeletal muscle 
wasting in DMD, the mechanism that eventually causes muscle failure and 
mortality in patients.  
 
For the current study both the mdx mouse model and the Cmah-/-mdx double-
mutant mouse model will be employed in all experiments in order to ascertain 
whether any phenotypic differences, regarding cognitive functioning, exist 










Figure 1.10: Differing expression levels of Neu5Ac and Neu5Gc in human 
and mice cells. A. N-glycolylneuraminic acid (Neu5Gc) differs from N-
acetylneuraminic acid (Neu5Ac) by an additional oxygen at the 5 position of this 
sialic acid. B. Since mice express a functional Cmah gene they are capable of 
incorporating sialic acids (Sias) at the outer ends of glycolipids and 
glycoproteins that is usually either Neu5Gc or Neu5Ac. Humans and Cmah null 
mice, by contrast, contain an inactivating deletion in Cmah, and therefore do not 
express Neu5Gc on the surface of glycoconjugates but instead have increased 
















1.12 Statement of aims 
 
1.12.1 Overall study aims: 
As therapy development for DMD has rapidly expanded in recent years, there is 
urgent need to develop reliable outcome measures to monitor disease 
progression and treatment effects. There is wide availability of standardised 
operating procedures (SOPs) to unify experimental protocols for 
characterisation of the mdx mouse muscle and cardiac phenotypes, which can 
subsequently be employed to monitor treatment effect, but no such SOPs exist 
for identifying and monitoring cognitive dysfunction in the mdx mouse. Non-
invasive methods are essential for detecting and monitoring CNS pathology in 
dystrophin deficient mice. The overall aim of this study was to employ non-
invasive methods: MRI and behavioural studies, to assess the CNS in DMD 
mice. The mdx mouse is routinely used for drug development studies and there 
is now an increased interest in understanding the origin of cognitive dysfunction 
in DMD. The lack of outcome measures to study the loss of dystrophin on brain 
function in the mdx mouse hinders the prospect of developing SOPs to ensure 
comparable, robust, and consistent findings between labs.  
 
Given that the current knowledge regarding brain dystrophin expression and 
function is sparse, it is envisaged that a combination of techniques will afford a 
better insight into the function of neuronal dystrophin. The major focus of this 
project will be the development and application of quantitative MRI, including 
contrast enhanced methods, to assess structural and pathological brain 
changes in mouse models of DMD. Non–invasive methods, such as in vivo 
imaging and behavioural studies are important for longitudinal measurements 
but additionally, we aim to complement these studies by utilising histological 
investigations and immunoanalysis of brain tissue to determine potential 
biochemical alterations.  
 
The mdx mouse will be compared against another mouse model of DMD, the 
Cmah-/-mdx mouse model, to establish whether the mdx mouse is the most 






1.12.2 Hypotheses to be tested 
 
1. Loss of the CMAH gene correlates with brain expansion in mice.  
2. A blood-brain barrier (BBB) impairment causes changes to brain osmotic 
equilibrium and becomes more apparent with increasing age in mdx mice. 
3. Cognitive impairment is progressive in mdx mice and cognition can be 
monitored using a battery of behavioural tests. 
4. Non-invasive imaging will reveal neuroimaging biomarkers that have the 































The aim of this chapter is to longitudinally monitor, in the same mouse, changes 
in DMD mouse brains between 4 and 18 months old. Specifically, this chapter 
will employ MR imaging techniques to gain an insight into how the brain 
develops over time in DMD mouse models (mdx and Cmah-/-mdx mice) 




This chapter aims to monitor if the cognitive dysfunction, due to the loss of full-
length dystrophin, progresses with increasing age in mdx mice. Additionally this 
study will characterise for the first time the Cmah-/-mdx mouse behavioural 
phenotype and determine how, if at all, the mdx and Cmah-/-mdx mice differ 




This chapter aims to determine if the BBB is disrupted due to the loss of full 
length dystrophin by utilising a combination of techniques including: 





This chapter aims to determine the biochemical changes occurring in the mdx 







Chapter 2. Materials and Methods 
2.1 Buffers and solutions 
Phosphate buffered solution (PBS) 
2 x PBS tablets  
1000 ml dH2O 
 
4% (w/v) paraformaldehyde (PFA) in PBS 
2 x PBS tablets 
500 ml dH2O 
3 pellet NaOH 
40 g PFA 
pH 7.4 (adjusted with NaOH)  
Volume adjusted to 1000 ml dH2O 
 
Tris-buffered saline (TBS) 10x  
60.5 g Trizma base 
87.6 g NaCl 
pH 7.5 (adjusted with HCL) 
 
0.5% (v/v) Tween 20 in TBS 
100 ml TBS 10x  
899.5ml dH2O 
500 μl Tween 20  
 
DNA digestion buffer 
50 mM Tris HCl 
100 mM EDTA 
100 mM NaCl 







Tris-EDTA (TE) buffer 
10 mM Tris 
1 mM EDTA  
7.4 pH  
 
Tris acetic acid EDTA (TAE) buffer 
400 mM Tris  
10 mM EDTA  
11.4% (v/v) acetic acid  
7.6 pH (with Trizma base and acetic acid)  
 
Protein lysis buffer (PLB) 
10 ml RIPA buffer  
1 tablet cOmplete ULTRA protease inhibitor  
  
MES SDS protein running buffer 
50 ml MES SDS protein running buffer (20x)  
950 ml dH2O  
 
Western Blot transfer buffer (10x)  
30.3 g Trizma base 
144 g glycine 
Volume adjusted to 1000 ml dH2O 
 
 Western Blot transfer buffer (1x) 
100 ml 10x transfer buffer 
200 ml methanol 
700 ml dH2O 
 
5% milk powder blocking solution 
5 g instant dried skimmed milk powder  






Alcian blue stock solution (filtered with Whatman paper (3 mm CHR)) 
0.6 g (0.3%) Alcian blue 8GX  
200 ml of 70% ethanol  
 
Alizarin red stock solution (filtered with Whatman paper (3 mm CHR)) 
0.2 g (0.1%) Alizarin red S  
200 ml of 95% ethanol  
 
Skeletal staining solution 
850 ml 70% ethanol 
50 ml Alcian blue stock solution 
50 ml Alizarin red stock solution 
50 ml Acetic acid 
 
1% KOH; 20% Glycerol  
10 g KOH 
800 ml dH2O 
200 ml glycerol (added whilst stirring)  
 
Cresyl Violet staining solution (filtered with Whatman paper (3 mm CHR)) 
2.50 g Cresyl Violet acetate crystal powder  
500 ml dH2O 
1.50 ml acetic acid  
Incubated at 60°C 
 
Sudan black B (filtered with Whatman paper (3 mm CHR)) 
0.3% w/v Sudan black B  
70 ml ethanol  
30 ml dH20 
 
Thiocarbohydrazide (TCH) solution (filtered with 0.22 µm Millipore syringe)   
0.1g thiocarbohydrazide  
10 ml dH2O  




Coomassie Blue staining solution (1 litre)  
400 ml ethanol 
500 ml dH2O 
100 ml acetic acid  
 
Coomassie de-staining buffer 1 (1 litre)  
477.5 ml dH2O 
100 ml acetic acid 
400 ml ethanol 
22.5 ml glycerol  
 
Coomassie de-staining buffer 2 (1 litre)  
877.5 ml dH2O 
500 ml acetic acid 
100 ml ethanol  






















2.2 Standard molecular biology techniques 
2.2.1 DNA extractions 
At weaning (~3 weeks old) mice were marked for individual identification by 
removing a small part of one or both ears in an individual-specific pattern. Ear 
clips were placed into Eppendorf tubes and 0.5 ml DNA Digestion Buffer was 
added to each tube. 12.5 µl of Proteinase K (20 mg/ml; Roche) was added to 
each tube (a final concentration of 0.5 mg/ml). Samples were incubated for 2 
hours at 55 °C on a heat block and were gently shaken to aid complete 
disruption of tissue. Samples were removed from the heat block and 700 µl of 
Phenol/Chloroform/Isoamyl Alcohol (25:24:1, v/v) (Invitrogen) was added. 
Tubes were then shaken vigorously until a uniform emulsion was obtained. 
Samples were centrifuged at 14, 000 rpm for 5 minutes and the top (aqueous) 
phase transferred to a new Eppendorf tube and 1 ml of 100% EtOH (VWR) 
added. Samples were inverted 15 times and stored at -80°C for 1 hour. 
Samples were then centrifuged at 14,000 rpm for 20 minutes at 4 °C. 
Supernatants were discarded and 1 ml of precooled 75% EtOH added to each 
tube. Samples were then centrifuged at 8, 000 rpm for 5 minutes at 4 °C. 
Supernatants were discarded and pellets left to air dry for ~30 minutes. Pellets 
were then re-suspended in 50 µl 1x TE buffer and incubated at 65°C to allow 
the DNA to re-dissolve.  
2.2.2 Measuring DNA concentrations 
Sample concentration was determined using a NanoDrop spectrophotometer 
(Thermo Scientific, NanoDrop 2000) and samples stored at -20°C until use. 
2.2.3 Genotyping 
Genotyping was performed by polymerase chain reaction (PCR) using genomic 
DNA isolated from ear punches. PCR amplification was conducted using a 
thermal cycler (SensoQuest, Labcycler 48).  
2.2.4 Genotyping mdx mice 
The mdx mouse is the result of a point mutation in exon 23 which means that it 
is difficult to distinguish between the wild type and mutant alleles. A long non-
specific tail was added to the wild type allele-specific primer which resulted in a 
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larger band for the wild type allele. Secondly, the wild type and mutant allele-
specific primers were mixed together in the reaction (Shin et al., 2011) . 
Competition between these two primers reduces erroneous binding and 
extension. 
 
Each 20 μL reaction contained 10 µl dH2O, 4 μL of 5 × GoTaq Flexi buffer 
(Promega, Fitchburg, WI), 1 µl of 10 mM dNTPs (Promega), 2 µl of 2 mM 
MgCl2, 1 µl GoTaq DNA polymerase (Promega), ~150 ng ear DNA, and three 
primers (Table 2.1) including 1 µl of common forward (0.66 μM), 1 µl wild type 
allele-specific primer (0.66 μM) and 1 µl mutant allele-specific primer (0.66 μM).  
PCRs were run using the following program: 
                                                                                          
1. Initial denaturing: 98°C for 2 minutes 
2. Denaturing: 88°C for 30 seconds 
3. Annealing: 58°C for 30 seconds 
4. Extension: 72°C for 30 seconds 
5. Last extension: 72°C for 30 seconds 
(30 cycles for steps 2-4) 
6. Hold at 4°C 
 
Primer name Primer sequences (5’-3’) Band size  
Common forward GCG CGA AAC TCA TCA AAT ATG CGT TAG TGT  
Wild type reverse GAT ACG CTG CTT TAA TGC CTT TAG TCA CTC 
AGA TAG TTG AAG CCA TTT G 
134 bp  
Mutant reverse CGG CCT GTC ACT CAG ATA GTT GAA GCC ATT 
TTA 
117 bp  
 
Table 2.1: Primers used for mdx mouse genotyping. The underlined 
nucleotides are not present in the dystrophin gene. The bolded letters represent 
allele-specific nucleotides at the position of the mutation (Shin et al., 2011). 
Copies of genotyping results can be found in the appendix. 
2.2.5 Genotyping Cmah mice 
Standard PCR was employed for amplification of the Cmah gene, each 25 μl 
reaction contained 14.5 μl of dH2O, 1 μl of 10 mM dNTPs (Promega), 2.5 μl 
MolTaq buffer (Molzym), 2 μl MolTaq enchancer (Molzym), 1 μl MolTaq 
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(Molzym) as the DNA polymerase, 1 μl of common forward (10 µM), 1 µl of 
mutant reverse (10 µM) and 1 µl wild type reverse (10 µM) primers (Table 2.2) 
and ~150 ng DNA. PCRs were run using the following program: 
 
1. Initial denaturing: 94°C for 5 minutes 
2. Denaturing: 94°C for 30 seconds 
3. Annealing: 60°C for 30 seconds 
4. Extension: 72°C for 30 seconds 
5. Last extension: 72°C for 5 minutes 
(30 cycles for steps 2-4) 
6. Hold at 4°C 
 
Primer name Primer sequences (5’-3’) Band size  
Common forward TCC CAG ACC AGG AGG AGT TA  
Wild type reverse CTT CCA GTT GTG CTT TGT GC ~297 bp 
Mutant reverse GTC AGG AAA CAG CAC CAA CA ~ 400 bp 
 
 
Table 2.2: Primers used for Cmah mouse genotyping. Copies of genotyping 
results can be found in the appendix. 
2.2.6 Agarose gel electrophoresis  
Agarose gels (2-3%) (NBS Biologicals) were prepared with 1x Tris-Acetate-
EDTA and Safe View (concentration 0.5 µg/ml) (NBS Biologicals). 15 µl of 
samples and 4 µl of 6x loading dye were loaded onto gels. Gels were subjected 
to electrophoresis at 90-120 volts in 1x TAE buffer for 60-90 minutes. DNA was 
then visualised under UV light, using GelDoc-it 310 Imaging system. The size of 
the DNA fragments was determined relative to 1 Kb or 100 bp ladders (25 
ng/ml) (Promega).  
2.2.7 DNA purification by gel extraction 
For the isolation and purification of a single DNA band, the desired product was 
visualised and excised under a UV transilluminator. The band was extracted 
and purified from the agarose gel using QIAquick Gel Extraction Kit (Qiagen) 
according to manufacturer’s instructions.  
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2.2.8 DNA sequencing and alignments 
Sequencing was carried out by sequencing service MWG Biotech in Ebersberg, 
Germany. 15 μl of purified plasmid DNA at a concentration of 100 ng/μl was 
sent with 15 μl of the appropriate primer at 5 pmol/μl. Sequence alignments 
were carried out using the online Basic Local Alignment Search Tool (BLAST).  
 
2.3 Animal work 
2.3.1 Animal care and husbandry 
Mice used for this study were housed under controlled temperature (~25°C) and 
light conditions (12:12 hour light: dark cycle), with food and water ad libitum. 
The investigations conformed to the Guidance for the Care and were performed 
under the terms of the Animals (Scientific Procedures) Act 1986, authorised by 
the Home Office UK under PPL70/8538 held by Professor Volker Straub. All 
experiments were performed at animal care facilities at Newcastle University, 
UK and were granted ethical approval by the Animal Welfare and Ethical 
Review Board, Newcastle University.  
2.3.2 Transgenic mice used in this study 
C57BL/10ScSnOlaHsd (control) mice were purchased from Harlan Laboratories 
(Indianapolis, USA) mdx (C57BL/10ScSn-mdx/J) mice and B10.Cg-
Cmahtm1Avrk Dmdmdx/PtmJ (Cmah-/-mdx) mice were purchased from The 
Jackson Laboratory (Maine, USA). All mice were bred and maintained in the 
Functional Genomics Unit (FGU) at Newcastle University. Control C57BL/10 
and mdx mouse colonies were maintained by Elizabeth Greally (PIL I3B796363) 
and Cmah-/-mdx and Cmah-/- mouse colonies were maintained by Emine 
Bagdatlioglu (PIL I34A747CC). Homozygous mdx mice are viable and were 
bred either as pairs of one male and one female or trios of one male and two 
females. Cmah-/-mdx homozygous mice are also viable but due to issues with 
breeding (small litters produced and lack of successful breeding) mice were 
either bred as homozygous or heterozygous pairs. Offspring were housed 
together in groups of 2-6 mice per cage.  
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2.3.2.1 Generation of Cmah-/- mouse  
In order to have the adequate control models for the Cmah-/-mdx mouse a 
Cmah-/- mouse was generated/bred (Figure 2.1) at the Functional Genomics 
Unit (FGU), Newcastle University.  
 
Figure 2.1: Generation of Cmah-/- mouse model. The model was generated 
by back crossing a Cmah +/-/Dmd +/- female with a Cmah+/-/Dmd -/* male in order 
to obtain a Cmah-/-/Dmd+/+ female and Cmah-/-/Dmd+/* male mice. Homozygous 
mice were bred to maintain the Cmah-/- mouse colony. Red star = gene not 
present on Y chromosome.  
Parents 
Parents 
F1 generation  
F2 generation  
73 
 
2.4 Behavioural testing  
Mice were transferred from the FGU to the Keith Unit, Newcastle University, at 
least 2 weeks prior to the beginning of behavioural testing. Mice were kept in 
home cages (4 mice per cage) at a constant temperature with food and water 
ad libitum. Mice from at least two different litters (for each genotype, at each 
time point investigated) were tested to avoid litter specific effects. All tests were 
reordered using Panasonic SDR-S26 SD video cameras and blank DVDS (TDK 
T19444 16x DVD+R). Video recordings were viewed using Windows media 
player.  
2.4.1 Barnes maze testing 
2.4.1.1 Procedure 
The Barnes maze is a task that measures spatial learning and memory aspects 
of cognition (Sunyer et al., 2007). The surface of the maze was coloured grey, 
acting as a contrasting colour for clear observation of the mouse movements. 
Surrounding the edges of the maze were 20 holes, 7.5 cm apart and each 5 cm 
in diameter (Figure 2.2). Four of these holes contained a place for a small, 
detachable, dark box containing an opaque chamber for the mouse to enter 
(Sunyer et al., 2007). This box was referred to as the target box and the hole 
containing this, the target hole. The openness of the maze surface should drive 
the mice into this chamber, no other aversive stimulus (e.g. bright light) was 
provided. Surrounding the maze were 4 boards (15 cm away from the edge of 
the maze and 30 cm above the maze), equally spaced from the maze and far 
enough away to prevent the mice from jumping onto them. Each board 
contained a different shape (triangle, circle, square and a cross) as a reference 
for the mice to find the target box, but also to prevent the mice observing the 
whole test room. The investigator also became a reference for each trial, 
wearing a white lab coat and remaining in the same position throughout the 
trials. Testing on the Barnes maze was split into phases, as described below. 
2.4.1.2 Adaptation phase 
Mice were given at least 15 minutes for habituation within the test room prior to 
the start of experiments. Mice were transported from their home cage to the 
Barnes maze in a black plastic tray where they were placed in a dark cylindrical 
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chamber at the centre of the maze (Sunyer et al., 2007). After 10 seconds had 
passed in the chamber the mouse was released. The investigator then carefully 
guided the mouse to the target box. The mouse was not forced into the box to 
avoid stress, but if the mouse would not enter the box then the mouse was 
placed facing the box and the base of the tail pulled gently to usher the mouse 
into the box (Berta et al., 2007). If this did not work, then the mouse was placed 
in the box directly (Berta et al., 2007). Once inside, mice were allowed to 
habituate in the target box for 2 minutes (Berta et al., 2007).  
2.4.1.3 Spatial Acquisition  
Before testing, the surface of the maze was cleaned using 70% w/v EtOH to 
remove olfactory stimuli. Mice were placed in the cylindrical chamber in the 
centre of the maze and after 10 seconds, released and allowed to explore the 
maze for 3 minutes (Berta et al., 2007). In this time the primary errors (nose 
pokes not in the target hole before it is found), total errors (nose pokes before 
mouse enters the target hole), primary latency (time to find the target hole) and 
total latency (time to enter the hole) were recorded. If the mice did not enter the 
target box in the 3 minutes they were guided carefully into the box (Berta et al., 
2007). If mice did not enter the target box in the 3 minute allocated time period 
they were given a 1 minute penalty in order to discriminate between the mice 
that took exactly 3 minutes to enter the target box. Once inside, the mice were 
left for 1 minute before returning to their home cages. There were 4 trials per 
day per mouse for 4 days and in between each trial the mice were given a 15 
minute interval, where they were returned to their home cage. In this time the 
remaining mice were tested. 
2.4.1.4 Short-term Memory 
On day 5 the target box was removed. The target hole for each mouse was the 
same as on previous days and the same procedure carried out for testing as 
previously described. This time the mice were allowed to explore the maze for 
90 seconds and in that time a number of measures were recorded: primary 
latency, primary errors, total errors and the preference for holes around the 
maze (total head pokes in individual holes around the maze). After the allocated 
90 seconds, mice were removed from the maze and testing was finished (Berta 
et al., 2007). From the head pokes in various holes around the maze a success 
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score was created. This was the number of head pokes in a hole, multiplied by 
a given value for that hole (Figure 2.2). Values were based on orientation 
around the target hole; with the target hole itself having a value of 10. The score 
for the individual holes was then totalled to create an overall success score. The 
amount of time the mouse spent in the target quadrant was also recorded.  
2.4.1.5 Long-term Memory 
On day 12, the same procedure as on day 5 is performed without any training 















Figure 2.2: Schematic representation of the Barnes maze test. Blue line 
separates out each quadrant. Values around the outside represent the distance 
from the target hole. Success scores were generated for short-term and long-
term memory where the number of head pokes in a hole is multiplied by a given 
value for that hole. The higher the success score the more successful the 
mouse has been in locating the target hole.  
2.4.2 Novel Object Recognition  
Mice were given a 10 minute habituation to an arena of dimensions 48×31×20 
cm, once a day for 4 days. On the fifth day, mice were exposed to Novel Object 
Recognition in two phases. In the first phase (sample), mice explored two 
identical objects (A1 and A2) for 3 minutes (Ennaceur and Delacour, 1988). 
Objects were either polystyrene spheres or stars, depending on randomization. 
























trials and also similarity in size to the mice. Mice were then given a 15 minute 
inter-trial retention delay (memory consolidation of objects and location). In this 
period, the objects and arena were cleaned with 70% w/v EtOH to remove 
olfactory stimuli and the mice were returned to their home cage. Mice were then 
exposed to the second (choice) phase, in which the identical objects were 
replaced by one novel object (B1) and one familiar object (A3) (Ennaceur and 
Delacour, 1988) and again mice explored these for 3 minutes. Location and the 
novel object itself were varied, to avoid condition place preference. During both 
phases an exploratory action of the objects was defined as the mouse touching 
the object with its nose or directing its nose ≤2 cm from the object. Sitting on the 
object was not considered exploratory movement. 
 
Average time spent with the objects was recorded in both phases of testing. 
From this, D2 ratios’ were calculated for statistical analysis of the choice (test) 
phase. These create a value between +1 and -1, where +1 is total preference 
for the novel object, -1 is total preference for the familiar object and 0 is no 
preference for either object. D2 ratios were calculated by determining the 
proportion of total time spent exploring either of the objects (B1-A3/B1+A3) 
(Ennaceur and Delacour, 1988; Ennaceur et al., 2005). 
 
2.5  Histological studies  
2.5.1 Sample Preparation  
Mice were killed by cervical dislocation and the brain excised from the cranial 
cavity. The Singer Protocol for the dissection of rodent brain was followed 
(Spijker, 2011). Tibialis anterior muscle served as control tissue for staining. 
The tissue was then weighed (PGW M Precision balances, AE Adam), mounted 
on a cork disc (20 mm Diameter x 3 mm thick) supported with a coverslip 
(VWR), and protected with OCT (Pyramid Innovation) before being snap frozen 
in isopentane on dry ice. Tissue was then stored at -80°C until use. 
 
Dissected brains were placed in PBS, to prevent dehydration. The cerebellum 
was then separated from the cerebral cortex by making an incision dorsally 
through the pons. When the majority of white matter had been removed the 
brain was rotated ventrally and the cerebellum was separated from the 
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colliculus inferior. Finally the remaining part of the pons was removed. The 
isolated cerebellum was snap frozen in isopentane on dry ice, placed in an 
Eppendorf tube and stored at -80°C. 
2.5.2 Cryosectioning 
10 μm -20 µm coronal sections of brain tissue and 8 µm sections of muscle 
tissue were cut using a cryostat. (Microm HM 560, Zeiss). For brain tissue the 
regions of interest (ROIs) were delineated by visualisation of their position in 
accordance to known landmarks or other noticeable characteristics and in 
congruence with The Mouse Brain Atlas in Stereotaxic co-ordinates (third 
edition) (Paxinos, 2008). Sections were mounted onto Superfrost Plus slides 
(VWR); air dried for 30 minutes, wrapped in cling film and then stored at -80°C 
until use.  
2.5.3 Staining Procedure with Cresyl Violet  
Slides were removed from the -80°C freezer and allowed to defrost at room 
temperature. After 30 minutes slides were removed from their cling film 
wrapping and given a further 10 minutes to fully defrost at room temperature. 
The slides were immersed in Cresyl Violet solution for 10 minutes and 
dehydrated through a series of alcohol steps (95% EtOH (VWR) for 10 minutes 
then 100% EtOH for 10 mins). Slides were then cleared with 2 x 3 minute 
immersions in Histoclear (National Diagnostics, USA). DPX mounting medium 
(BDH) and a coverslip were applied and the slides left to air dry overnight. 
Images of Cresyl Violet staining were captured using a Zeiss Axioplan 
Brightfield imaging microscope and AxioVision 4.8 software.  
2.5.4  Evans Blue Extravasation  
2.5.4.1 Evans Blue Dye Solution Preparation 
10 mg Evans blue dye (EBD) (Sigma) was diluted into 1 ml of PBS (life 
technologies). The solution was then passed through a 0.22 µl filter and stored 
at -20 °C until use.  
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2.5.4.2 Analysis of BBB Integrity Using Evans Blue Dye  
Mice were given an intraperitoneal injection, into the right side of the peritoneal 
cavity, with a bolus of 0.1 mL/10 g EBD. After injection, animals were returned 
to their cage and allowed food and water ad libitum. After 24 hours, the mice 
were killed by cervical dislocation and the brain excised and rapidly mounted 
and frozen in OCT medium (Pyramid). Serial 10 µm slices from the cerebral 
cortex were mounted onto Superfrost Plus slides (VWR). Slides were dipped in 
ice cold acetone (−20 °C) for 10 minutes and then washed in PBS 3 x 5 
minutes. The sections were then mounted with Vectashield mounting medium 
(Vector Laboratories, Inc.) and a glass coverslip. 
2.5.4.3 Image acquisition and quantification of EBD extravasation 
EBD was visualised on a Zeiss Axio ImagerZ1 (Carl Zeiss Germany Ltd.) fitted 
with a Zeiss Axiocam camera (Carl Zeiss Germany Ltd.) using the 20x and 40x 
objectives, Zeiss ApoTome and AxioVision version 4.8 software. By 
fluorescence microscopy analysis, EBD staining showed a bright red emission. 
In order to make comparisons between different genotypes and ages images 
were collected at standardised exposure settings. All digital images were stored 
as raw images (TIFF files) without any processing of the image. 
2.5.5  Immunofluorescence labelling  
Sides were thawed at room temperature and sections were circled with an 
ImmEdge Hydrophobic Barrier PAP Pen (Vector Laboratories). Sections were 
fixed in 4% PFA (Paraformaldehyde, Sigma) in 1 x PBS (Phosphate Buffered 
Saline, Gibco) for 15 minutes and permeabilised by passing slides through a 
series of methanol dilutions (70% methanol for 10 minutes, 95% methanol for 
10 minutes, 100% methanol for 10 minutes, 95% methanol for 10 minutes and 
70% methanol for 10 minutes). Sections were subsequently blocked in 8% 
bovine serum albumin (BSA) (Sigma) in 1x PBS for 1 hour at room temperature. 
Sections were incubated with 50 μl of primary antibody diluted in blocking 
medium at 4°C overnight. The next day sections were incubated with a 
secondary antibody diluted in blocking medium for 1 hour at room temperature. 
Sections were washed several times with 1x PBS between incubation periods. 
Sections were then covered with 0.3% w/v Sudan Black B (Sigma) for 3 
minutes. Sections were washed several times with 1x PBS-T, before they were 
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mounted in Vectashield mounting medium with DAPI (Vector Laboratories, Inc.) 
and a glass coverslip. Slides were stored at 4°C, protected from light, until 
imaging.  
2.5.5.1 Immunofluorescence Image acquisition 
Fluorescent immunostaining was visualised on a Zeiss Axio Imager (Carl Zeiss 
Germany Ltd.) fitted with a Zeiss Axiocam camera (Carl Zeiss Germany Ltd.) 
using the 20x and 40x objectives, Zeiss ApoTome and AxioVision version 4.8 
software. An average exposure time was taken for 594 nm and 488 nm 
channels using the C57BL/10 control cerebellar sections at the corresponding 
time points, and was then applied to mutant mouse images.  
2.5.6 Electron Microscopy 
6 month old and 12 month old control C57BL/10 and mdx mice (n=2 mice per 
genotype at each time point) were sacrificed via cervical dislocation. The 
cerebellum was separated from the midbrain and 1 mm3 region from the lateral 
cerebellar hemisphere was removed using a scalpel and fixed in 0.1M 
cacodylate buffer (pH 7.5) containing 4% PFA and 2.5% glutaraldehyde 
(Electron Microscopy Sciences).  
 
NCMIR method for 3D EM was followed (https://www.ncmir.ucsd.edu/sbem-
protocol/ ).Briefly, tissues were washed in cold cacodylate buffer (containing 
2mM calcium chloride) before incubation in osmium solution containing 3% 
potassium ferrocyanide in 0.3M cacodylate buffer with 4mM calcium chloride in 
4% aqueous osmium tetroxide (EMS), on ice for one hour. Tissues were then 
washed 5 x 3 minutes in dH2O at room temperature. Tissues were then placed 
in thiocarbohydrazide (TCH) solution for 20 minutes and washed again in dH2O 
(5 x 3 minutes). Tissues were incubated at room temperature in solution 
containing 2% osmium tetroxide. After washing with dH2O (5 x 3 minutes) 
tissues were stored in 1% uranyl acetate overnight at 4°C. The following day 
tissues were incubated in 0.6% lead aspartate solution, washed in dH2O and 
then dehydrated in gradient EtOH before being transferred to acetone. Tissues 
were then embedded in epoxy resin. Standard TEM was then performed on 
sectioned tissues to identify areas for serial block-face scanning electron 
microscopy (SBFSEM) (Purkinje cell and mitochondrial rich areas). A series of 
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serial 70 nm thick were captured on a Gatan 3view housed in a Zeiss Sigma 
FEG SEM and imaged stacks collected on Digital Micrograph v.3.31.734.0. 
Images were captured in this way in order to perform SBFSEM at a later stage.  
 
2.6 Skeletal investigations 
2.6.1 Radiography and Establishment of Kyphotic Index 
18 month old mice were identified by ear markings and then briefly 
anaesthetised with 5% isofluorane in an anaesthetic chamber. Radiographs (X-
rays) were performed on 18 month old mice with a Faxitron radiography system 
(Faxitron X-Ray, Lincolnshire, IL) at 23 kV for 5 seconds. X-rays were taken in 
two positions: mouse laid prone and mouse laid on its right-hand side, in order 
to image both scoliosis and kyphosis respectively. 
 
DICOM raw images were then imported into ImageJ (https://imagej.nih.gov/ij/), 
and measurements made using the measuring tool. A previously established 
protocol, to demonstrate the spine curvature of mice (the kyphotic index), by 
drawing two lines between the caudal margin of the seventh cervical vertebra 
and the caudal margin of the sixth lumbar vertebra was used (Laws and Hoey, 
2004) 
2.6.2 Skeletal preparation 
Adult male mice were sacrificed via CO2 inhalation. An incision was made into 
the abdominal cavity using a scalpel and the internal organs and any fat were 
carefully removed. The skin was removed, as was the skin covering the tail, 
ensuring the skeletal elements were not destroyed. The mouse carcass was 
then placed into glass container and incubated on a shaker at room 
temperature as follows: 
 
 4 days in 95% Ethanol (VWR) 
 3 days in Acetone (VWR) 
 1 day wash with dH2O 
 10 days in skeletal staining solution  
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 4 months in 1% KOH (Sigma); 20% Glycerol (Sigma). This solution was 
changed every two weeks and soft tissue was removed gently using 
forceps. 
 Skeletons were then transferred successively into 50% Glycerol, 70% 
Glycerol and 100% Glycerol before final storage in 100% Glycerol.  
 
Skulls were then imaged using a Zeiss stereomicroscope and AxioVision 
software and imported into ImageJ (https://imagej.nih.gov/ij/).  
 
2.7 Proteomic Analysis  
2.7.1 Protein sample preparation  
2.7.1.1 Tissue lysis and carbamidomethylation 
Comparative proteome profiles were generated for control C57BL/10 and mdx 
mouse cerebella (n=4/genotype) at 6 months old using a total global protein 
extraction method. Each cerebellum was ground and lysed in 1 mL of 50 mM 
Tris-HCl (pH 7.8) buffer containing 150 mM NaCl, 1% SDS. The suspension 
was then centrifuged at 13,500 x g for 30 min at 4°C and the cell lysate 
containing the extracted proteins was collected. 
 
As membrane proteins are notoriously underrepresented in global protein 
extraction procedures and in order to also identify changes in membrane 
proteins control C57BL/10 and mdx mouse cerebella (n=4/genotype) at 6 
months were separately used for enrichment of membrane-associated proteins. 
Each sample was lysed in 1 mL of 0.1 M NaHCO3 (pH 10.7) buffer containing 
cOmplete Mini protease inhibitor cocktail (Sigma) on ice for 30 min. Samples 
were then centrifuged at 68.000 x g for 30 min at 4°C to pellet the membrane 
fractions. The membrane fractions were re-suspended in 0.3 mL of 50 mM Tris-
HCl (pH 7.8) buffer containing 150 mM NaCl, 1% SDS, and cOmplete Mini 
protease inhibitor cocktail.   
 
Protein concentration for both the global and membrane fractions was 
determined by BCA assay according to the manufacturer’s protocol. Cysteines 
of the proteins were then reduced by addition of 10 mM DTT at 56°C for 30 min, 
82 
 
followed by alkylation of free thiol groups with 30 mM IAA at room temperature 
in the dark for 30 min. 
2.7.1.2 Sample preparation and trypsin digestion 
Sample preparation and proteolysis were performed using filter-aided sample 
preparation (FASP). Briefly, 100 µg of protein was diluted 10-fold with freshly 
prepared 8 M urea/100 mM Tris-HCl (pH 8.5) buffer and placed on a centrifugal 
device Nanosep 30 KDa Omega (Life Science). The device was centrifuged at 
13,800 g at room temperature for 20 minutes (this was used for all 
centrifugation steps). In order to eliminate residual SDS, three washing steps 
were carried out with 100 µL of 8 M urea/100 mM Tris-HCl (pH 8.5). For buffer 
exchange the device was washed three times with 100 µL of 50 mM NH4HCO3 
(pH 7.8). Next, 100 µL of proteolysis buffer comprising of trypsin (Promega) 
(1:25 w/w, protease to substrate), 0.2 M GuHCl and 2 mM CaCl2 in 50 mM 
NH4HCO3 (pH 7.8), was added to the device and incubated at 37°C for 14 
hours and 22 hours for global and membrane fractions respectively. Afterwards, 
the generated tryptic peptides were recovered by centrifugation with 50 µL of 50 
mM NH4HCO3 followed by 50 µL of dH2O. Finally, peptides were acidified by 
addition of 10 % TFA (v/v) and digests were quality controlled in a reversed-
phase HPLC. 
2.7.2 Liquid chromatography - mass spectrometry  
2.7.2.1 LC-MS/MS analysis  
Replicates were measured using a Dionex UltiMate 3000 RSLCnano System, 
coupled to an Orbitrap Elite Mass Spectrometer (both from Thermo Scientific). 
In brief, peptides were pre-concentrated on a 100 µm x 2 cm C18 trapping 
column for 10 minutes using 0.1 % TFA (v/v) at a flow rate of 20 µL/min 
followed by separation on a 75 µm x 50 cm C18 main column (both from 
Acclaim Pepmap, Thermo Scientific) with a 115 min LC gradient ranging from 3-
45 % of 84 % ACN, 0.1 % FA (v/v) at a flow rate of 250 nL/min. Mass 
spectrometry (MS) survey scans were acquired in the Orbitrap from m/z 300 to 
1500 at a resolution of 60,000 using the polysiloxane ion at m/z 371.101236 as 
lock mass. The ten most intense signals were subjected to collision induced 
dissociation (CID) in the ion trap, taking into account a dynamic exclusion of 30 
s. CID spectra were acquired with a normalized collision energy of 35 % and an 
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activation time of 10 ms. AGC target values were set to 106 for Orbitrap MS and 
104 for ion trap MSn scans, and maximum injection times were set to 100 ms for 
both full MS and MSn scans. 
2.7.2.2 Label free data analysis 
Data analysis of the acquired label free quantitative MS data was performed 
using the Progenesis Qi software from Nonlinear Dynamics (Newcastle upon 
Tyne, U.K.) in which alignment of MS raw data was conducted by automatically 
selecting one of the LC-MS files as reference. After peak picking, only features 
within retention time and m/z windows from 0-115 min and 300-1500 m/z, with 
charge states +2, +3, and +4 were considered for peptide statistics and analysis 
of variance (ANOVA). MS/MS spectra were exported in an mgf file as peak lists. 
 
The mgf peak lists were searched against a concatenated target/decoy version 
of the mouse Uniprot database, (downloaded on 22/07/2015, containing 16,473 
target sequences) using Mascot 2.4.0 (Matrix Science), X! TANDEM 
Vengeance (2015.12.15.2) and MS-GF+ Beta (v10282) (12/19/2014) with the 
help of searchGUI 2.8.0. Trypsin with a maximum of two missed cleavages was 
selected as enzyme. Carbamidomethylation of cysteine was set as fixed and 
oxidation of methionine was selected as variable modification. MS and MS/MS 
tolerances were set to 10 ppm and 0.5 Da, respectively. 
 
PeptideShaker software 1.9.2 (http://code.google.com/p/peptide-shaker/) was 
used for interpretation of peptide and protein identifications from searchGUI and 
Mascot. Combined search results were filtered at a false discovery rate (FDR) 
of 1% on the protein level and exported using the advanced PeptideShaker 
features that allow direct re-import of the quality-controlled data into Progenesis 
Qi. Peptide sequences containing oxidized methionines were excluded for 
further analysis. Only proteins that were quantified with unique peptides were 
exported. For each protein the average of the normalised abundances (obtained 
from Progenesis Qi) from the replicate analyses was calculated to determine 
the ratios between the mdx mice and control (C57BL/10) mice. Only proteins 
which were (i) commonly quantified in all the replicates with (ii) one or more 
unique peptides, (iii) an ANOVA p-value of <0.05 (Progenesis Qi) and (iv) an 
average log2 ratio of which protein that was either higher than the up-regulated 
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cut-off or lower than the down-regulated cut-off was considered as regulated. 
The cut-off values were determined based on the 2x standard deviation and the 
normal distribution from all identified protein’s log2 ratio in which the bell curve is 
symmetric around the mean. Therefore, an average log2 ratio of a protein which 
< -2.08 or > 2.38 (corresponding to ~5.22-fold regulation; log2 ratios of 1.10) for 
comparative membrane-associated profile and an average log2 ratio < -0.93 or 
> 0.99 (corresponding to ~1.99-fold regulation; log2 ratios of 0.98) for 
comparative global profile were considered as regulated. 
2.8 Protein extraction and Western Blotting 
2.8.1 Sample preparation 
Brain tissue was homogenised and lysed in protein lysis buffer and left on ice 
for 30 minutes. The lysates were transferred to Eppendorf tubes and 
centrifuged at 700 g, 4°C for 10 minutes. The supernatants containing the 
extracted proteins were collected and then centrifuged at 10 000 g at 4°C for 30 
minutes. The pellet was discarded and the supernatant from each tube was 
transferred to an Eppendorf tube and stored at -20°C until use. 
2.8.2 Protein quantification 
Protein concentration was measured using the Qubit Fluorometer (Invitrogen by 
Life Sciences) according to the manufacturer’s recommendations.  
2.8.3 SDS-PAGE and Western Blotting   
25 μg of brain lysates were mixed with 7.5 μl of 4xNuPage LDS sample buffer 
(Life technologies) and 3 μl 10xNuPage reducing agent (Life technologies) in a 
final volume of 20 μl in an Eppendorf tube and were then denatured in a heat 
block at 95°C for 5 minutes. 7 µl Chameleon Duo Ladder (Licor) and the total 
volume of samples (~30 µl) were resolved on 4-12% Novex NuPAGE Gels (Life 
Technologies) in a tank (Life Technologies, Novex Mini-Cell) filled with MES 
(Thermofisher Scientific) running buffer. Gels were run for 45 minutes at 200 
volts using an X cell SureLock Mini-Cell Electrophoresis system (Life 
Technologies). Proteins were then transferred to PVDF membrane (Licor) for 90 
minutes at 350 mA in ice-cold 1x transfer buffer in a transfer tank (Mini Trans-
Blot Electrophoresis Transfer Cell, BIO-RAD). Following transfer, the membrane 
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was soaked in methanol for 1 minute then rinsed in dH2O. Transfer was 
confirmed by staining the membrane with Ponceau S (Sigma) for 5 minutes. 
Following de-staining with dH2O the membrane was blocked for 1 hour in 5% 
milk in TBS-T on a shaker at room temperature. The membrane was incubated 
with primary antibodies (Table 2.3) diluted in 5% milk in TBS-T overnight at 4°C. 
The next day, primary antibodies were drained off and the membrane was 
rinsed three times in in 1x TBS-T for 5 minutes each. The membrane was 
incubated with secondary antibodies (Table 2.3) diluted in 5% milk in TBS-T at 
room temperature on a shaker for 1 hour in the dark. Membranes were washed 
with TBS-T 3 x 5 minutes each, followed by a wash in TBS. Protein bands were 
detected with an Odyssey Family Imaging System (Licor Biosicences). 
 
Membranes were stored in TBS at 4°C and protected from light. Stripping of 
membranes was carried out using a restore fluorescent stripping buffer 
(Thermofisher Scientific) as per manufacturer’s instructions. Membranes were 
stripped and re-probed a maximum of 2 times (for Oxphos 5 and VDAC/Porin 
antibodies only).   
2.8.4 Staining protein gels with Coomassie Blue  
Following electrophoresis the gel was washed with dH2O in a small tray. 10 ml 
of Coomassie Blue staining solution was applied to the gel and the gel left to 
incubate for 1 hour at room temperature on a shaker. The Coomassie Blue stain 
was then removed and 10 ml of de-staining buffer one was applied and the gel 
was left for 1 hour at room temperature on a shaker. De-staining buffer one was 
then removed and 10 ml of de-staining buffer two was applied for 1 hour at 
room temperature on a shaker. Following the removal of de-staining buffer two 
the gel was soaked in dH2O, covered with paper towels (to remove background 
staining) and left overnight at room temperature. The following day the protein 










Table 2.3: Antibodies used in this study.  (WB: Western Blot, IHC: 
Immunohistochemistry).  
2.9 Magnetic Resonance Imaging 
All MR imaging protocols were designed by either Dr Paola Porcari or Dr Dara 
O’Hogain. 
2.9.1 Data Acquisition 
Images were obtained following induction of anaesthesia with 4% Isofluorane 
(Abbott, USA) and 0.5 l/min oxygen in an anaesthetic chamber. For MRI brain 
Antibody Description Application 



















IHC (1:500) Life 
Technologies 
ab150076 
Anti-AQP1 Rabbit polyclonal  WB (1:1000) Abcam ab15080 




Rabbit polyclonal  WB (1:500) Alomone Labs AGT-003 
Anti-
GABA(A)α2 
Rabbit polyclonal WB (1:200) Alomone Labs AGA-002 
Anti-GAPDH Mouse 
monoclonal 
WB (1:1000) Abcam ab6276 
Anti-Gelsolin  Rabbit polyclonal WB (1:1000) Abcam ab74420 
Anti-GFAP Mouse 
monoclonal 
IHC (1:1000) Abcam ab10062 
Anti-Oxphos 5 Mouse 
monoclonal 
WB (1:1000) Abcam ab110413 
Anti-Porin Mouse 
monoclonal 
WB (1:1000) Abcam ab15895 






Rabbit polyclonal  WB (1:1000) 
IHC (1:1000) 
Abcam ab217931 












examination, mice were laid prone on a home-made mouse holder keeping the 
head fixed by a bite bar in order to ensure that the head was positioned at the 
isocenter of the magnet.  
 
Body temperature was maintained using a warm air device (SA Instruments) set 
at 37°C and anaesthesia was maintained using 1.5% Isofluorane and 0.5 l/min 
oxygen via a nose cone controlled with regard to respiratory effort (~50 bpm), 
monitored through an MRI-compatible small animal monitoring and gating 
system. A small amount of lubricating eye gel (Carbomer 0.2%, BluMont) was 
applied to prevent the corneas for drying during scanning. 
 
MRI images were acquired using a 7.0 Tesla horizontal bore Varian scanner 
(Varian Medical System, Palo Alto, CA, USA) equipped with a 12-cm inner 
diameter actively shielded 37 gradient set (Magnex Scientific, Oxford, UK). A 39 
mm (inner diameter) volume coil (Rapid Biomedical GmbH, Germany) was used 
as a radiofrequency (RF) transceiver for MR imaging of mouse brain. 
2.9.2 FSEM T2 and SEM T1 Imaging Parameters 
The MRI protocol included scout images to determine the correct positioning of 
the mouse brain, T2-weighted (T2-w) fast spin-echo (FSE) images and T1-
weighted (T1-w) spin-echo (SE) images. For each mouse, axial, sagittal and 
coronal T2-w images were acquired using the following parameters: repetition 
time/effective echo time (TR/TE eff) = (7000/40) ms, number of averages=4, 
field of view (FOV) = 25 x 25 mm2, matrix (MTX) = 256 x 256, in plane 
resolution = 98 μm x 98 μm, slice thickness = 0.7 mm. In order to ensure that 
the whole brain was imaged, the numbers of slices for coronal, sagittal and axial 
acquisitions were 23, 19 and 15, respectively. Coronal T1-w SE images were 
acquired for each mouse using the following parameters (TR/TE) = (900/16.07) 
ms, number of averages = 4, field of view (FOV) = 25 x 25 mm2, matrix (MTX) = 
256 x 256, in plane resolution = 98 μm x 98 μm and slice thickness=0.7 mm.  
2.9.3 Brain Volumetric Analysis  





Total Volume = Σnj=1 d· Aj        [1]  
 
Where Aj is the cross sectional area on the jth slice through the mouse brain, n 
indicates the total number of the considered slices and d the slice thickness 
(0.7mm).  
 
The cross sectional areas of the mouse brain were determined by drawing the 
ROIs on the MRI images of mouse brain by using ImageJ software 
(https://imagej.nih.gov/ij/). Specifically, ROIs were outlined according to the 
Mouse Brain Atlas (Paxinos and Franklin 2001) on coronal T2-w images of 
mouse brain. Areas of morphological brain regions; cerebellum (including 
colliculus), ventricle system (LV=lateral ventricle, 3V= third ventricle, D3V= 
dorsal third ventricle, 4V= fourth ventricle) and hippocampus were also 
estimated, according to formula [1], by drawing the cross sectional areas on 
coronal T2-w images. 
 
2.9.4 MEMS T2 Imaging Parameters 
T2 relaxation times of different brain regions (hippocampus, caudate putamen, 
cerebral cortex, corpus callosum, cerebellum) of C7BL/10, mdx, Cmah-/-mdx, 
and Cmah-/- mice aged 6 and 18 months old (n=4/genotype/time point) were 
determined using a multi-echo-multi-slice (MEMS) sequence (TR/TE = 3500/8 
ms, NE = 12, slice thickness = 1 mm, in plane resolution = 196 x 196 µm2). T2-
maps of mouse brain were computed for each slice on a voxel by voxel basis as 
a function of TE (12 echo times were employed, starting from 8 to 96 ms with an 
echo spacing of 8 ms).  
 
For each mouse, the total scan time for brain volume measurements was 1.5 
hours and approximately 2 hours when T2 measurements were included. 
Following each experiment mice were recovered and returned to their cages 
with food and water ad libitum. 
2.9.5 T1 mapping with Gadolinium enhancement 
Mice were first anaesthetised using 4% Isofluorane and 0.5 l/min oxygen in an 
anaesthetic chamber. Mice were then transferred to a heated blanket and 
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anaesthetic was maintained using 1.5% Isofluorane and 0.5 l/min oxygen via a 
nose cone. A heat lamp was briefly placed next to the mouse’s tail in order to 
dilate the tail vein. Once a vein was visible by eye a custom-made cannula was 
inserted and flushed with a small volume of saline to ensure the cannula was 
correctly placed. Tissue glue was then applied to avoid disruption of the cannula 
throughout the procedure.  
 
The mouse was then transferred to the MRI scanner and onto a home-made 
mouse holder keeping the head fixed by a bite bar in order to ensure that the 
head was positioned at the isocenter of the magnet. An IV infusion line was 
attached to the end of the cannula, once the mouse was in the correct position, 
a syringe containing 0.2 mmol/kg Gd (Gadovist) was attached to the end. The 
concentration of gadolinium given to the mouse was calculated based on 
mouse weight and diluted in saline to a volume of 150 µl. 
 
Following power calibration a series of scout images was obtained to determine 
the correct positioning of the mouse brain. Pre-contrast baseline imaging was 
performed using a modified T1- mapping Look-Locker multi-slice sequence (Kim 
et al., 2011). The look-locker protocol is a gradient-echo multi-slice sequence 
(GEMSLL) optimized for efficient T1- mapping. This method is advantageous 
because it acquires the series of inversion time (TI) time points rapidly following 
a single inversion. GEMSLL images were acquired using the following 
parameters: repetition time/echo time (TR/TE) = 13.2/6.63 ms, number of 
averages= 2, matrix (MTX) = 96 × 96, field of view (FOV) = 20 × 20 mm2, flip 
angle = 5°, 6 TI (0.005, 0.12, 0.24, 1.5, 2.5, 3.5), TR (inv) = 34.46 s, number of 
slices=9 and slice thickness= 1.2 mm. Following the T1- mapping scan a series 
of eight coronal T1-w SEM images was acquired with the following parameters 
(TR/TE) = (900/16.07) ms, number of averages = 2, field of view (FOV) = 25 x 
25 mm2, matrix (MTX) = 256 x 256, in plane resolution = 98 μm x 98 μm and 
slice thickness=1 mm. GAD was injected 20 seconds before the end of the 
second T1-w SEM scan (Figure 2.3). A post-contrast agent T1- mapping scan 
was performed, after the acquisition of eight T1-w SEMS images, approximately 




The total time spent by each mouse in the magnet was 2 hours. Following each 
experiment mice were recovered and returned to their home cages with food 
and water ad libitum.  
 
Tissue infiltration of the tracer was assessed using T1- mapping where a relative 
increase in T1 contrast indicates increased Gadovist uptake. Gadovist (Gd-
DO3A-butrol) is a gadolinium based contrast enhancing agent referred to from 




Figure 2.3: Timeline for T1 mapping experiment with gadolinium 
enhancement. 
 
Acquired images were processed using VNMRJ Math function to calculate 
apparent T1 maps, as well as M(0) (apparent equilibrium magnetisation), S(0) 
(true equilibrium magnetisation) and RMS residual (error) maps. 
Scans were converted to Matfiles and a correction for the effects of the Look-
Locker RF-pulse train on magnetization was implemented (using a Matlab script 








IV bolus 0.2 mmol/kg Gadovist 
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M(t)= A-B exp (-t/T*1) 





















∗ ) − 1}         [3] (Deichmann et al., 1999) 
 
 
Images were then analyzed using the freely available analysis software ImageJ. 
Quantification of the concentration of Gadolinium in brain tissue in vivo is 
possible using both the T1 mapped values and Formula 4:  
 
R1post = R1pre + r1[Gd] , where  r = 1/T1                                                                                          [4] 
                        
Where R1post and R1pre are the relaxation rates of the tissue post and pre Gd 
injection, [Gd] is the concentration of contrast agent and r1 is the relaxivity of the 
contrast agent at 7T.  
 
In order to measure the relative relaxation rate of Gd, Gadovist 1.0 mmol/ mL, 
was diluted with saline in an Eppendorf and measured as 6.49 mM-1 s-1 using 
an inversion recovery spectroscopy pulse sequence. The r1 relaxation rates 
before and after contrast enhancement were measured from the T1 maps of 
brain tissue, which in turn could be used to calculate the concentration of 











Figure 2.4: Representative images created using VNMRJ Math 
function.VNMRJ was used to calculate apparent T1 maps, as well as M(0) 
(apparent equilibrium magnetisation), S(0) (true equilibrium magnetisation) and 
RMS residual (error) maps. Taken together these maps are used to create a 
corrected T1 map used for calculating correct concentration and T1 value shows 
accurate comparison with that of the literature ((DiFrancesco et al., 2008), 
Mouse cortex at 7 T = 1.612).   
2.9.5.2 BBB permeability index calculation  
ROI’s were assigned to a number of brain regions (cerebellum, hippocampus, 
ipsilateral cortex and contralateral cortex) and an average T1 value was 
obtained from each ROI in T1 maps acquired pre-and post-Gd administration. 
The BBB permeability index defined as the difference of R1 (=1/T1) values 
between post-and pre-Gd administration was calculated for each ROI at all time 
points.  
T1 apparent map M(0) M(eq)apparent RMS residual 
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2.9.6 Brain Water Content Measurements 
Brain water content was determined using a dry and wet method. C57BL/10, 
mdx, Cmah-/-mdx, and Cmah-/- mice aged 6 months (n=4/genotype) were 
sacrificed by cervical dislocation and brains were rapidly excised from the 
cranial cavity. After brains were removed the hemispheres were separated 
along the interhemispheric plane and the cerebellum was removed. Both 
hemispheres and the cerebellum were then weighed (PGW M Precision 
balances, AE Adam) separately to assess their wet weights and then dried for 
24 hours at 100°C to determine their dry weights. The water content was 
expressed as the following formula 5: Brain water content measurements were 
taken to compare against T2 in vivo measurements. 
 
  [(wet weight)-(dry weight)]/ (wet weight)] x 100%       Formula [5] 
 
2.10 Statistical analysis  
Statistical analyses were performed with IBM SPSS Statistics 22.0 software. 
Repeated measures ANOVA were used for measurements taken from the same 
mouse over time (longitudinal MRI study), with students paired t-test used as 
post-hoc testing where a significant main effect was identified. A one-way 
ANOVA was used to measure kyphotic index and T1-mapping data with 
Bonferroni post-hoc testing. A two-way ANOVA was used to measure wet:dry 
brain measurements, T2 relaxation rates (6 and 18 months old), D2 ratio from 
the NOR task (4, 6, and 12 months old), and Barnes maze probe trials (4, 6, 
and 12 months) with Bonferroni post-hoc testing. Mixed measures repeated 
ANOVA was used to measure the Barnes maze test parameters (primary 
latency, total latency, primary errors, total errors) over time (4, 6, and 12 
months).  
 
Proteomic data were analysed using ANOVA (Progenesis Stats) and unpaired 
students t-test, p<0.05 was considered statistically significant and p<0.01 was 





Chapter 3. Using magnetic resonance imaging to detect and 
monitor changes in the mouse brain 
3.1 Introduction  
Magnetic resonance imaging (MRI) is a non-invasive imaging technique which 
provides spatially sensitive information on tissue structure. Sequences are 
specifically designed to quantify the proton density and the relaxation times (T1 
and T2) of the mobile protons (Dunn and Zaim-Wadghiri, 1999). T1-weighted 
(T1-w) images (short TR and TE) with recovery of magnetisation occurring along 
the Z-axis, where the contrast between grey and white matter allows for 
accurate identification of anatomical structures. Whereas T2- weighted (T2-w) 
images, with contrast produced by fast spin echo (FSE) sequences (long TR 
and TE) and recovery occurring in the X-Y plane, allows for the identification of 
pathological features due to fat appearing dark and water appearing bright. T1-w 
and T2-w scans provide qualitative information regarding brain changes.  
3.1.1 Studies in DMD patients 
Post-mortem studies in the brains of DMD patients have failed to find consistent 
abnormalities, although only a few studies have been performed (Dubowitz and 
Crome, 1969a; Jagadha and Becker, 1988). Brain MRI studies in DMD patients 
have been very limited until recently, with studies restricted to case reports and 
there is only one study reported which used a quantitative voxel based 
morphometry analysis and resting state functional MRI with a region of interest 
in the motor cortex (Lv et al., 2011). Recent studies in DMD patients 
increasingly use MRI to investigate the effect of dystrophin-deficiency on brain 
morphology (Doorenweerd et al., 2014; Doorenweerd et al., 2017a; 
Doorenweerd et al., 2017b; Suzuki et al., 2017).  
 
A study looking at 30 DMD patients (aged 8-18 years old) detected a change in 
grey matter and total brain volume, both of which were found to be smaller in 
comparison to 22 age-matched controls (Doorenweerd et al., 2014). 
Interestingly, the study found that DMD patients who were predicted to have a 
loss of the Dp140 isoform (hypothesised to have particular importance in CNS 
function (Lidov et al., 1995)) were more severely affected in terms of total brain 
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and grey matter volumes in addition to a lower neuropsychological performance 
(Doorenweerd et al., 2014). This study found that the reduced grey matter 
volume in DMD was global, whereas previously reported data isolated changes 
to the left primary somatosensory cortex, although no analysis of absolute grey 
matter volumes was performed in this case (Lv et al., 2011). On the other hand, 
white matter examination showed no difference in volume between DMD 
patients and healthy controls, but detailed a significant difference on a 
microstructural level as shown by diffusion tensor imaging (DTI). DMD patients 
demonstrated structural changes suggestive of reduced fibre density, increased 
membrane permeability, or decreased structural organisation (Doorenweerd et 
al., 2014). Whole brain quantitative MRI allowed the detection of reduced grey 
matter volume and white matter alterations in DMD boys that had not previously 
been reported. The reduction in grey matter volume was seen in both patients 
where Dp140 was present and Dp140 was absent, suggesting that this change 
in grey matter volume was related to the loss of full-length dystrophin (Dp427). 
The limitations of this study included the ages of the DMD boys investigated, as 
maximum global grey matter volume was reached between 6-9 years of age 
(Courchesne et al., 2000), and the use of steroid treatment, which may have 
effects on brain morphology.  
 
Radiological studies in DMD patients detailed glucose hypometabolism utilising 
positron emission tomography (PET) and altered metabolic concentrations by 
magnetic resonance spectroscopy (MRS) (Rae et al., 1998; Lee et al., 2002). 
The authors suggested this might indicate cytoarchitectural alterations, but it 
might also be a result of lower cerebral blood flow (CBF). A recent study looking 
at 28 DMD patients (aged 8-16 years old) and healthy aged matched controls 
demonstrated that CBF was reduced by 17%. Moreover, this study 
demonstrated that the changes in CBF were independent to the change in grey 
matter volume (Doorenweerd et al., 2017a).  
 
Interestingly the CBF was lowest in DMD patients null for Dp140 expression. 
Dp427 has previously been identified in neuronal post-synaptic membranes 
(Lidov et al., 1990) whereas Dp140 was hypothesised to interact with astrocytic 
end feet (Nico et al., 2005), which are associated with pericytes and 
microvessels, where pericytes closely regulate oxygen and glucose demands 
96 
 
upon sensory stimulation (Hall et al., 2014). The limitations of this study 
included the presence of cardiac dysfunction in DMD patients. Indeed, 
cardiomyopathy is a common clinical symptom affecting 95% of patients by the 
age of twenty (Judge et al., 2011) and previous studies have outlined a reduced 
CBF correlating to cognitive impairment in patients awaiting a heart transplant 
(Gruhn et al., 2001).  
3.1.2 Studies in the mdx mouse 
Studies in the mdx mice have used in vivo MRI, high resolution localised 
magnetic resonance spectroscopy (1H MRS), and ex vivo DTI to investigate 
alterations in brain structure and metabolites from mature brains (9 months old) 
(Xu et al., 2015). They detailed an obvious difference in ventricle size and 
volume in mdx mice, in the absence of any changes in total brain volume. They 
suggested that the enlargement of ventricles was most likely due to grey matter 
atrophy or compression from excess CSF. The study also detailed changes in 
DTI measurements between mdx and aged matched controls. These findings 
were suggestive of a more continuous movement of water molecules with less 
restrictions and boundaries in the mdx mouse prefrontal cortex (PFC), although 
no statistical difference in DTI was found between grey and white matter 
regions of the cerebellum (Xu et al., 2015). Utilising MRS, the study found 
alterations in metabolite concentrations in mdx mouse brains particularly in the 
hippocampus (HP) and the PFC regions, where dystrophin is normally 
abundantly expressed. Significant elevations of taurine (in PFC), glutathione (in 
HP), phosphocholine (in HP), and a significant reduction in GABA (in HP), were 
observed in mdx mice (Xu et al., 2015). An imbalance of such metabolites has 
important consequences for functions such as osmoregulation, oxidative stress, 
membrane phospholipid synthesis, and GABAergic neurotransmission in the 
brain. Historical studies in the mdx mouse brain also detailed abnormal brain 
metabolism utilising 31P- MRS, which can potentially influence CBF and glucose 
metabolism (Tracey et al., 1996).  Moreover, similarly to DMD patients the mdx 
mouse has showed an 18% reduction in CBF compared to wild type mice and a 
reduction in AQP4 in the brain, associated with swollen perivascular astrocyte 





As therapy development has rapidly expanded in recent years there is an 
urgent need to develop reliable outcome measures to monitor disease 
progression and treatment effect. The limited number of sensitive outcome 
measures to measure and monitor the DMD brain phenotype, together with the 
need to avoid invasive techniques in patients makes MRI a particularly 
attractive option. This is also reflected in the increasing interest in quantitative 
MR from pharmaceutical industry and regulatory bodies, where trial protocols 
are encouraged to include these techniques.  
3.1.3 Aims  
To date, almost all studies investigating cognitive dysfunction in DMD patients 
and in the mdx mice have detailed outcomes from one age group. There is 
conclusive evidence that the muscle pathology seen in DMD is progressive but 
it remains unclear if the cognitive impairment exhibited by approximately one-
third of DMD patients is also progressive. Unlike muscle tissue, where invasive 
diagnostic measures such as a muscle biopsy are feasible (but are not 
desirable), non-invasive imaging is the only acceptable method for monitoring 
changes in the brain. Recent reports alluded that cognitive disability increases 
in DMD patients with increasing age (Suzuki et al., 2017), therefore the overall 
aim of this chapter is to assess if qualitative and quantitative MRI protocols can 
detect changes in DMD mouse brains over time. Specifically, the aims of this 
chapter are: 
 
 To establish structural MR imaging protocols for the application in mutant 
mouse brains to determine and monitor potential morphological changes. 
 To monitor a cohort of control C57BL/10 and DMD mice over a period of 
18 months to evaluate the long-term effect of dystrophin-deficiency on 
the brain. 
 To determine if there are structural brain differences or changes in 
regions of the mouse brain with age (utilising voxelwise tools in the 




3.2 Total brain volume (TBV) measurements 
In order to determine total brain volume (TBV), images in T1-w coronal, T2-w-
coronal, -sagittal, and –axial planes were acquired on a 7T MRI scanner (Figure 
3.1). The same eight mice per genotype were repeatedly scanned between 4 
and 18 months old in order to longitudinally monitor changes in TBV in the 
same animal over time. Images were analysed using the polygon tool in ImageJ 
(https://imagej.nih.gov/ij/) to manually outline around each brain slice from T1-w 
coronal (25 slices), T2-w coronal (25 slices), T2-w sagittal (19 slices), and T2-w 
axial (15 slices) images. The TBV was then calculated according to formula [1] 
(Figure 3.2).  
 
Following a repeated measures ANOVA, there was a significant interaction 
between age and genotype on TBV (F3, 26=19.39, p<0.01). At 4 months old 
Cmah-/-mdx mice exhibited a substantial enlargement in TBV (Table 3.3) 
compared to age matched control C57BL/10, mdx, and Cmah-/- mice. 
Interestingly, at 4 months old Cmah-/- mice also had an enlarged total brain 
volume (Table 3.4) compared to control C57BL/10 and mdx mice, however, it 
was not as large as Cmah-/-mdx mice indicating that it is the loss of both 
Neu5Gc and dystrophin which contributes to a significant increases in TBV. At 4 
months old control C57BL/10 (Table 3.1) and mdx (Table 3.2) mice had 
comparable TBV. 
 
Between 4 months and 18 months old control C57BL/10 mouse brains 
increased by a total of 5.29±1.03 %, with the largest increase in TBV observed 
between 4 months and 6 months old (3.05±1.03 %). The mdx mouse brain also 
increased in volume between 4 months and 18 months old with an even larger 
TBV increase of 7.52±1.38 %. In contrast to the surge in increase of TBV 
observed in control C57BL/10 mice, the mdx mice brains steadily increased in 
size between 4 months and 18 months old (Figure 3.3 and Figure 3.4). 
Remarkably, between 4 months and 6 months old the Cmah-/- and Cmah-/-mdx 
mouse brain volumes remained unchanged in volume. The Cmah-/-mdx mice 
did however have a 4.43±0.91 % increase in TBV between 4 months and 18 
months old. In contrast, Cmah-/- mice (2/8 mice) MR images showed clearly 
focal atrophy of the brain restricted to the outer layer of the cortex which can be 
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traced to the primary somatosensory cortex, lateral parietal association cortex, 
and medial parietal association cortex (mouse brain atlas(Paxinos, 2008)) 
(Figure 3.5). Counter to the increase in TBV observed in the other genotypes, 
the Cmah-/- mice had a reduction in TBV of 3.25±1.76 % between 4 and 18 
months old (Figure 3.4). Interestingly, the largest change in TBV was observed 
between 6 and 12 months old regardless of genotype. 
 
Taken together, the results indicate that the control C57BL/10 mouse brain 
increases in size by a small but significant amount between 4 months and 
18 months old (p<0.05). However, the mdx mouse brain volume increased 
considerably more (p<0.01).  
 
Figure 3.1: Representative T2-w magnetic resonance images (MRI) of axial 
(left panel), sagittal (upper right panel) and coronal (lower right panel) 









Total Volume = Σnj=1 d. Aj                                                Formula [1] 
Where Aj is the cross sectional area on the jth slice through the mouse brain, n indicates the 
total number of the considered slices and d is the slice thickness (0.7mm).  
 
Figure 3.2: Representative MR images demonstrating the method used for 
the estimation of total brain volume (TBV) in all mice using the polygon 
tool in ImageJ. The outline of each brain from representative T1-w coronal, T2-
w -coronal, -axial, and -sagittal images are delineated in green. Formula [1] was 
used for calculating total brain volume. Images are shown for control C57BL/10 
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Figure 3.3: Bar graph displaying longitudinal comparison of total brain 
volume (TBV). MRI derived TBV for the same mice at 4 months old 
(n=8/genotype), at 6 months old (n=8/genotype), at 12 months old 
(n=8/genotype), and 18 months old (n=8/genotype). Interestingly, control 
C57BL/10 mouse brain increased in volume between 4 and 18 months old. 
Cmah-/-mdx mice had the largest TBV at all time points investigated. Control 
C57BL/10, mdx, and Cmah-/-mdx mouse TBV increased between 4 and 18 
months old, whereas Cmah-/- mouse TBV gradually decreased between 4 and 
18 months old. Data presented as mean ±SEM, *p<0.05, **p<0.01, ^ denotes 
difference to mdx mice, < denotes difference to Cmah-/-mdx mice. 
 
 












































Figure 3.4: Line graph displaying longitudinal comparison of total brain 
volume (TBV). Estimated TBV in the same mice at 4 months old 
(n=8/genotype), at 6 months old (n=8/genotype), at 12 months old 
(n=8/genotype), and 18 months old (n=8/genotype). Although TBV varied 
between each mouse, an overall increase in TBV was evident in control 
C57BL/10, mdx and Cmah-/-mdx mouse brains but Cmah-/- mice showed brain 
atrophy from 6 months onwards. Control C57BL/10 mouse brain increased 
significantly with increasing age. DMD mice (mdx and Cmah-/-mdx mice) had 








Figure 3.5: Focal atrophy in the Cmah-/- mouse brain. A. Coronal MR 
images where the red arrow indicates an area of focal brain atrophy seen only 
in Cmah-/- mice at 18 months old, which is evident on both T1- and T2-weighted 
images. B. Sagittal MR images where the red arrow indicates the same region 
of atrophy observed on coronal MR images. The representative sagittal images 
are from control C57BL/10 and Cmah-/- mice at approximately the same slice. 
The effect of atrophy, which is clearly visible on MR images, was observed in 
2/8 Cmah-/- mice at 18 months old. Atrophy such as this was not observed in 
any other mouse strain. C. T2-w coronal image from the same Cmah-/- mouse 
at 12 months old displaying no sign of atrophy. D. T2-w coronal image from a 
second Cmah-/- mouse at 18 months old showing similar but less severe signs 
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Table 3.1: Volumetric comparison between all C57BL/10 mice using T2-w images acquired across all orthogonal planes. 
Comparable values were obtained across all orthogonal planes. 
 
C57BL/10 mice total brain volumes at 4 months old 
 Mouse  Coronal T2-w  Axial T2-w  Sagittal T2-w  Mean volume across all  orthogonal planes (mm3) 
Total Volume (mm3) Total Volume (mm3) Total Volume (mm3) 
C57Bl/10_1 
 










































Average brain volume for C57Bl/10=  512 
 
 
Mean Volume for each MRI 
acquisition (mm3)  














Table 3.2: Volumetric comparison between all mdx mice using T2-w images acquired across all orthogonal planes. Comparable 
values were obtained across all orthogonal planes.   
 mdx mice total brain volumes at 4 months old 
 
 Mouse  Coronal T2-w Axial T2-w Sagittal T2-w Mean volume across all  orthogonal planes (mm3) 
Total Volume (mm3) Total Volume (mm3) Total Volume (mm3) 
mdx _1  
 
519 510 511 513 
mdx _2 
 
521 522 523 522 
mdx _3 516 
 
515 516 516 
 










































Average brain volume for mdx =  519 
 
 
Mean Volume for each MRI 
acquisition (mm3)  













Table 3.3: Volumetric comparison between all Cmah-/-mdx mice using T2-w images acquired across all orthogonal planes.  
Comparable values were obtained across all orthogonal planes.   
 Cmah-/-mdx mice total brain volumes at 4 months old 
 
 Mouse  Coronal T2-w  Axial T2-w  Sagittal T2-w  Mean volume across all orthogonal planes (mm3) 
Total Volume (mm3) Total Volume (mm3) Total Volume (mm3) 






Cmah-/-mdx _2 562 552 540 551 






























531 538 534 
534 
Average brain volume for Cmah-/-mdx =  550 
 
 
Mean Volume for each MRI 
acquisition (mm3)  














Table 3.4: Volumetric comparison between all Cmah-/- mice using T2-w images acquired across all orthogonal planes. 
Comparable values were obtained across all orthogonal planes. 
 
 Cmah-/- mice whole brain volumes at 4 months old 
 
 Mouse  Coronal T2-w  Axial T2-w  Sagittal T2-w  Mean volume across all orthogonal planes (mm3) 
Total Volume (mm3) Total Volume (mm3) Total Volume (mm3) 
Cmah-/- _1  
 




























536 537 545 
539 
Average brain volume for Cmah-/- =  
538 
 
Mean Volume for each MRI 
acquisition (mm3)  
535 539 541  
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3.3  Morphological findings 
3.3.1 Brain ventricle system 
The brain ventricle system was visible in all planes of the MR images acquired. 
ROI’s were identified on T2-weighted coronal images for volumetric 
measurements within the brain ventricular system (Figure 3.6). The mouse 
brain atlas served as a reference for the accurate depiction of brain structures 
with the anatomical points on the skull, Bregma and Lambda (Paxinos, 2008). 
Following a repeated measures ANOVA there was a significant interaction 
between age and genotype on ventricle volume (F3, 28=5.79, p<0.05). The first 
striking difference identified using MRI was the significant reduction in the 
ventricular volume and size of the Cmah-/- mice (Figure 3.7). This effect was 
apparent in all eight Cmah-/- mice and although the ventricle system did 
increase in volume as the mice aged (between 4 and 18 months), they still 
remained much smaller in volume compared to age matched control C57BL/10 
mice (Figure 3.8, Figure 3.10 and Figure 3.11). In addition to the lateral 
ventricular (LV) volume reduction, the third ventricle (including ventral (V3V) 
and dorsal third ventricle (D3V)) was also significantly smaller in volume in 
Cmah-/- mice (Figure 3.10). A notable loss of CSF from the ventricular spaces 
was also seen in 3/8 Cmah-/- mouse brains (Figure 3.8). 
The DMD mouse lateral ventricles (LV) were enlarged compared to age 
matched control C57BL/10 mice (Figure 3.8 and Figure 3.9). The dilation of LVs 
was particularly prominent in the coronal and axial MR images acquired. 
Although this effect was significant in Cmah-/-mdx between 4 and 18 months 
old, it eluded significance in mdx mice until 12 months old (Figure 3.10). There 
was no difference in the volume of the 4V between any genotype at any time 
point investigated (Figure 3.10). The total relative ventricular volume was also 
increased in DMD mice brains and was significantly increased in mdx mice 
compared to control mice from 12 months onwards. Although there was a 
difference observed between ventricles at 4 months, 12 months, and 18 months 
old, at 6 months old there was no difference found in the ventricle system of 
control C57BL/10, mdx, and Cmah-/-mdx mouse brains. Interestingly, the 6 
month old time point was where the largest observation of total brain volume 
increase was detected (Figure 3.3), suggesting that the brain volume increases 
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Figure 3.6: Representative T2-w axial, sagittal, and coronal MR images. 
Images show the lateral ventricle (LV), ventral third ventricle (V3V), dorsal third 
ventricle (D3V), fourth ventricle (4V), and cerebellum (CER) for control 
C57BL/10, mdx, Cmah-/-md, and Cmah-/- mice at 4 months old. Ventricles 







































































Figure 3.7: Changes in Cmah-/- mouse brain ventricular system. A. 
Representative T2-w coronal MR images from control C57BL/10 and Cmah-/- 
mice displaying lateral ventricles (LV), ventral third ventricle (V3V), and dorsal 
third ventricles (D3V) at 4 months old. Red arrows highlight particular ventricles 
in Cmah-/- mice which are abnormal compared to control mice. Substantial 
reduction in the LV, V3V, and D3V was evident across all MR images acquired, 
delineating these ventricles in the Cmah-/- mouse brain. B. The Allen mouse 
brain histology atlas showing the correct formation of the LV, V3V, and D3V. C. 
Cresyl violet stained cryosection (20 µm) of a Cmah-/- mouse brain 
corresponding to the mouse brain atlas image, detailing the reduction in size of 
the LV, 3V, and D3V. D. Sagittal MR image where red lines indicate the regions 
where the coronal images were acquired, black arrow indicates the direction of 



































 Figure 3.8: MR images of the mouse brain ventricular system. A. Representative T2-w coronal images of control C57BL/10, mdx, 
Cmah-/-mdx, and Cmah-/- lateral ventricles highlighting the substantial reduction in lateral ventricle size in the Cmah-/- mice brains (red 
arrows) and the notable absence of CSF (n=8 mice/genotype). Images were taken from 4 month old mice, however, the effect was also 
evident at all other time points (6, 12, and 18 months old). Interaural and Bregma points, from the mouse brain atlas, are provided for 
accurate depiction of brain structures with the anatomical points. B. Sagittal images where the red line indicates approximately where the 
coronal slice was acquired through the mouse brain. 
B. Cmah-/- Cmah-/-mdx C57BL/10 mdx 
Absence of CSF 
Interaural 3.22 mm 






















Figure 3.9: T2-w-coronal MR images of control C57BL/10, mdx, Cmah-/-mdx and Cmah-/- lateral ventricles taken from the same 
mouse between 4 months and 18 months old. There is an enlargement of the lateral ventricular volume in DMD mouse models (mdx 
and Cmah-/-mdx mice) between 4 and 18 months old (red arrows). Cmah-/- mouse lateral ventricles (LV) also increased slightly with age. 
Little to no changes were observed in control C57BL/10 mouse brain ventricles over time.



































Figure 3.10: Bar graphs displaying relative ventricular volume in the same 
mice between 4 and 18 months old. LV= lateral ventricle, 3V= third ventricle, 
D3V= dorsal third ventricle, and 4V= fourth ventricle. A. Relative ventricle 
volume at 4 months old, showing that Cmah-/-mdx mice have significantly larger 
LVs compared to mdx and aged matched control mice. Cmah-/- mice also 
displayed a large reduction in the 3V volume compared to age matched control 
C57BL/10 mice. B. Relative ventricle volume at 6 months old. Interestingly no 
significant difference in ventricle volume was observed between control 
C57BL/10, mdx, and Cmah-/-mdx mice, only Cmah-/- mice showed a reduction 
in LVs, 3V and D3V volume. C. Relative ventricle volume at 12 months old, 
showing that both mdx and Cmah-/-mdx have significantly larger LVs compared 
to aged matched control C57BL/10 mice. D. Relative ventricle volume at 18 
months old, showing a significant reduction in Cmah-/- mice LVs compared to 
all other genotypes. Cmah-/-mdx mice had the largest increase in LV volume 
between 4 and 18 months old. Data presented as mean± SEM, *p<0.05, 



























Figure 3.11: Bar graph displaying the relative total ventricular volume of 
the same mice between 4 and 18 months old. Relative total ventricle volume 
is calculated based on the total volume of the ventricle system expressed as a 
percent of total brain volume. At 4 months old the Cmah-/-mdx mice had a 
significantly larger total ventricular volume, whereas the Cmah-/- mice had the 
smallest total ventricular volume. From 12 months onwards both DMD mice 
models had a significantly larger total ventricle volume compared to age 
matched controls. Total ventricular volume increased with increasing age in all 
genotypes. Data presented as mean ± SEM, *p<0.05, **p<0.01 vs control 











The ventricles in Cmah-/-mdx mice appeared morphologically different 
compared to the ventricles of age matched control C57BL/10 and Cmah-/- mice 
(Figure 3.12). The D3V merged into the LV at a more posterior position than 
that observed in the control C57BL/10 mice indicating that there were changes 
in the development of the ventricular system in Cmah-/-mdx mice. This effect 
was apparent in 2/8 Cmah-/-mdx mice scanned in the longitudinal study and 
was also evident at all time points investigated. The formation of this ‘fifth brain 
ventricle’ was similar to the human disorder known as Cavum Septum 
Pellucidum (CSP), which is a normal variant CSF space between the leaflets of 
the septum pellucidum. CSP is present in all foetuses but by the age of 6 
months the septal leaves fuse in an anterior-posterior manner, forming the 
normal ventricle system. Less than 15% of adults have CSP but it has been 
associated with neurological disorder, including schizophrenia and post-
traumatic stress disorder, due to under development of the limbic system 
(Khanra et al., 2016). This suggests that Cmah-/-mdx mice could have 
additional cognitive abnormalities, due to the presence of CSP and its 























Figure 3.12: Abnormalities in the brain ventricular system of Cmah-/-mdx 
mice. A. Representative T2-w coronal MR images from control C57BL/10 mice 
at 4 months old which delineates the normal formation of the lateral ventricles 
(LV), dorsal third ventricle (D3V), and ventral third ventricle (V3V). B. 
Representative T2-w coronal MR images from Cmah-/-mdx at 4 months old 
showing changes in the structure of the LV and D3V (red arrow). C. The Mouse 
Brain Histology atlas (Paxinos, 2008) showing the correct formation of the LV 
and D3V. D. Representative T2-w axial MR images from control C57BL/10 and 
Cmah-/-mdx mice at 12 months old demonstrating the persistent nature of this 
ventricular abnormality (red arrow indicates CSP). E. Sagittal images where the 
red line indicates approximately where the coronal slice was acquired through 
the mouse brain. 
E. 
1 4 
Interaural 3.82 mm 
Bregma 0.02 mm 
Interaural 3.58 mm 















3.3.2 Cerebellar volume measurements 
The cerebellum is a grey and white matter structure at the posterior end of the 
brain which has a distinctive web-like appearance seen in all three orthogonal 
views (Figure 3.6). The distinctive appearance is the result of the white matter 
cerebellar lobule strips appearing hypointense in a T2-weighted image. The 
cerebellum can be found from Bregma -4.96 mm to Bregma -8.24 mm in the 
histology atlas (Paxinos, 2008). In the axial view, the cerebellum is located 
superior to the 4V, the pons and the medulla. Figure 3.13 shows the 
paraflocculus and flocculus lobules, which with the crus 1 ansiform lobule and 
the simple lobule, make up the lateral cerebellar regions and have thus been 
included in all cerebellar volume measurements.  
 
The volume of the cerebellum was measured from serial coronal T2-weighted 
MR images of control C57BL/10 and mutant mice, covering the same 
anatomical region in the brain and collected between 4 and 18 months old 
(Figure 3.13 and Figure 3.14). Following a repeated measures ANOVA, no 
difference in the cerebellar volume was observed in any genotype between 4 
and 18 months old (Figure 3.15) (F3, 26 =1.11, p=0.38). There was also no 














Figure 3.13: Cerebellar volume measurements.  A.T2-w coronal MR image 
showing the paraflocculus and floculus lobules of the lateral cerebellum (red 
arrows) and the corresponding image from the mouse brain atlas (black arrows) 
B. The mouse brain atlas image corresponding to the coronal section of the 
mouse brain displayed in C. C. Representative coronal T2-w MR images of 
control C57Bl/10, mdx, Cmah-/-mdx, and Cmah-/- mouse cerebellum delineated 
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Figure 3.14: No morphological changes were identified in the cerebellum.  
A. T2-w coronal MR images of control C57BL/10, mdx, Cmah-/-mdx, and Cmah-
/- cerebellum taken from the same mouse between 4 months and 18 months 
old. There were no morphological or volume changes between any genotype in 
the cerebellum. B. Sagittal image where the red line indicates the approximate 








































Figure 3.15: Bar graph displaying the relative cerebellar volume in the 
same mice between 4 and 18 months old. Relative cerebellar volume is 
calculated based on the volume of the cerebellum expressed as a percentage 
of total brain volume (TBV). Overall, there was no difference between relative 
cerebellar volume in any genotype between 4 and 18 months old. Data 
presented as mean ± SEM.  
3.3.3 Hippocampal volume measurements 
The volume of the hippocampus was measured using representative T2-
weighted MR images from C57BL/10, mdx, Cmah-/-mdx, and Cmah-/- mice, 
covering the same anatomical region in the brain and collected between 4 and 
18 months old (Figure 3.16). The whole hippocampus (CA1, CA3, DG and 
general hippocampal areas) was utilised for hippocampal volume estimations 
which were delineated according to the Mouse Brain atlas (Paxinos, 2008).  
Serial T2-weighted MR images were considered in order to accurately measure 
the entire volume of the hippocampus (Figure 3.7). Following a repeated 
measures ANOVA, there was a significant interaction between age and 
genotype on ventricle volume (F3, 26=3.45, p<0.05). 
The hippocampal volume varied between genotypes and between age groups. 
The hippocampal volume was comparable between control C57BL10 and mdx 
mice at all time points (Figure 3.17) although the hippocampus was slightly 
larger in mdx mice at 4 months old. The hippocampus was largest in Cmah-/-
121 
 
mdx mice at 12 months old. The hippocampal volume was reduced in the 
Cmah-/- mice between 4 and 12 months old compared to both Cmah-/-mdx 
mice and control C57BL/10 mice. However by 18 months old all mice had 



















Figure 3.16: No morphological changes detected in the hippocampus. 
(Red arrow delineates hippocampus on first panel of images). A. T2-w coronal 
MR images of control C57BL/10, mdx, Cmah-/-mdx, and Cmah-/- hippocampus 
taken from the same mouse between 4 months and 18 months old. There were 
no morphological changes, but volume fluctuated in DMD mouse models 
between 4 and 18 months old. B. Sagittal image where the red line indicates the 

















































Figure 3.17: Hippocampal volume measurements. A. Images taken from the 
Mouse Brain atlas (Paxinos, 2008) delineating the hippocampus with 
corresponding interaural and bregma points for accurate depiction of structures. 
B. Representative coronal MR image where filled ROI corresponds to the 
hippocampus. C. Representative coronal T2-w MR images of control C57BL/10, 
mdx, Cmah-/-md, and Cmah-/- mouse hippocampus delineated in red following 
ROI analysis on ImageJ. D. Bar graph displaying the relative hippocampal 
volume between 4 and 18 months old taken from the same mice. The relative 
hippocampal volume was calculated based on the volume of the hippocampus 
expressed as a percent of total brain volume. There was no significant 
difference between relative hippocampal volume in any genotype by 18 months 
old, although the hippocampal volume appeared to vary across the time points 
investigated. Data presented as mean ± SEM, *p<0.05, **p<0.01 vs control 
C57BL/10 mice, < vs Cmah-/-mdx mice. 
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3.3.4 Heterozygous Imaging  
In order to determine if the changes in TBV and ventricular volume were due to 
the loss of the Cmah gene, a heterozygous mouse was scanned at 4 months 
old. Heterozygous and homozygous mice, for a particular gene, can show 
differences in phenotypes, therefore we sought to determine if the homozygous 
deletion of the Cmah gene was responsible for the changes we observed in 
ventricular volume.  
 There was a slight reduction in the Cmah+/- lateral ventricular volume, but 
overall the relative total ventricular volume was comparable to that of control 
C57BL/10 mice rather than the Cmah-/- mice (p>0.05) (Figure 3.18). The TBV 
of the Cmah+/- mouse was slightly increased compared to that of the control 
C57BL/10 mice TBV, but it was slightly smaller in volume compared to the 
Cmah-/- mice, suggesting that it is the homozygous loss of the Cmah gene 
responsible for the increase in TBV and reduction in ventricular volume (p>0.05) 


















Figure 3.18: Volume measurements from a Cmah+/- mouse brain. A. 
Representative coronal T2-w MR images of control C57BL/10, Cmah-/-, and 
Cmah+/- mice at 4 months old. A slight reduction in ventricle volume was 
observed in the Cmah+/- mice compared to control C57BL/10 mice, but it was 
not as severe as in Cmah-/- mice (red arrows). B. Bar graph displaying total 
brain volume (TBV) comparison between Cmah+/- mouse, Cmah-/- mice, and 
control C57BL/10 mice. C. Bar graph displaying relative ventricle volume at 4 
months old. Interestingly Cmah+/- mouse displayed a comparative ventricular 
volume to control C57BL/10 mice. LV =lateral ventricles, 3V =third ventricle, 
D3V= dorsal third ventricle and 4V= fourth ventricle. D. Sagittal image where 
the red line indicates the approximate slice corresponding to the coronal 
images. (n=8 for control C57BL/10 and Cmah-/- mice, and n=1 for Cmah+/- 
mice).  
 






3.4 Impact of muscle hypertrophy on skeletal development 
3.4.1 Alteration of head shape  
DMD is characterised by muscle hypertrophy and muscle weakness, which in 
turn can have subsequent effects on skeletal growth and development, such as 
facial and dental morphology changes (Egli et al., 2017). It has previously been 
demonstrated that the average temporal muscle thickness was significantly 
increased in DMD patients when compared to aged matched controls (Straathof 
et al., 2014). In addition a rounder shape of the head compared to more ovoid 
shaped in healthy controls was also observed. It has been implied that such 
skeletal changes in the oral-facial region may result in a decreased bite force 
(Straathof et al., 2014). Interestingly, the skull and overall head shape of DMD 
mouse models differ from that of control C57BL/10 mice and Cmah-/- mice, as 
indicated by temporal muscle hypertrophy observed qualitatively (Figure 3.19). 
There appeared to be changes in the head circumference with the DMD mice 
showing a larger, slightly rounder head shape. Temporalis muscles were wider 
in DMD mice between 6 and 12 months old (Figure 3.20), following a repeated 
measures ANOVA there was a significant interaction between age and 











Figure 3.19: Representative T
2
-weighted coronal images showing changes in head shape of DMD mouse models. Hypertrophy of 









Figure 3.20: Quantification of temporal muscle thickness longitudinally in 
the same DMD mice. A. Average thickness of left and right temporal muscles 
in control C57BL/10, mdx, Cmah-/-mdx, and Cmah-/- mice at 12 months old. 
There is bilateral temporal muscle hypertrophy in DMD mice at similar levels in 
both models. B. Correlation between temporal muscle thickness (averaged 
values for left and right) and age in control C57Bl/10, mdx, Cmah-/-mdx, and 
Cmah-/- mice (n=8 mice per genotype at each time point). C. Representative T2-
w coronal MR image where yellow line represents the measurements taken for 
temporal muscle thickness. The widest part of the temporalis muscle from the 
approximately the same slice was measured in each mouse at corresponding 
time points. D. Representative T2-w coronal image demonstrated increased 
amount of fat in head muscles of mice at 18 months old which hindered correct 
measurements of temporal muscle thickness and this time point was excluded 
from the analysis. Data presented as mean ± SEM, **p<0.01 vs control 











Changes in cranial head shape, as previously reported by MRI analysis, and as 
seen in DMD boys was further investigated using X-ray analysis. Mechanical 
forces exerted by skeletal muscles can influence bone structure and, therefore, 
secondary effects of muscle weakness or hypertrophy could lead to differences 
in bone development, particularly the development of the skull. It has been 
suggested that reduced bite force is related to skeletal changes in the oral-facial 
region (Egli et al., 2017). Dental malocclusion in DMD has been reported as the 
result of imbalance of muscle strength along with changes in jaw bone 
development (Straathof et al., 2014). Additionally, a larger skull may allow for 
further expansion of the brain, given that the mouse TBV increases with 
increasing age. There is a dynamic interaction between the developing brain 
and skull growth in humans, with 25 to 27% increase in whole brain and 
intracranial volume between early childhood and adolescence (Reiss et al., 
1996; Courchesne et al., 2000). 
 
In DMD mice, particularly the Cmah-/-mdx mice, there was widening of the 
squamosal bones (Figure 3.21). This widening may allow for further expansion 
of the brain and could account for the larger brain volume observed in these 
models (Figure 3.3). In addition to the changes in skull shape, further skeletal 
abnormalities were found associated with spinal development. By the age of 18 
months old DMD mice had developed severe thoracolumbar kyphosis and 
scoliosis (Figure 3.22 and Figure 3.23). 
 
It has also previously been reported that the Cmah-/-mdx mice have a 
significantly reduced lifespan compared to both control C57BL/10 and mdx 
mice, suggesting that they were a better mouse model for DMD 
(Chandrasekharan et al., 2010) but in this study all eight Cmah-/-mdx mice 
survived to the 18 months old time point and it was the mdx mice which 
struggled to survive due to the increased susceptibility of spontaneous 
rhabdomyosarcoma causing severe spinal deformities (Figure 3.23) 










Figure 3.21: Skull measurements. A. Representative skeletal prepared skulls 
from mice aged 4 months old (n=2 mice per genotype) showing changes in the 
skulls of DMD mice (mdx and Cmah-/-mdx) particularly widening of the 
squamosal bones. Scale bar= 5 mm. B. Representative radiographs of the 
mouse skull aged 18 months old (n=4 mice per genotype). Yellow arrow 
represents widening of the squamosal bones. C. Labelled radiograph of mouse 


























Figure 3.22: Kyphosis index (KI) in mice calculated from radiographs of 
anesthetised mice positioned in right lateral recumbency. Line AB is the 
length of a line drawn from the posterior edge of C7 to the posterior edge of L6, 
usually where it contacts the wing of the ilium (which is more consistently 
identifiable than the sacral border). Line CD is the distance from line AB to the 
dorsal border of the vertebral body farthest from that line. Increase in line CD 
indicates an increase in kyphosis. KI = AB/CD. A. Bar graph displaying the KI in 
mice aged 18 months old. DMD mice had significant kyphosis compared to 
control C57BL/10 mice. Data presented as mean ± SEM, *p<0.05 compared to 
control C57BL/10 mice B. Example radiographs from mice aged 18 months old 
(n=4 mice per genotype). Scale bar= 5 mm.   






















Figure 3.23: Examples of mouse whole body radiographs at 18 months old. A. DMD mice exhibit scoliosis (red arrows) which is not 
present in control C57BL/10 or Cmah-/- mice (n=4 mice/ genotype). B. Radiograph of an mdx mouse at 18 months showing a large 
spontaneous rhabdomyosarcoma leading to excessive spinal deformities observed in 3/8 mdx mice. Scale bar= 5 mm in part A.  






3.4.2 Changes in mouse body weights  
Prior to MRI scanning each mouse was weighed and their body weights 
recorded. A repeated measures ANOVA revealed that there was a significant 
interaction between age and genotype on body weight (F3, 27=10.62, p<0.01). At 
4 months old all mice had a similar body weight of approximately 30 g 
regardless of genotype (Figure 3.24). Body weight steadily increased in all 
genotypes between 4 and 6 months old with an average body weight of 36 g 
recorded. However, by the time the mice reach 12 months old the mdx mice 
weighed considerably less than the other genotypes (Figure 3.24). At 12 
months old mdx mice had an average body weight of 37 g whereas control 
C57BL/10, Cmah-/-mdx, and Cmah-/- mice body weights averaged between 41-
43 g. Additionally at 18 months old both DMD mouse models weighed 
substantially less than aged matched control C57BL/10 and Cmah-/- mice. At 
18 months old mdx mice averaged a body weight of 36 g and Cmah-/-mdx mice 
weighed on average 41 g (Figure 3.24). Whereas at 18 months old the control 
C57BL/10 mice weighed 48 g and the Cmah-/- mice weighed 52 g. Interestingly, 
it has previously been reported that mice lacking dystrophin often weigh more 
than age matched controls due to muscular pseudohypertrophy at young ages. 
This study has demonstrated that old DMD mice begin to lose weight 
particularly from 12 months onwards when disease symptoms are becoming 
increasingly evident in these models. The weight loss may be as a result of 
increasing spinal deformities causing restricted movement (Figure 3.22 and 
Figure 3.23). 
 
These findings are particularly important for studies of age related changes and 
extra consideration needs to be accounted for when using old mice for long-
term experiments. For example, issues arise when MRI scanning a mouse as 
the scanner is built to optimally house a mouse weighing ~35 g, therefore 
positioning the mouse correctly in the isocentre of the magnet takes 
considerably longer. This means the mice are exposed to a higher amount of 







Figure 3.24: Bar graph showing average body weights of the same mice 
used for the longitudinal MR imaging study. At 4 months old all mice had a 
comparable body weight. Between 12-18 months DMD mice begun to lose 
weight, whereas control C57BL/10 and Cmah-/- mice gained weight. Data 
presented as mean ± SEM, *p<0.05 compared to control C57BL/10 mice (n=8 













3.4 Voxel-based morphometry validation  
Voxel-based morphometry (VBM) describes the automated process of 
analysing morphological differences between images of brains by performing 
voxel-wise statistics comparing groups of animals.  Images are registered into 
the same stereotactic space and usually segmented into grey matter (GM), 
white matter (WM) and CSF. VBM has wide spread applications in human 
imaging, forming the basis for detection of changes in brain morphometry, but 
has rarely been applied to mouse brain imaging. To the best of our knowledge 
Voxel-based morphometry (VBM) has not been applied in the mdx brain, 
therefore we applied the VBM approach to our previously acquired MRI data 
sets to determine if VBM was a useful tool for detecting changes in grey matter 
(GM) volume.  
 
VBM investigates focal differences in brain morphology. Traditional methods for 
morphometry analysis are calculated by drawing ROIs to determine the TBV or 
the volume of its sub regions on acquired MR images and calculating the 
volume enclosed. However, this method is time consuming and can only 
provide information on volume measurements from larger areas, thus smaller 
differences in volume can be overlooked. VBM registers all brains to a relevant 
template, which helps to eliminate the large differences in brain anatomy among 
subjects. The brain images are then smoothed such that each voxel represents 
the average of itself and its neighbours. Ultimately, this allows the image 















The steps involved in VBM as illustrated in Figure 3.25 and discussed in more 
detail below. 
 
Figure 3.25: Steps involved in voxel based morphometry (VBM). Blue box 
highlights unified segmentation. 
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Following acquisition of images voxel-wise statistics need to be calculated. 
Images are first registered into the same stereotactic space and then 
segmented to give tissue probability maps provided by SPMMouse 
(http://www.spmmouse.org/). 
Affine registration refers to a global geometric transformation applied identically 
to each part of the image which preserves parallel lines. Non-linear registration 
provides a finer match between images by allowing local transformations that 
adjust different parts of the image in different ways.   
 
Before images were processed in statistical parametric mapping software 
version 12 (SPM12) (Wellcome Department of Clinical Neurology, 
London; http://www.fil.ion.ucl.ac.uk), the skull needed to be removed, leaving a 
mask of the brain and this was performed manually in ImageJ (Figure 3.26).  
3.4.3 Affine registration  
The SPMMouse package was used as a reference providing tissue probability 
maps for main tissue types. SPMMouse is a plug-in package for SPM created 
by calculating the distribution of affine parameters from a large number of ex-
vivo mouse scans. Utilization of this package has previously been shown to 
improve the quality of affine registration (Sawiak et al., 2009).  
 
 
Figure 3.26: Representative images depicting the pre-processing steps for 
voxel based morphometry (VBM) carried out in ImageJ and statistical 




3.4.4 Non-linear registration and segmentation 
VBM normally considers the brain to consist of 4 classes including GM, WM, 
CSF, and ‘everything else’. SPM models each voxel as a weighted sum of each 
tissue type based on a mixture of (typically two) Gaussian distributions. This 
helps deal with partial volume effects which confound the segmentation 
process. The SPMMouse interface allows templates to be created with 
smoothing parameters, commensurate with the scale differences between 
human and mouse brains so that these more advanced algorithms can be used 
readily with the mouse brain. 
3.4.5 Image smoothing and modulation 
If parameters encoding morphological difference are considered as a signal that 
can be obtained amongst the noise of a random field, then the matched filter 
theorem suggests the optimal spatial smoothing kernel has the same scale as 
the signal to be found (Sawiak et al., 2013). In addition, smoothing confers 
benefits on the normality of the statistics and reduces the impact of 
misregistration between images. According to standard methodologies a spatial 
smoothing was applied to all images (Sawiak et al., 2013). 
3.4.6 Statistics  
Following pre-processing, structural measures were modelled in a general 
linear model (GLM) to test hypotheses. An appropriate model for our mutant 
mouse study was a two-sample Student’s t-test between the mutant (mdx, 
Cmah-/-mdx and Cmah-/-) and the control C57BL/10. The images of this 
longitudinal brain study were acquired in-vivo with a relatively short scan time 
per mouse (15 minutes for a T2-weighted image) and as such the image quality 
was lower than the ex-vivo SPMMouse brain template used for the 
segmentations steps. With such a large number of tests, correction for multiple 
comparisons was necessary and we used the false-discovery rate (FDR) 







3.4.7 Problems with VBM 
Problems arose whilst performing the VBM analysis due to the misalignment of 
images, which provided a large amount of false positives either indicating that 
there was a reduction/increase in GM posterior or anterior of the SPMMouse 
GM template (Figure 3.27). The segmented GM volume from our mouse brains 
did not properly align to the GM template provided in the SPMMouse plugin. 
This was because the mice were positioned via a bite bar inside the MRI 
scanner, but given the previously reported spinal deformities (Figure 3.19 and 
Figure 3.22) and larger size of control C57BL/10 and Cmah-/- (from 12 months 
onwards), the mice did not always lie in the same position whilst fixed by the 
bite bar.  
 
In order to circumvent this issue, prior to segmentation, images were realigned 
individually to the GM template using the SPM12 software package and images 
reoriented using the roll, pitch, and yaw functions (Figure 3.27 and Figure 3.28). 
Once all mouse brains had been correctly angulated the usual VBM approach 
was followed (Figure 3.25).  
 
 
Figure 3.27: SPMMouse tissue probability map for mouse brain grey 
matter (GM) (Sawiak et al., 2013). A. Coronal GM, B. sagittal GM, and C. axial 
GM. Blue cross represents the same point in the mouse brain across all 
orthogonal planes. This SPMMouse template was used to separate the GM 








Figure 3.28: Problems with voxel based morphometry (VBM).  A. 
Photographs of mice showing overt spinal deformities in DMD mice. B. 
Representative T2-w sagittal MR images of mouse heads. Note the downward 
angulation of the DMD mouse model heads compared to the more horizontal 
positioning of the control C57BL/10 and Cmah-/- mice. C. Example screenshot 
of SPM12 displaying the orientation of control C57BL/10 mouse brains at 18 












3.4.8 Maximum intensity projections 
Maximum intensity projections were created using SPM12 and SPMMouse to 
demonstrate changes identified following statistical analysis (two tailed 
student’s t-test for control C57BL/10 vs mutant mouse brains) (Figure 3.29). 
 
 
Figure 3.29: Presentation of the voxel based morphometry (VBM) results 
produced by the SPM software with the SPMMouse plugin. An example of a 
maximum-intensity projection (MIP) of the results for grey matter (GM) of control 
C57BL/10 vs mdx mice at 18 months old is shown in sagittal, coronal, and axial 
planes and the corresponding design matrix for the study. The grey overlay 
indicated areas of changes detected between the two genotypes.  
3.4.9 VBM in control C57BL/10 vs mutant mouse brains 
3.4.9.1 VBM in control vs mdx mice brains  
VBM registered all mice into the same stereotaxic space accounting for 
differences in overall brain size and shape and then detected morphological 
changes regardless of changes in the overall TBV. VBM was first applied to the 
mdx mouse brain between 6 and 18 months old. At 6 months old there was little 
difference between the GM of control C57BL/10 and mdx mice, with changes 
observed mainly around the lateral ventricles and hippocampus, as well as the 
vermal cerebellum (Figure 3.30).  
 
Interestingly, by 12 months old the number and extent of differences observed 
between control C57BL/10 and mdx mouse brains had drastically increased. 
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The control C57BL/10 mouse brain was larger compared to the mdx in regions 
of the caudate putamen (striatum), the prefrontal cortex, and the olfactory bulbs. 
On the other hand, the mdx mouse was larger than the control C57BL/10 
mouse primarily in the cingulate cortex, primary somatosensory cortex, and 
cortical amygdaloid nucleus (Figure 3.31). 
 
Furthermore, at 18 months old the control C57BL/10 and mdx mouse brains 
displayed the largest number of differences detected by VBM. The control 
C57BL/10 mice were larger in numerous regions including the thalamus, the 
inferior colliculus, the somatosensory cortex, and the hippocampus (Figure 
3.32). In contrast, the mdx mouse brain was larger than the control C57BL/10 in 
various regions, mainly the cortex (lower layers), basal lateral amygdala 
nucleus, and the cingulate cortex.  
 
This data suggests that there are progressive changes occurring in the mdx 
mouse brain structures with age. Interestingly, the brain structures showing the 
highest level of changes between 6 and 18 months old are those known to 































Figure 3.30: Presentation of the voxel based morphometry (VBM) results 
produced by the SPM12 software with the SPMMouse plugin for grey 
matter (GM) of C57BL/10 vs mdx at 6 months old. The GM average shown is 
for the control C57BL/10 mice and a coloured overlay showing the location of 
significant clusters. Red clusters indicate where the control C57BL/10 mouse 
brain was larger than the mdx brain and blue indicates where the mdx brain is 
larger than the control C57BL/10 brain (in terms of GM volume). Colour intensity 
on the scale bar refers to the level of significance with a lighter colour indicating 
a higher level of significance (p<0.05, student’s t-test). A. Coronal images 
numbered 1-5 with a corresponding sagittal image detailing the image plane 
where the coronal image lies. B. Sagittal representation of VBM findings. C. 
Two coronal grey matter slices detailing VBM findings. Grey matter average is 
from 8 control C57BL/10 mice. Few changes were detected using VBM in the 
mdx mouse brain at 6 months old. The asymmetry of findings could be as a 
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Figure 3.31: Presentation of the voxel based morphometry (VBM) results 
produced by the SPM12 software with the SPMMouse plugin for grey 
matter (GM) of C57BL/10 vs mdx at 12 months old. The GM average shown 
is for the control C57BL/10 mice and a coloured overlay showing the location of 
significant clusters. Red clusters indicate where the control C57BL/10 mouse 
brain is larger than the mdx brain and blue indicates where the mdx brain is 
larger than the control C57BL/10 brain (in terms of GM volume). Colour intensity 
on the scale bar refers to the level of significance, with a lighter colour indicating 
a higher level of significance (p<0.05, student’s t-test). A. Coronal images 
numbered 1-5 with a corresponding sagittal image detailing the image plane 
where the coronal image lies. B. Sagittal representation of VBM findings. C. 
Two coronal grey matter slices detailing VBM findings. Grey matter average is 
from 7 control C57BL/10 mice. Many more changes were detectable by VBM at 
12 months old in the mdx mouse brain. Increased GM volume was detected in 
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Figure 3.32: Presentation of the voxel based morphometry (VBM) results 
produced by the SPM software with the SPMMouse plugin for grey matter 
(GM) of C57BL/10 vs mdx mice at 18 months old. The GM average shown is 
for the control C57BL/10 mice and a coloured overlay showing the location of 
significant clusters. Red clusters indicate where the control C57BL/10 mouse 
brain is larger than the mdx brain and blue indicates where the mdx brain is 
larger than the control C57BL/10 brain (in terms of GM volume). Colour intensity 
on the scale bar refers to the level of significance with a lighter colour indicating 
a higher level of significance (p<0.05, student’s t-test). A. Coronal images 
numbered 1-5 with a corresponding sagittal image detailing the image plane 
where the coronal image lies. B. Sagittal representation of VBM findings. C. 
Two coronal grey matter slices detailing VBM findings. Grey matter average is 
from 7 control C57BL/10 mice. The largest amount of changes were detected at 
18 months old in the mdx mouse brain with the control C57BL/10 mice having a 
higher GM volume in the thalamus, the inferior colliculus, the somatosensory 
cortex, and the hippocampus. 
3.4.9.2 VBM in control vs Cmah-/-mdx mice brains  
VBM was next applied to the control C57BL/10 vs Cmah-/-mdx mice brains 
between 6 and 12 months old. Similarly there was an increase in the number of 
changes detected using VBM in the older Cmah-/-mdx mice compared to the 
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the vermal cerebellum, the caudate putamen (striatum), the primary and 
secondary motor cortices, and the primary somatosensory cortex, all of where 
the control C57BL/10 mice were had a larger GM volume than the Cmah-/-mdx 
mice (Figure 3.33). Remarkably at 12 months old there were more changes in 
the cerebellum, hippocampus and the lateral septal nucleus surrounding the 
lateral ventricles (Figure 3.34). Again the Cmah-/-mdx mice showed more GM in 














Figure 3.33: Presentation of the voxel based morphometry (VBM) results 
produced by the SPM software with the SPMMouse plugin for grey matter 
(GM) of C57BL/10 vs Cmah-/-mdx mice at 6 months old. The GM average 
shown is for the control C57BL/10 mice and a coloured overlay showing the 
location of significant clusters. Red clusters indicate where the control 
C57BL/10 mouse brain is larger than the Cmah-/-mdx brain and blue indicates 
where the Cmah-/-mdx brain is larger than the control C57BL/10 brain (in terms 
of GM volume). Colour intensity on the scale bar refers to the level of 
significance with a lighter colour indicating a higher level of significance 
(p<0.05, student’s t-test). A. Coronal images numbered 1-5 with a 
corresponding sagittal image detailing the image plane where the coronal image 
lies. B. Sagittal representation of VBM findings. C. Two coronal grey matter 
slices detailing VBM findings. Grey matter average is from 8 control mice. Few 
changes were detected using VBM in the Cmah-/-mdx mouse brain at 6 months 
old. The asymmetry of findings could be as a consequence of incorrect 
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Figure 3.34: Presentation of the voxel based morphometry (VBM) results 
produced by the SPM software with the SPMMouse plugin for grey matter 
(GM) of C57BL/10 vs Cmah-/-mdx mice at 12 months old. The GM average 
shown is for the control C57BL/10 mice and a coloured overlay showing the 
location of significant clusters. Red clusters indicate where the control 
C57BL/10 mouse brain is larger than the Cmah-/-mdx brain and blue indicates 
where the Cmah-/-mdx brain is larger than the control C57BL/10 brain (in terms 
of GM volume). Colour intensity on the scale bar refers to the level of 
significance with a lighter colour indicating a higher level of significance. 
(p<0.05, student’s t-test). A. Coronal images numbered 1-5 with a 
corresponding sagittal image detailing the image plane where the coronal image 
lies. B. Sagittal representation of VBM findings. C. Two coronal grey matter 
slices detailing VBM findings. Grey matter average is from 8 control mice. Many 
more changes were detectable by VBM at 12 months old in the Cmah-/-mdx 
mouse brain. Increased GM volume was detected in the Control C57BL/10 mice 
compared to the Cmah-/-mdx mice at 12 months old in the cerebellum, 
hippocampus and the lateral septal nucleus surrounding the lateral ventricles 
 
3.4.9.3 VBM in control C57BL/10 vs Cmah-/- mice brains  
VBM was applied to Cmah-/- mice brains between 6 and 18 months old. In the 
Cmah-/- mouse brains, the greatest differences in GM were detected with VBM 
compared to any other genotype. The Cmah-/- mouse brain had larger GM 
volume than the control C57BL/10 mouse brain in numerous brain regions 
including the cerebellum, the hippocampus, and the somatosensory cortex 
(Figure 3.35). The largest differences at 6 months old detected by VBM were 
changes in the GM surrounding the third ventricle (including the dorsal third 
B. 
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ventricles) and the lateral ventricles, which is not surprising given the 
aforementioned change in ventricle volume detected by T2-weighted imaging 
(Figure 3.9).The only region that was larger in GM volume in the control 
C57BL/10 mice at 6 months old was the olfactory bulbs (Figure 3.35). 
 
At 12 months old the control C57BL/10 mice had numerous brain regions where 
their volume was larger than that of the Cmah-/- mice, including the 
somatosensory cortex (primary and secondary), cingulate cortex, and the 
cerebellum (simple lobule). Again, the Cmah-/- mice had larger GM brain 
regions compared to the control C57BL/10 mice surrounding the lateral 
ventricles in particular (Figure 3.7).  
 
By 18 months old the control C57BL/10 mice had the highest number of regions 
where the brain regional GM volume was larger than the Cmah-/- mice. These 
regions included the somatosensory cortex and the caudate putamen (Figure 
3.37). Given that the total brain volume of the Cmah-/- mice decreased with 
increasing age (Figure 3.3) it was interesting to also detect reduced GM volume 






















Figure 3.35: Presentation of the voxel based morphometry (VBM) results 
produced by the SPM software with the SPMMouse plugin for grey matter 
(GM) of C57BL/10 vs Cmah-/- mice at 6 months old. The GM average shown 
is for the control C57BL/10 mice and a coloured overlay showing the location of 
significant clusters. Red clusters indicate where the control C57BL/10 mouse 
brain is larger than the Cmah-/- brain and blue indicates where the Cmah-/- 
brain is larger than the control C57BL/10 brain (in terms of GM volume). Colour 
intensity on the scale bar refers to the level of significance with a lighter colour 
indicating a higher level of significance. (p<0.05, students t-test). A. Coronal 
images numbered 1-5 with a corresponding sagittal image detailing the image 
plane where the coronal image lies. B. Sagittal representation of VBM findings. 
C. Two coronal grey matter slices detailing VBM findings. Grey matter average 
is from 8 control mice. The largest amount of changes detected by VBM were 
found in the Cmah-/- mouse brain. At 4 months old the Cmah-/- mice had larger 
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Figure 3.36: Presentation of the voxel based morphometry (VBM) results 
produced by the SPM software with the SPMMouse plugin for grey matter 
(GM) of C57BL/10 vs Cmah-/- mice at 12 months old. The GM average 
shown is for the control C57BL/10 mice and a coloured overlay showing the 
location of significant clusters. Red clusters indicate where the control 
C57BL/10 mouse brain is larger the than Cmah-/- brain and blue indicates 
where the Cmah-/- brain is larger than the control C57BL/10 brain (in terms of 
GM volume). Colour intensity on the scale bar refers to the level of significance 
with a lighter colour indicating a higher level of significance. (p<0.05, students t-
test). A. Coronal images numbered 1-5 with a corresponding sagittal image 
detailing the image plane where the coronal image lies. B. Sagittal 
representation of VBM findings. C. Two coronal grey matter slices detailing 
VBM findings. Grey matter average is from 8 control mice. At 6 months old the 
Cmah-/- mice continued to have a larger GM volume in areas surrounding the 
brain ventrcicle but additionally control C57BL/10 mice had an increased GM 
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Figure 3.37: Presentation of the voxel based morphometry (VBM) results 
produced by the SPM software with the SPMMouse plugin for grey matter 
(GM) of C57BL/10 vs Cmah-/- mice at 18 months old. The GM average 
shown is for the control C57BL/10 mice and a coloured overlay showing the 
location of significant clusters. Red clusters indicate where the control 
C57BL/10 mouse brain is larger than the Cmah-/- brain and blue indicates 
where the Cmah-/- brain is larger than the control C57BL/10 brain (in terms of 
GM volume). Colour intensity on the scale bar refers to the level of significance 
with a lighter colour indicating a higher level of significance. (p<0.05, students t-
test). A. Coronal images numbered 1-5 with a corresponding sagittal image 
detailing the image plane where the coronal image lies. B. Sagittal 
representation of VBM findings. C. Two coronal grey matter slices detailing 
VBM findings. Grey matter average is from 8 control mice. At 18 months old the 
control C57BL/10 mice had a larger GM volume in many brain regions, which is 
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3.4.10 Grey matter volume comparison 
Cross animal mean GM volume images were generated using the SPMMouse 
template and SPM12 and were compared between the genotypes at 18 months 
old. Figure 3.38 shows that the highest difference in GM was between the 
control C57BL/10 and the Cmah-/- mice. The DMD mouse models display 
changes in GM structure particularly around the lateral ventricles. 
 
 
Figure 3.38: Average grey matter (GM) volume for control C57BL/10, mdx, 
Cmah-/-mdx, and Cmah-/- at 18 months old generated using the 
SPMMouse plugin and SPM 12. (n=8/genotype). The Cmah-/- mice showed 
the largest change in grey matter volume compared to control C57BL/10 mice. 
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MRI provides invaluable information about the brain as a whole, identifying 
many malformations in a non-invasive manner. This was the first study 
investigating longitudinal changes in DMD mouse brains, scanning the same 
mouse at each time point. A major finding of this study was that at all time 
points investigated (4 months, 6 months, 12 months and 18 months old) the 
Cmah-/-mdx mice had a statistically significant increase in their TBV compared 
to all other genotypes. This was an interesting finding as the original 
assumption was that the Cmah-/-mdx double mutant mice would serve to 
exacerbate the mdx brain phenotype, as they have already demonstrated a 
more severe muscle phenotype to that exhibited by mdx mice 
(Chandrasekharan et al., 2010). This assumption may in part be true, given that 
the mdx mouse TBV was significantly larger than that of control C57BL/10 
mouse brain from 12 months onward (Figure 3.3) and this effect of increased 
TBV volume might be enhanced in Cmah-/-mdx mice from 4 months onwards. 
 
A particularly interesting finding of the study was the increase in TBV in control 
C57BL/10 mice, which was not an expected result. We observed significant, 
progressive, whole brain and regional volume increases (brain ventricle system) 
in mature control C57BL/10 mice, where the increase began at 4 months old 
and brain growth slowed down from 12 months onward (Figure 3.4). In contrast, 
the human brain grows significantly between birth until our mid-teens, when 
brain growth begins to plateau, followed by a prolonged period of stability in 
brain size before a very slow decline (atrophy) in later life (Giedd et al., 1999; 
Courchesne et al., 2000). In rodents, the closure of the growth plates is long 
delayed, which is opposite to that in humans (Kilborn et al., 2002). The 
synchondroses of the neocranium permits skull enlargement in mice (Lobe et 
al., 2006), especially the basisphenoid, basioccipital, presphenoid and 
supraoccipital bones, up to at least 60 days of age (Vilmann, 1969), but most 
likely even longer. In the mature normal mouse brain, there is no literature 
reporting neurocranial changes. If in fact the mouse neurocranium can expand 
with maturity to accommodate an increase in TBV in control mice (5.29±0.68 % 
between 4 and 18 months old), this could account for the presence of an 
increased ventricle volume with increasing age. Since the mouse skull does not 
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provide a ‘rigid box’ like the human skull does, the brain and brain regions are 
able to expand, and any uncompensated increase in regional tissue volume 
should result in a balanced reduction in CSF and/or other tissue volume, which 
was not observed in this study (Figure 3.10). This finding is important when 
using transgenic mice to model human brain diseases at the macroscopic level; 
the brain and skull growth could be the underlying ontological feature which 
should be considered.  
 
It has been previously reported that thicker temporal muscles are associated 
with a more ovoid head shape in DMD patients compared to age matched 
controls (Straathof et al., 2014). We also observed a thickening of the temporal 
muscle in our DMD mouse models and a rounder head shape (Figure 3.20). In 
addition, skeletal preparation of the skull and X-rays of the cranium detected a 
shorting of the nasal plate and a widening of the squamosal bones, particularly 
in the Cmah-/-mdx mice, but also in the mdx mice (at 4 months and 18 months 
old respectively).  Taken together, this could suggest that the weaker, 
hypertrophic cranial muscles, including the temporal muscles, influence the 
development of the skull, resulting in a rounder shape. The majority of DMD 
patients in whom this effect has been reported have been taking long-term 
corticosteroids and authors suggested they could have an impact on muscle 
hypertrophy. However, the mice in this study did not receive any corticosteroids 
and hence we hypothesise that this effect is due to the loss of full length 
dystrophin. The skull size is also known to directly correlate with brain volume 
and there was 25-27% increase in whole brain and intracranial volume between 
early childhood and adolescence (Reiss et al., 1996; Courchesne et al., 2000). 
It could therefore be possible that the change in skull shape observed in the 
Cmah-/-mdx and mdx mice could facilitate the further expansion of the brain, 
given the aforementioned change in skull bone fusion between mice and 
humans, and could account for the extensive increased TBV observed in the 
DMD mice.  
In this study we found that brain regions increased in volume, but normalising 
the region to TBV allowed us to better understand their relative trajectories. In 
humans there is a pattern of progressive, maturity-onset, relative grey matter 
(GM) loss, but white matter (WM) and ventricular gain with aging (Giedd et al., 
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1999; Bartzokis et al., 2001). We have demonstrated an increased ventricular 
volume with increasing age in the control C57BL/10 and interestingly also in the 
Cmah-/- mice, which have a more similar glycoprofile to that of humans, and 
suggest a similar aging effect on the brain occurs between these two species. 
The LV appeared to dilate significantly more in the DMD mouse models, relative 
to TBV increases, suggesting that this is a pathological feature associated with 
full-length dystrophin loss. The cerebral ventricle system is a specialised series 
of connected cavities which are filled with CSF and surrounded by 
neuroepithelium (Lowery and Sive, 2009). The adult brain consists of four 
connected ventricles: two LV within the cerebrum, a 3V within the diencephalon, 
and a 4V lying between the cerebellum and pons (Lowery and Sive, 2009). The 
LV are connected to the 3V, which is linked to the 4V via the cerebral aqueduct. 
In turn, the 4V joins to the spinal cord canal and the subarachnoid space that 
envelops the brain. The choroid plexus (CP) consists of epithelial tissue masses 
highly vascularised with fenestrated blood vessels of which there are four within 
the brain, located in each ventricle and in turn produce two thirds of the CSF in 
the brain. The remaining third of CSF is thought to be produced by the surface 
of the ventricles and the lining of the subarachnoid space (Liddelow, 2015). This 
fluid circulates in the ventricular system, subarachnoid spaces, and spinal 
canal, where the plexuses are essential for controlling the homeostasis of its 
composition through regulation of movement of essential ions and molecules 
into, and metabolites out of the CSF (Liddelow, 2015). The blood cerebrospinal 
fluid barrier (BCSFB) is compromised predominately of the choroid plexus (CP) 
with other contributions from the arachnoid and arachnoid villi on the outer 
surface of the brain. Within the CP the basolateral membrane utrophin A and 
colocalises with dystrophin to control structural stability, transmembrane 
signalling, and ion/water homeostasis (Johanson et al., 2011).The loss of full-
length dystrophin in these mice could potentially alter the structural stability of 
the BCSFB and cause abnormalities in osmotic regulation leading to an 
increase in CSF circulating in the ventricle system causing dilation of the lateral 
ventricles (LV).  
Furthermore, the enlargement of brain ventricles has been described for various 
brain disorders with cognitive impairment, including multiple sclerosis (Bakshi et 
al., 2002), Klinefelter syndrome (Itti et al., 2006) and fragile X mental retardation 
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(Reiss et al., 1995). Moreover, several studies have described correlations 
between the degrees of ventricular enlargement and the level of the cognitive 
dysfunction or mental retardation (Reiss et al., 1995). Although obstruction of 
the 4V and/or the cerebral aqueduct has been known to cause ventricular 
expansion (Ishihara et al., 2010) this was not evident on any of the MR images 
acquired for the DMD mice. Enlargement of the ventricular system may also be 
caused by a failure of absorption or an overproduction of CSF, structural or 
functional impairments of cilia, and impaired cell proliferation around ventricles 
(Garton and Piatt, 2004).  
The Cmah-/-mdx mice displayed further potentially pathological abnormalities in 
their ventricular system. A hypoplastic septum was present in 2/8 Cmah-/-mdx 
mice participating in the longitudinal scanning and this effect has also been 
reported in a platelet-derived growth factor C (PDGFC) deficiency mouse 
model, where the study identified abnormalities in the ependymal layer of the 
ventricle system (Fredriksson et al., 2012). The ependymal cells of DMD mice 
were not investigated in this study, but future studies could investigate this to 
determine whether dystrophin is necessary for the development of normal 
cerebral ventricles and neuroependymal integrity. Furthermore, mice 
participating in the in vivo BBB study (chapter five) displayed extreme 
hydrocephalus manifested as an abnormal accumulation of CSF and 
enlargement of the LV. 
The Cmah-/- mice had an enlarged TBV at 4 months old compared to control 
C57BL/10 mice, but surprisingly the TBV decreased with increasing age (Figure 
3.4). This effect was similar to that of humans in terms of brain size and aging 
and it was unusual that given these mice also express Neu5Ac and not Neu5Gc 
like the control C57BL/10 and mdx mice, where the largest amounts of TBV 
increase occurred between 4 -18 months old, it may be that this change in 
sialyation capacity has an influence on brain size. Contrasting with other organs 
that express varying ratios of Neu5Gc and Neu5Ac, depending on the variable 
expression of Cmah, Neu5Gc expression in the brains of all vertebrae is 
extremely low, suggesting that neuronal expression may be detrimental to 
animals (Okerblom and Varki, 2017). Focal atrophy was clearly evident on the 
MR images acquired from 2/8 Cmah-/- mice at 18 months old, where the 
atrophy was not present in the same animal at 12 months old and was 
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additionally observed via VBM analysis. The effect of reduction in brain volume 
in the Cmah-/- mice is most likely a global TBV reduction as these focal areas of 
atrophy were not enough to account for the significant reduction in TBV 
overserved in all 8 Cmah-/- mice investigated in this longitudinal study.  
 
Interestingly, the Cmah-/- mice have previously been reported to show other 
signs of ‘normal human aging’ not exhibited by wild type mice, including age 
related hearing loss. By 9 months of age, Cmah-/- mice displayed reduced  
hearing sensitivities across all frequencies,  increased outer hair cell 
degeneration throughout the cochlea, and collapse of the outer organ of Corti, 
compared to wild type control mice (Kwon et al., 2015). Since the Cmah-/- mice 
have a more similar glycoprotein to that of humans, it could therefore be 
possible that this effect on brain tissue and on the hearing are two effects seen 
in the Cmah-/- mice as a consequence of Neu5Gc loss, although the 
biochemical mechanisms in this phenotype have not been characterised or 
described. Only a small number of Cmah-/- mice participated in this study and 
diet was not controlled for and this is the first time Cmah-/- mice on a C57BL/10 
background have been investigated utilising MRI. Many additional studies will 
be needed to be pursued in these, and other phenotypic features resulting from 
this human-like genetic defect. 
 
Voxel-based morphometry (VBM) is routinely applied to the human brain to aid 
in the diagnosis of neurological disorders but its application in mouse brain is 
limited. VBM has been successfully applied in various brain disorders including 
mouse models of Huntington’s disease (Sawiak et al., 2009), where it has 
proved instrumental in determining underlying differences in brain morphology.  
 
This is the first study to demonstrate VBM in the DMD mouse brain. We 
identified numerous changes with VBM in the mdx mouse brain where, the 
complexity of these changes increased between 6 and 18 months old. 
Interestingly, the mdx and Cmah-/-mdx mice almost identically demonstrated 
enlargements in GM volume in the lower layers of the cortex. The DMD mice 
also showed reduced GM volume in the cerebellum and hippocampus, regions 
known to be rich in dystrophin, where the decreased in GM volume of these 
regions increased with age. These changes in the GM volume of the 
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hippocampus and cerebellum could be linked to the cognitive dysfunction 
observed in DMD. The increased GM volume in the amygdala may be linked to 
the increased anxiety related behaviour which we observed in older mdx mice 
(see chapter four for details).  
 
The Cmah-/- mice displayed the highest number of changes detectable by 
VBM, which is not surprising given how different their brains appeared during T1 
and T2 weighted imaging (Figure 3.5). The GM was larger in the Cmah-/- mice 
surrounding the LV and 3V, which was not surprising given the huge reduction 
ventricular volume we have previously observed (Figure 3.10). Additionally, 
since the Cmah-/- mice were the only genotype to demonstrate a TBV reduction 
between 4 and 18 months old, the VBM analysis illustrated a reduction in GM 
volume in various brain regions in comparison to the control C57BL/10 mice.  
 
In accordance with studies investigating the brain in patients with DMD we did 
not observe any gross structural abnormalities of regions known to be rich in 
dystrophin (cerebellum, hippocampus, cerebral cortex) (Dubowitz and Crome, 
1969a; Doorenweerd et al., 2014). We did however observe changes in the 
ventricles of DMD mice, particularly increased LV volume in relation to TBV 
which has also been reported in mouse models of autism (Bertram et al., 2016). 
We observed an increased TBV in mdx mice from 12 months old and Cmah-/-
mdx mice at all time points (Figure 3.4). Autism is a heterogeneous disorder 
with multiple behavioural and biological phenotypes and has been strongly 
associated with DMD where a deficiency in dystrophin expression is believed to 
be the key etiological factor of this comorbidity (Hendriksen et al., 2016a). The 
term “dystrophin associated neurodevelopmental syndrome”  was recently 
coined (Ricotti et al., 2016) relating to autism spectrum disorders (ASD)  and 
attention deficit hyperactivity disorder (ADHD). One striking feature of autistic 
patients is an enlarged brain compared to healthy aged matched control 
subjects (Sparks et al., 2002; Courchesne et al., 2003). GM is gradually pruned 
in favour of higher WM density in normal brain development. In ASD changes in 
cortical pruning have been reported such that children with ASD have shown a 
thickened cortex in regions associated with ASD relating to behavioural 
changes and social difficulties (Mensen et al., 2017). Additionally, mouse 
models of ASD have shown changes in TBV, including increased TBV. 
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Although there are reports of decreased TBV the changes in TBV appear to be 
related to the underlying genetic cause (Ellegood et al., 2015).  
 
Overall, this chapter has demonstrated that MRI is useful and sensitive 
technique to monitor changes in the same DMD mouse brains longitudinally. 
We have identified an increase in total brain volume (TBV) in the mdx mouse 
and increased ventricular volume with age. Voxel-based morphometry (VBM) 
identified changes in grey matter (GM) volume, where larger changes in GM 
volume were detected in older mdx mice. The data presented in this chapter 
suggests that morphologically the mdx mouse brain changes with age, and 
therefore this provides the first piece of evidence to suggest that dystrophin-
deficiency leads to progressive brain changes. The increase in ventricular 
volume with age could be used as an outcome measure to monitor treatment 
effect in mdx mice.  
 
We observed various differences between the mdx and Cmah-/-mdx mouse 
brains. The Cmah-/-mdx mice had a larger TBV at all time points, larger total 
ventricular volume at all time points, and a hypoplastic septum (CSP) was 
present in 2/8 Cmah-/-mdx mice. Additionally, in the Cmah-/- mice we observed 
various differences in brain size and morphology, in comparison to both the 
control C57BL/10 and Cmah-/-mdx mice, including: decreased TBV with age, 
focal brain atrophy, and reduced ventricular volume. These findings suggest 
that the loss of the Cmah gene, from mice, has an impact on brain morphology 
and consequently we would not recommend studying the Cmah-/-mdx mouse 














Figure 3.39: Summary of findings, in comparison to control C57BL/10 mice, from longitudinal brain magnetic resonance 
imaging (MRI) investigations. GM= grey matter, TBV= total brain volume. 
Observation mdx Cmah-/-mdx Cmah-/- Cmah+/- 
Increased TBV      
Decreased TBV      
Enlarged ventricles      
Reduced ventricles     
Focal brain atrophy     
Morphological abnormalities      
Thoracolumbar Kyphosis      
Scoliosis      
Temporalis muscle hypertrophy     
Skull size changes      
Hippocampal volume changes     
Cerebellum GM volume reduction with 
age  
    
Hippocampal GM volume reduction with 
age 
    
Increased GM volume in cortex     
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Chapter 4. Monitoring the progression of cognitive dysfunction 
in mouse models for Duchenne muscular dystrophy 
4.1 Introduction 
The dystrophin-deficient mdx mouse has been studied for over twenty years 
and is the most common and best characterised mouse model of DMD (Bulfield 
et al., 1984). The mdx mouse has also been extensively investigated for the 
detection of cognitive dysfunction associated with DMD (Muntoni et al., 1991; 
Vaillend et al., 2004; Grounds et al., 2008; Vaillend and Chaussenot, 2017).  
 
DMD patients often exhibit psychiatric abnormalities including self-depreciation, 
marginalisation, minor depression, signs of insecurity, hypochondria, poor 
adaptation to the environment, and high levels of anxiety (Komoto et al., 1984; 
Fitzpatrick et al., 1986; Zwaigenbaum and Tarnopolsky, 2003; Wu et al., 2005). 
DMD patients display a varying degree of memory impairments, which have 
been attributed to the loss of dystrophin in brain structures involved in cognition, 
including the neocortex and hippocampus (Anderson et al., 2002). A more 
specific comorbid diagnosis of autism was also strongly associated with DMD 
and BMD, with dystrophin and other members of the DGC now being proposed 
as new candidate risk loci for autism spectrum disorder (ASD) (Komoto et al., 
1984; Hinton et al., 2009; Sekiguchi et al., 2009). The phenotypic heterogeneity 
in dystrophinopathies is likely due to individual genetic background differences 
with a variety of mutation profiles linked to differing levels of cognitive 
impairment, either due to the loss of Dp427 or the cumulative loss of shorter 
dystrophin brain isoforms (Dp140 and Dp71), likely resultant from internal 
promotor mutations (Taylor et al., 2010). While approximately one-third of DMD 
patients demonstrate a varying degree of cognitive impairment, there have been 
recent suggestions of a genotype-phenotype relationship with mutations 
affecting C-terminal forms of dystrophin showing higher correlation with 
cognitive dysfunction (Hinton et al., 2007; Hinton et al., 2009). However, there 
still remains no concrete genotype-phenotype relationship (Pagnamenta et al., 
2011) and flaws exist in this theory. One patient with DMD and autism was 
shown to carry a submicroscopic deletion encompassing exons 12–25 of the 
dystrophin transcript, suggesting that the loss of Dp427 is sufficient to induce 
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vulnerability to autism and learning difficulties (Erturk et al., 2010). The mdx 
mouse is therefore a relevant model to study the effect of the loss of Dp427 on 
cognitive abilities.  
 
Brain alterations associated with a lack of Dp427 are predominately located at 
the synaptic level and involve impaired GABAergic function, including the 
excitation/inhibition balance which is also a key mechanism thought to be 
involved in ASD (Zikopoulos and Barbas, 2013). The autism-associated trans-
synaptic neurexin-neuroligin complex interacts with dystroglycan, which has a 
central role in the DGC implying a putative mechanism underlying the alteration 
in social behavioural or communication seen in DMD (Craig and Kang, 2007; 
Südhof, 2008). 
 
Male mdx mice aged between 3-5 months old have shown abnormal behaviour 
and communication on behavioural and bioacoustic measures, validated to 
identify autistic traits in mice (Miranda et al., 2015). In particular when mdx mice 
were confronted with an intruder in their home cage they displayed an 
increased freezing response during physical contacts, only reverting to normal 
exploratory activity upon interruption of social contact. This is suggestive that 
enhanced fear-related responses could contribute to altered social behaviour in 
mdx mice, with such behaviour confirming that executive functions enabling 
adaptation of behaviour to distinct contexts are also affected (Miranda et al., 
2015). Moreover, mdx mice also showed altered ultrasonic communication. In 
particular adult male mice used an abnormal vocal repertoire when exposed to 
anesthetised females showing a reduction in expression of peak and composite 
calls (Miranda et al., 2015). Importantly, studies investigating autism-like 
behaviour in mdx mice reported a lack of stereotypic behaviours often observed 
in mouse models of autism, such as altered patterns of grooming activity or 
repetitive jumping (Silverman et al., 2010).   
 
Previous studies have identified dystrophin expression in the hippocampus 
(CA1 – CA4 fields, but not the DG), cerebral cortex, and cerebellum (Lidov et 
al., 1990; Lidov et al., 1993). The brain stem (with the exception of the facial 
nucleus and trigeminal complex), thalamus, hypothalamus, basal ganglia and 
spinal cord are thought to be devoid of dystrophin (Lidov, 1996). A recent study 
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in mdx mice found emotional defensive behaviours; fear-motivated 
unconditioned and conditioned defensive responses were altered, which was 
linked to the expression of dystrophin in the amygdala (Sekiguchi et al., 2009). 
The amygdala was important for association learning, which is necessary for 
conditioned fear learning. Abnormal GABAergic synaptic activity observed in the 
amygdala was linked to the alteration of fear-motivated unconditioned and 
conditioned defensive response in mdx mice (Sekiguchi et al., 2009). The study 
found attenuation of GABAergic inhibition in the basolateral nucleus of the 
amygdala (BLA) correlated with enhancement of conditioned fear memory, as 
local GABAergic inhibition is one of the crucial factors regulating amygdala 
neuronal circuit activity (Sah et al., 2003). Fear conditioning responses have 
highlighted the importance of efferent projection of the amygdala to the 
periaqueductal grey (PAG) freezing response (Brandao et al., 1999). 
Projections from the CA1 field and subiculum of the central hippocampus to the 
BLA are involved in contextual fear (Maren and Fanselow, 1995). The CA1 field 
and BLA are connected with each other and this interaction is known to be 
important for contextual fear memory, and hippocampal synaptic plasticity 
(Nakao et al., 2004). 
 
Cognitive assessment in mdx mice has utilised both male and female mice and 
focused upon one time point. Studies have shown that a rodent’s biological 
response to stress is affected by gender differences. Chronic stress has been 
shown to have a direct effect on brain plasticity and function with an emphasis 
on morphological changes in the hippocampus, prefrontal cortex, and 
amygdala, characterised by dendritic arborisation. These brain structures, 
known to be dystrophin–rich, are highly interconnected and sensitive to stress 
and gonadal hormones and influence a variety of cognitive abilities (McLaughlin 
et al., 2009). For example, when researching other neurodevelopmental 
disorders the mouse model for Down’s Syndrome (DS), showed gender 
differences in defensive behaviour to predator exposure (Martinez-Cue et al., 
2006). In the case of mdx mice, female mice showed a reduced but significant 
freezing response to a brief restraint with the duration of freezing shorter than 
that of males (Yamamoto et al., 2010). Interestingly female wild type mice did 
not show any freezing response suggesting that the freezing response occurs 
with the loss of dystrophin in both male and female mice, although male mice 
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are more susceptible. Heterozygous females did not show a freezing response 
at all, given that they express near 50% levels of dystrophin this is suggestive 
that this amount is enough to avert the abnormal freezing response induced by 
restraint (Yamamoto et al., 2010).  
 
Previous studies in the mdx mice have also shown deficits in passive avoidance 
learning (Muntoni et al., 1991), impairments in memory consolidation (both 
spatial and non-spatial learning) (Vaillend et al., 2004), and retention deficits at 
long delays in spontaneous alteration and bar pressing tasks (Vaillend et al., 
1995). One major caveat of the cognitive assessment testing in mdx mice is the 
lack of monitoring of potential progressive cognitive defects. Recent studies 
have alluded to worsening cognitive performance with increasing age in DMD 
patients (Suzuki et al., 2017) and there is now an increasing need for a 
behavioural assessment to test cognitive function of mdx mice at different ages. 
Additionally, assessing the cognitive/behavioural profile of male mdx mice at 
both young and old time points will provide a better understanding regarding the 
level of cognitive dysfunction and how this may decline with age.  
 
 
4.1.1 Aims:  
The experiments described in this chapter aim to monitor if the cognitive deficits 
seen in DMD mice are progressive utilising male mice only. Specifically, this 
chapter aims to: 
 Verify if the Barnes maze test and Novel object recognition (NOR) task; 
which measures hippocampal spatial learning and non-spatial 
recognition memory respectively, are sufficiently sensitive to detect a 
cognitive impairment in DMD mice. 
 Monitor behavioural changes in control C57LBL/10 and mutant mice 
between 4 and 12 months old using the Barnes maze test and NOR task.  
 Assess the cognitive profile of mice lacking the Cmah gene. There is 
currently no data regarding the cognitive abilities of Cmah-/-mdx mice 
and studies in the Cmah-/- mice remain ambiguous. 
 
.   
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4.2  Barnes maze testing  
4.2.1 Overview of procedure  
Mice were trained during a four day period to learn the location of the target box 
associated with a target hole and target shape (square, triangle, circle or cross). 
Habituation to the maze was carried out on day one before the acquisition 
phase began (Figure 4.1). The first probe trial measured short-term memory 
(day five), whereas long-term memory was assessed during the second probe 
trial (day twelve). Primary latency to locate the target hole served to measure 
learning during the acquisition phase (day 1-4). During the first probe trial (day 
five) the target box was removed and mice were given 90 seconds to explore 
the maze. Short-term memory was monitored by measuring the time spent in 
the target quadrant, primary latency, and a success score (number of head 
pokes x hole value). Mice received no training between probe trial 1 and probe 
trial 2. During the second probe trial long-term memory was assessed by 
measuring the time spent in the target quadrant, primary latency, and a success 






















Figure 4.1: Overview of Barnes maze test. 
Habituation occurred on day one to familiarise the mouse with the test. Training occurred between days 1-4 where there are four trails 
per day per mouse, with an inter-trial interval of 15 minutes. During training days mice are given 3 minutes to explore the maze and 
locate and enter a target box, under a target hole, associated with a target shape. Primary latency, total latency, primary errors, total 
errors, and search patterns were recorded during training sessions. On day 5 short-term memory was assessed (probe trial 1). The target 
box was removed and the mouse had 90 seconds to explore the maze. Long-term memory was assessed on day 12 (probe trial 2) and 
there was no training between days 5 and 12. The memory probe trails calculate a success score which is the hole value x number of 
nose pokes. A higher success score indicated a good short- or long-term memory in relation to remembering the location of the target 
hole. The percentage of time the mice spent in the quadrants (target, left, right, and opposite) was also recorded. 




















































4.2.2 Primary latency  
During Barnes maze testing, primary latency (the time it takes to find the target 
hole regardless of the time it takes to enter the target hole), was used as the 
primary measure. A repeated measures ANOVA revealed that all mice showed 
significant spatial acquisition (learning) across all four days of testing at 4 
months old (F3,84 = 20.9, p<0.01). On day 4 (the last day of training) the control 
C57BL/10 mice had an average primary latency of 15±3 seconds whereas mdx 
mice had an average primary latency of 52±15 seconds. Although this was 
significantly longer (p<0.05), mdx mice performed similarly to the control 
C57BL/10 mice on the other days of training at 4 months old, for example on 
day 2 the control C57BL/10 mice average primary latency was 37±8 seconds 
and the mdx mice average primary latency was 43±8 seconds. The average 
primary latency was comparable between all genotypes at 4 months old (Figure 
4.2A). Interestingly, the Cmah-/-mdx mice had the lowest recorded primary 
latencies on all four days of training compared to all other genotypes.  
 
A repeated measures ANOVA revealed that all mice showed significant spatial 
acquisition (learning) across all four days of testing at 6 months old (F3,81=25.3, 
p<0.01). However, by the 6 months old time point a significant difference in 
performance on the Barnes maze test was observed between control C57BL/10 
and mdx mice in terms of primary latency measurements. On day 4 of training 
mdx mice took considerably longer to find the target hole compared to control 
mice (40±8 seconds average primary latency for control C57BL/10 mice 
compared to 80±20 seconds for mdx mice) (Figure 4.2B). Again, the Cmah-/-
mdx mice had a performance similar to that of control C57BL/10 mice and 
better than that of Cmah-/- and mdx mice.  
 
A repeated measure ANOVA revealed that all mice showed significant spatial 
acquisition (learning) across all four days of testing at 12 months old 
(F3,84=16.8, p<0.01). At 12 months old the mdx mice showed a severe cognitive 
deficit in the ability to locate the target hole compared to control C57BL/10 mice 
during all four days of training (Figure 4.2C). The 12 months old mdx mice also 
took far longer to locate the target hole than they did at 4 and 6 months old. For 
example on day 4 of training 6 months old mdx mice had an average primary 
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latency of 56±15 seconds and at 12 months old 150±25 seconds (p<0.05) 
compared to control C57BL/10 mice, whose average primary latency at 6 
months old was 15±3 seconds and at 12 months 20±8 seconds. 
 
Mixed measures repeated ANOVA revealed that there was no significant 
interaction between day, genotype and age with respect to average primarily 




















Figure 4.2: Spatial acquisition times for all mice across the four days of training. Primary latency is the time it takes to find the 
target hole regardless of the time that it takes to enter the target hole. A. Average primary latency at 4 months old. B. Average primary 











4.2.3 Total latency  
Total latency is the time it takes for the mouse to enter the target hole 
regardless of the time it took the mouse to locate the target holes. There was a 
significant interaction between day and total latency with all mice demonstrating 
learning of the task by entering the target hole faster each day (mixed measures 
repeated ANOVA, p<0.01).  
 
A repeated measures ANOVA revealed that all mice showed increased learning 
by entering the target hole faster between days 1-4 of training at 4 months old 
(F3,84 = 14.61, p<0.01). At 4 months old the average total latency was 
comparable between all four genotypes (Figure 4.3A) during initial training. 
However, by day 4 of training mdx mice had shown a reduced ability to enter 
the target hole and had an average total latency of 168±30 seconds compared 
to control C57BL/10 mice, who had an average total latency of 86±36 seconds. 
On the whole, mdx mice had the longest average total latency compared to the 
other genotypes during all four days of training at 4 months old. Interestingly the 
lowest average total latency was observed was in the Cmah-/-mdx mice who on 
day 4 of training had an average total latency of 69±16 seconds whereas, 
control C57BL/10 mice had an average total latency of 86±36 seconds, and 
Cmah-/- mice had an average total latency of 87±26 seconds (Figure 4.3A).  
 
A repeated measures ANOVA revealed that all mice showed increased learning 
by entering the target hole faster between days 1-4 of training at 4 months old 
(F3,81 = 12.6, p<0.01). At 6 months old there was a significant difference in the 
performance of all genotypes with all genotypes demonstrating an increase in 
the average total latency to enter the target hole (Figure 4.3B) The mdx mice 
took longer to enter the target hole than they did at 4 months old during the first 
two training days. However, by day 4 of training the mdx mice had a 
comparable average total latency to that of 4 months old, with an average total 
latency of 56±15 seconds and 43±7 seconds respectively. Cmah-/-mdx mice 
displayed a large deficit in average total latency between 4 and 6 months old by 
taking longer to enter the target hole during all four days of training and having 
an average total latency of 70±16 seconds and 122±27 seconds respectively 
(on day 4 of training).  
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A repeated measures ANOVA revealed that all mice showed increased learning 
by entering the target hole faster between days 1-4 of training at 4 months old 
(F3,84 = 23.8, p<0.01). At 12 months old both DMD mouse models had a 
considerably reduced performance than control C57BL/10 mice in terms of 
average total latency during the Barnes maze test. The mdx mice had the 
largest increase in average total latency with a performance of 147±25 seconds 
compared to control C57BL/10 mice at 61±15 seconds on day 4 of training 
(p<0.05) (Figure 4.3C). The average total latency on day 4 of training at 12 
months was more than twice the latency recorded at 6 months old for mdx mice 
(43±7 seconds vs 147±25 seconds, p<0.05). Interestingly, at 12 months old 2/8 
mdx mice exhibited a ‘total freezing response’, whereby they sat in the centre of 
the maze for a total of 3 minutes. Other mdx mice showed a similar freezing 
response, remaining immobile for a minute or more, but eventually began 
searching the maze. This total freezing response, seen only in the mdx mice at 
12 months old, may account for the sudden difference in average total latency 
between 4 and 12 months old. The control C57BL/10 mice showed little change 
in their average total latency (65± 25 seconds at 4 months old and 62±19 
seconds at 12 months old on day 4 of training). Cmah-/-mdx mice also 
demonstrated an increase in average total latency at 12 months old (144±28 
seconds, on day 4 of training), showing a similar time to that of mdx mice. The 
Cmah-/- mice did not differ significantly from the control C57BL/10 mice 
between 4 and 6 months old, showing comparable average total latency times 
(e.g. at 4 months old on day 4 of training control C57BL10 mice had an average 
total latency of 65±25 seconds and Cmah-/- mice had an average total latency 
of 73±13 seconds). However, at 12 months old the Cmah-/- mice had a poor 
performance with a huge increase in their average total latency to 138±19 
seconds (day 4 of training).  
 
Mixed measures repeated ANOVA revealed that there was a significant 
interaction between day, genotype and age with respect to average total latency 





















Figure 4.3: Spatial acquisition times for all mice across the four days of training. Total latency is the time it takes to enter the 
target hole regardless of the time it takes to locate the target hole . A. Average total latency at 4 months old. B. Average total 
latency at 6 months old. C. Average total latency at 12 months old. Data presented as mean ± SEM, *p<0.05 vs control C57BL/10 mice, 







4.2.4 Mean primary errors  
The primary error is the number of nose pokes that the mouse has until it 
reaches the target hole regardless of entering the target hole. At 4 months old 
there was a significant interaction between genotype and day showing that all 
mice made fewer mistakes as they learnt the position of the target hole (mixed 
measures repeated ANOVA, p<0.05) (Figure 4.4A). However, by day 4 of 
training the mdx mice had the largest number of primary errors at 8±2 errors 
compared to control C57BL/10 mice, who made the fewest primary errors of 
3±1 error. Overall all mice, regardless of genotype, made the fewest number of 
errors at 4 months old.  
 
At 6 months old all mice, regardless of genotype, showed a comparable number 
of primary errors (Figure 4.4B). Interestingly, the mdx mice displayed an 
unusually high number of errors on day 3 of training with mean primary errors of 
8±1 error, which was double that of control C57BL/10 mice with a mean primary 
error of 4±0.5 errors (Figure 4.4B). 
 
At 12 months old both DMD mouse models took longer to learn where the target 
hole was located by displaying a high number of errors on day 1 of training 
which were much higher than at 4 and 6 months old (Figure 4.4C). On day 1 of 
training mdx mice had a primary number of errors of 10±1 error compared to 
control C57BL/10 mice that had a primary number of errors of 6±1 error.   
 
Mixed measures repeated ANOVA revealed that there was a significant 
interaction between day, genotype and age with respect to mean primary errors 















Figure 4.4: Mean number of primary errors (locating the target box for the first time) in the Barnes maze test acquisition phase 
are shown for each day of the trial. The performance improved in all genotypes at all time points during the course of training. A. Mean 
primary errors at 4 months old. B. Mean primary errors at 6 months old. C. Mean primary errors at 12 months old. Data presented as 







4.2.5 Mean total errors  
The mean total number of errors is defined as the number of nose pokes the 
mouse makes into any hole before it enters the target hole. At 4 months old 
there was a significant interaction between genotype and day showing that all 
mice made fewer mistakes as they learnt the position of the target hole (mixed 
measures repeated ANOVA, p<0.05) (Figure 4.5A). On day 4 of training the 
mdx mice displayed the highest number of total errors compared to control 
C57BL/10 mice (13±3 errors for mdx mice compared to 9±3 errors for control 
C57BL/10 mice). Surprisingly, at 4 months old the Cmah-/-mdx mice had the 
lowest number of mean total errors out of all four genotypes with 6±3 errors on 
day 4 of training.  
 
At 6 months old all genotypes showed a comparable number of mean total 
errors to that at 4 months old except for day 3 of training (Figure 4.5B). On day 
3 of training the Cmah-/-mdx mice had the fewest mean total errors with 3±0.5 
errors and mdx mice had the largest number of mean total errors with 13±2 
errors compared to control C57BL/10 with 7±1 mean total errors.  
 
At 12 months old both DMD mouse models took longer to learn where the target 
hole was located by displaying a much higher number of errors on day 1 of 
training than at 4 and 6 months old (Figure 4.5C). On day 1 of training mdx mice 
had a total number of errors of 17±2 errors compared to control C57BL/10 mice, 
who had a primary number of errors of 12±2 errors. The mdx mice had a 
comparable number of errors to that of control C57BL/10 mice during training 
days 3 and 4 at 12 months old. The control C57BL/10 mice displayed an 
increased number of errors with increasing age, but the numbers of errors was 
always higher in the mdx mice.  
 
Mixed measures repeated ANOVA revealed that there was no significant 
interaction between day, genotype and age with respect to mean total errors 
made during the Barnes maze test (F18, 249 =0.8, p<0.6). However, there was a 
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significant interaction between genotype and day with respect to mean total 




























Figure 4.5: Mean number of total errors (entry into the escape box) in the Barnes maze test acquisition phase are shown for 
each day of the trial.  The performance improved in all genotypes at all time points during the course of training. A. Mean total errors at 
4 months old. B. Mean total errors at 6 months old. C. Mean total errors at 12 months old. Data presented as mean ± SEM, *p<0.05 vs 






4.2.6 Short and long-term memory assessment  
4.2.6.1Mean latency to target hole 
Probe trails 1 and 2 were carried out to measure short- and long-term memory 
respectively (Figure 4.1). The target box was removed from the target hole and 
mice were given 90 seconds to explore the maze. There was no training 
between days 5 (short-term memory) and day 12 (long-term memory). The mdx 
mice had the longest mean latency to find the target hole for both short- and 
long-term memory between 4 and 12 months old (Figure 4.6). At 4 months old 
there was no significant difference between control and mdx mice with regard to 
short-term memory (F3,28 = 1.9, p=0.1). At 12 months old the short-term memory 
of mdx mice was impaired compared to at 4 months old, when the mean latency 
was recorded as 50±14 seconds and 21±0.5 seconds respectively (p<0.05). 
The long-term memory of mdx mice was also impaired between 4 and 12 
months old with a mean latency of 26±2.5 seconds and 59±13 seconds 
recorded respectively (p<0.05). The control C57BL/10 mice also showed a 
small decline in their short- and long-term memory abilities with a 10 second 
increase in the mean latency to target for both short- and long-term memory 
between 4 and 12 months old. 
 
Surprisingly the Cmah-/-mdx mice had a shorter mean latency to locate the 
target hole for short-term memory between 4 and 6 months old compared to 
control C57BL/10 mice. However, by 12 months old the Cmah-/-mdx mice had a 
substantial increase both in their short- and long-term mean latency to target. 
Interestingly, the Cmah-/- mice exhibited a similar effect at 12 months old with a 














Figure 4.6: Short- and long-term memory retention on the Barnes maze test. Short-term and long-term memory were assessed on 
day five (probe trail 1) and day twelve (probe trial 2) respectively. A single trial was given to each mouse on the Barnes maze test and the 
primary and total latency, to find the target hole, were evaluated. Data are presented as mean ± SEM, *p<0.05 vs control C57BL/10 mice, 







4.2.6.2 Mean number of errors before locating the target hole  
The number of errors, before the mouse located the target hole, was measured 
for short- and long-term memory trials. The mdx mice had the largest mean 
number of errors between 4 and 12 months old, when locating the target hole, 
compared to all other genotypes for both short- and long-term memory. The 
number of errors also increased with increasing age in the mdx mice (Figure 
4.7). In the mdx mice the number of errors declined between 6 and 12 months 
old (for long-term memory assessment, 23±3 errors and 16±2 errors 
respectively) (p>0.05); this may be due to the increased freezing response 
exhibited by mdx mice at 12 months old, resulting in reduced exploration of the 
maze. An increase in the number of errors was seen in the Cmah-/-mdx mice 
between 4 and 12 months old, for both short- and long-term memory. On 
average the Cmah-/- mice made the fewest errors between 4 and 12 months 
old, for both short- and long-term memory (Figure 4.7) during the Barnes maze 
test. 
 
Control C57BL/10 mice showed a slight increase in the number of errors 
between 4 and 12 months old for short-term memory, 3±4 errors and 8±1 error 
respectively. This was not seen for long-term memory, where the number of 
errors decreased between 4 and 12 months old, 10±4 errors and 9±1 error 













Figure 4.7: Bar graph displaying mean number of errors, during short- and long-term memory trails, between 4 and 12 months 
old. The mdx mice had the largest number of errors between 4 and 6 months old for both short- and long-term memory assessment 
during the Barnes maze test. At 12 months old both DMD mouse models displayed increased numbers of errors compared to control 
C57BL/10 and Cmah-/- mice for short- and long-term memory. Data presented as mean ± SEM, *p<0.05 vs control C57BL/10 mice, 











4.2.6.3 Success score  
The success score is calculated by multiplying the hole value by the number of 
nose pokes (Figure 4.1). The highest success score was recorded during the 
short-term memory probe trial for all genotypes (Figure 4.8). The mdx mice had 
the lowest recorded success score for both short- and long-term memory at all 
time points. The success score in the mdx mice decreased between 4 and 12 
months old for both short- and long-term memory. At 4 months old, the mdx 
mice had a short-term memory success score of 99±3 and 83±1 for long-term 
memory (Figure 4.8). Whereas at 12 months old the mdx mice had a shot-term 
memory success score of 75±1.5 and 53±1 for long-term memory (p<0.05). In 
contrast, the control C57BL/10 mice had a success score of 136±3 for short-
term memory and 105±2 for long-term memory. Interestingly the Cmah-/-mdx 
mice had the highest success score for short-term memory between 4 and 6 
months old, higher than that recorded for control C57BL/10 mice (146±4 and 
136±1, respectively) (Figure 4.8). The Cmah-/- mice had slightly lower success 
scores to those of control C57BL/10 mice between 4 and 12 months old (125±2 














Figure 4.8: Success score (hole value multiplied by the number of head pokes) observed during short- and long-term memory 
retention trials. The highest success scores were observed during the short-term memory retention trials across all genotypes on the 
Barnes maze test. The mdx mice had the lowest success score, at all time points, for both short- and long-term memory. Data are 




4.2.6.4 Preference for the target hole  
During the probe trials a preference for the target hole was measured by 
recording the number of nose pokes the mice made into the target and other 
holes (Figure 4.1). At 4 months old during the short-term memory assessment 
the Cmah-/-mdx mice had the highest preference for the target hole, although 
the other genotypes also showed a significant preference for the target hole 
(Figure 4.9). At 4 months old the mdx mice showed the lowest preference for 
the target hole during the long-term memory assessment (Figure 4.9). At 6 
months old control C57BL/10 mice had the largest preference for the target 
hole. Mdx mice showed the lowest number of nose pokes into the target hole 
during both the short- and long-term memory assessment (Figure 4.10). At 12 
months old, again the control C57BL/10 mice showed the highest preference for 
the target hole, mdx and Cmah-/-mdx mice showed a reduced preference for 
the target hole (Figure 4.11). During the long-term memory assessment the mdx 
mice were least active at 12 months old, due to increased anxiety-related 
behaviour and freezing response, and had the fewest number of nose pokes 
















Figure 4.9: Short- and long-term assessment for mean number of nose pokes into the target hole at 4 months old. The mdx mice 12 
displayed the lowest number of target nose pokes during both short- and long- term memory assessment, (n=8 mice per genotype). Data 13 






















































































Figure 4.10: Short- and long-term assessment for mean number of nose pokes into the target hole at 6 months old. The mdx 27 
mice displayed the lowest number of target nose pokes during both short- and long- term memory assessment, (n=8 mice per genotype). 28 


















































































Figure 4.11: Short- and long-term assessment for mean number of nose pokes into the target hole at 12 months old. The mdx 41 
mice displayed the lowest number of target nose pokes during long- term memory assessment, (n=8 mice per genotype). Data presented 42 










































































4.2.7  Search strategy  
During training days 1-4 the search strategy used to locate the target hole was 
recorded for each mouse. A direct strategy was when the mouse moved directly 
to the target hole or adjacent hole before visiting the target hole (≤2 errors). A 
serial search strategy was where the target hole was located by searching holes 
adjacent to one another in a clockwise or counter clockwise direction. A mixed 
search strategy was where the hole searches were separated by crossing 
through the centre of the maze or unorganised searching. 
 
The direct search strategy was employed the most by the control C57BL/10 
mice between 4 and 12 months old (Figure 4.12). The mdx mice utilised the 
direct search strategy the least between 4 and 12 months old and favoured the 
mixed search strategy (Figure 4.12). The serial search strategy was used the 
most at the 12 month old time point across all genotypes. Interestingly at 6 
months old the Cmah-/-mdx mice favoured a direct search strategy (Figure 
4.12). This is also when the Cmah-/-mdx mice had the lowest mean latency to 



















Figure 4.12: Search strategies used during the acquisition phase of the 
Barnes maze test. Each trial was categorised into different search strategies 
(1) direct- moving directly to the target hole or adjacent hole before visiting the 
target hole (≤2 errors); (2) serial- target hole was located by searching holes 
adjacent to one another in a clockwise or counter clockwise direction; (3) mixed- 
hole searches separated by crossing through the centre of the maze or 
unorganized searching. Data are shown as total percentage of trials in which 
each strategy was used. A. Search pattern at 4 months old. B. Search pattern 
at 6 months old and C. Search pattern at 12 months old. At all ages n=8 mice 
per genotype. Overall, younger mice favoured a direct search strategy, whereas 






4.2.7.1 Time spent in target quadrant  
During the short-term memory probe trial the time spent in the target quadrant 
(TQ) was recoded for each mouse between 4 and 12 months old (Figure 4.13). 
The mdx mice spent less time in the TQ as they got older (55±9 seconds at 4 
months old, 36±4 seconds at 6 months old and 32±5 seconds at 12 months 
old). The control C57BL/10 mice spent a similar amount of time in the TQ 
between 4 and 6 months old (46±4 seconds and 41±6 seconds, respectively) 
and an increased amount of time in the TQ at 12 months old (59±6 seconds) 
(Figure 4.13). This was the same for the Cmah-/-mdx mice, who spent 69±4 
seconds in the TQ at 12 months old. The Cmah-/- mice also spent less time in 
the TQ between 4 and 6 months old, however, this was not found to be 
significant until 12 months old (27±7 seconds). 
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Figure 4.13: Bar graph displaying the percentage of time that mice spent in the target quadrant (TQ) during short-term memory 
assessment between 4 and 12 months old. The mdx mice spent considerably less time in the TQ as they got older. Interestingly 
control C57BL/10 mice spent a much longer time in the TQ as they got older. Data presented as mean ± SEM, *p<0.05 (n=8 mice per 










































4.3 Novel object recognition  
4.3.1 Basis for novel object recognition (NOR) task 
Ennaceur and Delacour provided the preliminary development for the basis of 
the NOR task (Ennaceur and Delacour, 1987) (Ennaceur and Delacour, 1988), 
(Ennaceur et al., 2005). The NOR task is based on the natural propensity of 
animals to explore new environments (Ennaceur and Delacour, 1987). In brief, 
mice explore two identical objects (for 3 minutes), before a delay for memory 
consolidation of these objects (where mice are placed back into their home 
cage, in this case for 15 minutes). One of the objects is then replaced by a 
novel object and a familiar object remains. The natural response of animals is to 
then recognise the novel object and thus exhibit a preference for this object, 
depicted by more time spent with the novel object compared to the familiar 
object (in the 3 minute allocated time period) (Figure 4.14). More specifically, 
the task measures visual memory recognition abilities of animals (Ennaceur and 
Delacour, 1987). Cognitively impaired animals will not recognise the novel 
object as novel and thus show no preference for this object (no visual 
recognition memory). The same time points used in Barnes maze testing were 
also employed for the NOR task (4, 6, and 12 months old). 
 
4.3.2 Novel object recognition at 4 months old  
The NOR task was first performed on mice aged 4 months old. During the 
sample phase all mice spent equal amounts of time with the two identical 
objects regardless of genotype (Figure 4.15). Interestingly, overall mdx mice 
spent less time with the objects when compared to the other genotypes who 
showed comparable amounts of time spent with the two identical objects 
(Figure 4.15). During the choice phase of the NOR task the mdx mice showed 
significant preference for the familiar object (11±2 seconds) and spent 
significantly longer exploring the familiar object compared to the novel object 
(6±1 second) (Figure 4.16). 
In contrast the control C57BL/10, Cmah-/-mdx, and Cmah-/- mice all showed a 
preference for the novel object with the Cmah-/- mice showing the highest 
preference for the novel object (15±2 seconds). The D2 ratio, calculated based 
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on the amount of time the mouse spent with the novel and familiar objects 
during the choice phase, showed that control C57BL/10, Cmah-/-mdx, and 
Cmah-/- mice spent considerably longer with the novel object than they did with 
the familiar object (positive D2 ratio), whereas the mdx mice spent significantly 
longer exploring the familiar object (negative D2 ratio) (Figure 4.17). 
Surprisingly the Cmah-/-mdx mice were most active at 4 months old, spending 
the highest amount of time with the objects compared to both control C57BL/10 


















Figure 4.14: A: Summary of the orientation of the objects in the novel object recognition (NOR) task. A. The diagram shows two 
possible sample phases and two possible choice phases. The orientation and choice of objects varied between all four genotypes at all 
three time points. B. The two polystyrene objects used during the test phase. C. Formula for calculating the D2 ratio recorded on the test 
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Figure 4.15: Time spent with objects in the sample phase of the novel 15 
object recognition (NOR) task at 4 months old. Graph shows that in all 16 
genotypes, mice showed no preference for either of the identical objects at 4 17 
















Figure 4.16: Times spent with familiar and novel objects in the choice 34 
phase of the novel object recognition (NOR) task at 4 months old. Control 35 
C57BL/10, Cmah-/-mdx, and Cmah-/- mice showed a preference for the novel 36 
object whereas mdx mice showed a higher preference for the familiar object, 37 
n=8/genotype. Data presented as mean ± SEM, *p<0.05 vs control C57BL/10 38 















































































































Figure 4.17: D2 ratios expressing preference for the novel and familiar 53 
objects in the choice phase of object recognition task at 4 months old. 54 
With the exception of the mdx mice, all mice showed a significant preference for 55 
the novel object at 4 months old, n=8/genotype. Data presented as mean ± 56 
























4.3.3 The novel object recognition task at 6 months old  
The NOR task was also performed on mice aged 6 months old. During the 
sample phase all mice spent equal amounts of time with the two identical 
objects regardless of genotype (Figure 4.18), as was the case at 4 months old. 
Again the mdx mice spent less time with the objects when compared to the 
other genotypes, who showed comparable amounts of time spent with the two 
identical objects (Figure 4.18). The Cmah-/-mdx mice again were the most 
active mice, spending the highest amount of time exploring the identical objects. 
During the choice phase of the NOR task the mdx mice showed a significant 
preference for the familiar object (17±5 seconds) and spent significantly longer 
exploring the familiar object compared to the novel object (7±1.5 seconds) 
(Figure 4.19). In contrast, the control C57BL/10, Cmah-/-mdx, and Cmah-/- 
mice all showed preference for the novel object with the Cmah-/- mice showing 
the highest preference for the novel object (23±3 seconds). The D2 ratio 
showed that control C57BL/10, Cmah-/-mdx, and Cmah-/- mice spent 
considerably longer with the novel object than they did with the familiar object 
(positive D2 ratio), whereas the mdx mice spent significantly longer exploring 
the familiar object (negative D2 ratio) (Figure 4.20). The control C57BL/10 mice 
had the highest D2 ratio, thus showing the best overall object recognition 


















Figure 4.18: Time spent with objects in the sample phase of the novel 
object recognition (NOR) task at 6 months old. Graph shows that in all 
genotypes, mice showed no preference for either of the identical objects at 6 











Figure 4.19: Times spent with familiar and novel objects in the choice 
phase of the novel object recognition (NOR) task at 6 months old. Control 
C57BL/10, Cmah-/-mdx, and Cmah-/- mice showed a preference for the novel 
object whereas mdx mice showed a higher preference for the familiar object, 
















































































































Figure 4.20: D2 ratios expressing preference or no preference for the 
novel and familiar objects in the choice phase of object recognition task 
at 6 months old. With the exception of the mdx mice, all mice showed a 
significant preference for the novel object at 6 months old. Objects were either 
polystyrene sphere or star and varied to avoid condition place preference 

































4.3.4 Novel Object Recognition task at 12 months old  
Finally, the NOR task was performed on mice aged 12 months old. During the 
sample phase all mice spent equal amounts of time with the two identical 
objects regardless of their genotype (Figure 4.21). This was the same effect as 
seen at 4 and 6 months old. Although the Cmah-/-mdx mice spent slightly 
longer with the A1 object than the A2 object, this was not found to be significant 
(p>0.05) (Figure 4.21). Interestingly, the Cmah-/-mdx mice did not display the 
increased activity for exploring the objects like they did at 4 and 6 months old. 
During the choice phase of the NOR task, the mdx mice showed a significant 
preference for the familiar object (9±2 seconds) (Figure 4.22). This effect was 
the same as that seen at 4 and 6 months old, but at 12 months old the mdx 
mice spent considerably less time exploring any of the objects.  
 
In contrast to the mdx mice, the control C57BL/10, Cmah-/-mdx, and Cmah-/- 
mice all showed a preference for the novel object, with the control C57BL/10 
mice showing the highest preference for the novel object (24±2 seconds). The 
D2 ratio showed that control C57BL/10, Cmah-/-mdx, and Cmah-/- mice spent 
considerably longer with the novel object than they did with the familiar object 
(positive D2 ratio) whereas the mdx mice spent significantly longer exploring the 
familiar object (negative D2 ratio) (Figure 4.23). The control C57BL/10 mice had 
the highest D2 ratio, showing the best overall object recognition memory. The 
Cmah-/-mdx and Cmah-/- mice both showed a reduced D2 ratio compared to 
those at 4 and 6 months old (Figure 4.23). The anxiety of the mdx mice had 
increased significantly at 12 months old, as represented by the reduced amount 
of time the mice spent exploring the objects and the increased amount of time 
the animals sat in the corners of the NOR arena (Figure 4.24 and Figure 4.25). 
This effect, of increased anxiety-related behaviour, was the same as that 
observed on the Barnes maze test at 12 months old, resulting in a reduced 
















Figure 4.21: Time spent with objects in the sample phase of the novel 
object recognition (NOR) task at 12 months old. Graph shows that in all 
genotypes mice showed no preference for either of the identical objects at 12 










Figure 4.22: Times spent with familiar and novel objects in the choice 
phase of the novel object recognition (NOR) task at 12 months old. Control 
C57BL/10, Cmah-/-mdx, and Cmah-/- mice showed a preference for the novel 
object whereas mdx mice showed a higher preference for the familiar object, 






















Figure 4.23: D2 ratios expressing preference or no preference for the 
novel and familiar objects in the choice phase of object recognition task 
at 12 months old. With the exception of the mdx mice, all mice showed a 
significant preference for the novel object at 12 months old. Objects were either 
polystyrene sphere or star and varied to avoid condition place preference 






























Figure 4.24: Comparison of D2 ratios between 4 and 12 months old. The 
control C57BL/10 mice had an increasing D2 ratio between 4 and 12 months 
old, demonstrating an increased preference for the novel object. The mdx mice 
showed an increased preference for the familiar object at all time points; 
however, the D2 ratio increased over time, as the mice spent less time 
exploring the object in total. Data presented as mean ± SEM, *p<0.05, vs 
control C57BL/10 mice.  
Figure 4.25: Bar graph displaying the amount of time that mice spent in 
the corners of the novel object recognition (NOR) arena between 4 and 12 
months old. The control C57BL/10 mice spent considerably less time in the 
corners of the NOR arena during both the sample and choice phase compared 
to the mdx mice. The mdx mice spent significantly longer in the corners of the 
NOR arena during the sample and choice phases of the NOR task and this time 
increased with increasing age. Data presented as mean ± SEM, *p<0.05 vs 
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Memory tests are important indices of brain functions that control for rodents’ 
behaviour. Many memory tasks require external forces (e.g. electric shocks) or 
intrinsic forces (e.g. hunger and thirst) to trigger the responses, potentially 
affecting the natural behaviour. High levels of anxiety have previously been 
reported in mdx mice (Sekiguchi et al., 2009), consequently no aversive 
stimulus was employed in either of our behavioural studies.  
 
Unlike DMD patients, adult mdx mice do not show obvious impairments in motor 
ability, presumably as a consequence of differences between mice and men 
regarding body size/architecture and a better regenerative muscle capacity in 
mice (Turk et al., 2005). Only when the endurance of mdx mice is challenged 
does muscle impairment become apparent, for example during the endurance 
hanging test (van Putten et al., 2012). The Barnes maze test and the NOR task 
are not described as strenuous activity tests, and thus were deemed acceptable 
behavioural assays to employ for the monitoring of a potential progressive 
cognitive dysfunction in DMD mouse models up to 12 months old. Although we 
did not use equipment necessary to directly measure mouse speed to reach the 
target hole, we do not think that the muscle weakness of DMD mice would 
considerably impair their ability to perform the Barnes maze test. In addition, the 
Cmah-/-mdx mice outperformed the control mice in multiple parameters and 
they are supposed to have a more severe muscle pathology to that of the mdx 
mouse (Chandrasekharan et al., 2010).  
 
On the cellular level, dystrophin loss causes alterations in calcium homeostasis 
and hippocampal neuronal function (Mehler et al., 1992), particularly 
hippocampal alterations in long-term potentiation (LTP), a form of plasticity 
widely believed to be critical for memory formation (Vaillend et al., 2002). It is 
not yet clear whether mdx mice have deficits in memory retention. Some studies 
describe no deficits (Vaillend et al., 1998), but other studies outline some 
memory retention impairment (Muntoni et al., 1991). One study described how 
altered expression of full length dystrophin or C-terminal dystrophin proteins in 
the brain (Dp140 and Dp71) did not markedly affect hippocampus-dependent 
spatial learning and CA1 hippocampal LTP in mdx and mdx3cv mice aged 3-4 
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months old (Vaillend et al., 1998). However, recent studies have emphasised 
that long-term but not short-term hippocampal spatial learning was affected in 
mdx mice (aged 3-5 months) using the water maze (Vaillend et al., 2004), 
suggesting a normal acquisition of spatial learning but impaired long-term 
memory capabilities. Studies in female mdx mice at 6 months old did not show a 
memory deficit during the Barnes maze test, as during the initial learning probe 
trial female mdx mice performed similar to control C57BL/10 mice (Remmelink 
et al., 2016). The female mdx mice did however display an inflexible search 
strategy during the Barnes maze probe trial reversal learning and a profound 
impairment in cognitive flexibility during an automated home-cage task 
(between 15 and 21 weeks old). However, this study did not investigate long-
term memory retention ability and investigated female mdx mice at one time 
point only (Remmelink et al., 2016). Given the previously established effect of 
gender difference on cognition in mdx mice, our studies investigated the loss of 
Dp427 on male mouse behaviour only.  
 
In this present study we utilised the Barnes maze test and numerous 
parameters (primary latency, total latency, primary errors, total errors, search 
pattern, and time spent in target quadrants) to monitor if cognitive impairment is 
progressive in DMD mice. It is only with a combination of these parameters that 
the progressive cognitive dysfunction becomes apparent. The aging control 
C57BL/10 mice showed a reduction in their success score (calculated during 
probe trials) between 4 and 12 months old with the largest reduction detected in 
long-term memory ability. The number of errors (primary and total errors) also 
increased with increasing age in control C57BL/10 mice, but time spent in the 
target quadrant remained relatively constant between 4 and 12 months old 
during probe trials. These findings are consistent with previously published data 
regarding the effect of aging on control mice (C57BL6J) behaviour (Shoji et al., 
2016), which suggested that impaired spatial and learning memory on the 
Barnes maze test is evident with increasing age, and further indicates that 
relatively narrow age differences can produce significant behavioural 
differences during adulthood in mice. In the mdx mice these parameters 
(success score, number of errors, time spent in the target quadrant) were 
affected to a greater extent. In particular, the time spent in the target quadrant, 
during short-term memory probe trial, was significantly reduced between 4 and 
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12 months old, as was the short-term memory (as shown by a decreasing 
success score and an increased number of errors). The long-term memory of 
mdx mice appears to show the highest deficit between 4 and 12 months old 
compared to long-term memory defect of control C57BL/10 mice. 
 
Long-term memory impairment in DMD has recently been reported (Vaillend et 
al., 2004) (Chamova et al., 2013). Dp427 appears to play a role in acquisition of 
associated learning as well as in general processes involved in memory 
consolidation following the assessment of DMD mice in this current study. 
Furthermore, it has been reported that long-term spatial memory is a function of 
the CA1 hippocampal sub-region and that this area has less of a role in short 
term memories (Vago et al., 2007). Given that the Barnes maze test we 
performed, highlighted in particular a reduction in long-term memory ability in 
the mdx mice between 4 and 12 months old (and the Cmah-/-mdx mice at 12 
months), it is likely down to abnormalities in the CA1 field of the hippocampus. 
A recent study demonstrated a reduced neuronal density in the anterior dorsal 
hippocampus (CA1 field), highlighting a reduction in pyramidal neurons in the 
mdx mouse, associated with Dp427 loss (Miranda et al., 2016). The CA1 dorsal 
hippocampus is known to be especially vulnerable to hypoxic insults, which may 
selectively damage neurons in this subfield, while sparing neurons in the CA3 
and DG (Schmidt-Kastner, 2015). Mdx mice have also been shown to be more 
susceptible to hypoxic induced hippocampal damage (Mehler et al., 1992). The 
long-term memory impairments in mdx mice suggest a direct link with the loss 
of full length dystrophin, therefore affecting all DMD patients. However, previous 
studies in the mdx identified that loss of Dp427 has no effect on perception and 
gating of sensory input and does not impair spatial working memory 
performance (mdx mice aged 3-4 months old) (Vaillend et al., 2004). Our study 
has highlighted that whilst at 4 months old spatial learning and memory in the 
mdx mice is comparable to that of control mice as the mdx mice age (6 months 
onwards), spatial learning and memory becomes significantly impaired.  
 
With respect to learning during the Barnes maze test, at 4 months old, the mdx 
mice had a tendency to make an increased number of errors during the first two 
days of training compared to the control C57BL/10 mice. However, by day 4 of 
training at 4 months old the mdx mice had comparable parameters (primary and 
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total errors, primary and total latency) to that of the control C57BL/10 mice. 
Interestingly this initial delay in performance has previously been reported in 
mdx mice (Chaussenot et al., 2015). During the first 3 days on the water maze 
task 4 month old male mdx mice had an initial delay in locating the platform, 
suggesting a transient deficit in procedural learning that could be linked to 
reduced motor coordination (Chaussenot et al., 2015). Performance (aged 4 
months) was comparable during additional training sessions between 
genotypes, with performance optimisation in the mdx mice found to be less 
efficient, suggesting that defective control processes that normally enable 
performance optimisation in cognitive tasks is affected by the loss of dystrophin 
(Chaussenot et al., 2015). The authors suggested that qualitative alterations in 
learning and memory processes could be masked by these apparently 
normal/borderline cognitive performances.  
 
Novelty and behaviour has gained much attention and interest from 
researchers. Novelty can be defined as an alteration from the expected 
likelihood of an event on the basis of both previous information and internal 
estimates of conditioned probabilities (Antunes and Biala, 2012). A novel 
stimulus can affect an animals’ behaviour and the NOR task relies on the 
rodents’ innate exploratory behaviour in the absence of externally applied rules 
or reinforcement (Ennaceur and Delacour, 1987). The preference for the novel 
object means that presentation of the familiar object exists in the animals’ 
memory (Antunes and Biala, 2012). The recognition of novelty requires more 
cognitive skills from the subject, relative to tasks measuring exploration of novel 
environments. The NOR paradigms have been shown to be influenced by both 
hippocampal and cortical lesions (Buckmaster et al., 2004). It is widely accepted 
that within the rodent brain the perirhinal cortex plays an important role in object 
recognition memory, i.e. the ability to evaluate a previously encountered item as 
familiar depends on the integrity of the medial temporal lobe (Hammond et al., 
2004). Other studies in rodents have highlighted the importance of the 
parahippocampal regions for visual object recognition memory (Antunes and 
Biala, 2012). 
 
For half the mice the novel object was the sphere and the familiar object was 
the star, while for the other half the novel object was the star and the familiar 
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object was the sphere. These modifications were made to reduce object and 
place preference effects (Ennaceur et al., 2005). These objects have no natural 
significance for the mice and had never been associated with reinforcement. 
The mdx mice displayed a preference for the familiar object, and were opposed 
to the novel object, at all time points, which indicates that the mdx mice have an 
impaired recognition memory. Additionally, DMD patients have also 
demonstrated impairments in visual recognition memory (during Peabody 
picture vocabulary test) (Anderson et al., 1988). Interestingly, the time spent 
with the familiar object did not increase over time but the amount of time that 
the mice spent with the objects in total decreased between 4 and 12 months 
old. The amount of time the mdx mice spent in the corners (frozen) of the NOR 
arena increased between 4 and 12 months old and is indicative of increased 
anxiety-related behaviour. The mdx mice often sat in the corners of the NOR 
arena and displayed elevated freezing, sniffing, and rearing compared to the 
other genotypes. Complete immobilisation of the mouse, except for respiration, 
was regarded as a freezing response and was most prominent in the mdx mice 
at 12 months old. Interestingly, at 12 months old during the Barnes maze test 
2/8 mdx mice displayed a complete freezing response (no movement on the 
maze during the test) during both training and probe trials. This freezing 
behaviour has previously been reported in mdx mice, but this is the first time 
this anxiety-like behaviour has been observed to increase with increasing age in 
mdx mice. The mdx mice have previously been reported to demonstrate an 
unimpaired startle reflex to auditory threshold testing, suggesting that auditory, 
cochlea, and brain stem function are largely unaffected by the loss of 
dystrophin. The amygdala is therefore the main candidate responsible for the 
fear conditioning and enhanced defensive behaviour in mdx mice. Interestingly, 
we observed increased grey matter volume in the mdx amygdala with age (see 
chapter 3 for details), changes to amygdala volume in rodents is linked to 
anxiety levels (Yang et al., 2008) . The control C57BL/10 mice showed an 
increased preference for the novel object with increasing age and these findings 
are in congruence with previous literature examining the effects of aging on 
rodents performance during the NOR tasks (Ilay et al., 2013). 
 
Remarkably, mdx mice also displayed repetitive behaviour, consistent with 
autistic-like traits in mice (Silverman et al., 2010). At 12 months old 3/8 mdx 
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mice displayed stereotypical behaviours associated with autistic traits in mice 
including spontaneous motor stereotypes: circling the inside walls of the arena 
and jumping repeatedly. These characteristics were most obvious in mdx mice 
at 12 months old.  
 
Previous studies assessing cognitive functioning of Cmah null mice described a 
battery of tests (fear conditioning, passive avoidance, and water maze testing) 
and reported that no statistically significant differences were observed in gross 
physical assessment, sensorimotor reflexes, nociception, and learning and 
memory, compared to aged matched controls (Hedlund et al., 2007). Cmah null 
mice did however display an age related hearing loss, similar to that seen in 
humans, which is associated with hair cell loss causing late-onset deafness 
(Hedlund et al., 2007). Authors emphasised the need to pursue additional 
studies to assess both cognitive ability and hearing abnormalities. During both 
our Barnes maze test and NOR task the Cmah-/- mice performed similarly to 
control C57BL/10 mice. During the Barnes maze probe trials the Cmah-/- mice 
displayed similar success scores to that of control C57BL/10 mice for both 
short- and long-term memory between 4 and 12 months old. During the NOR 
task the Cmah-/- mice displayed a preference for the novel object and opposed 
the familiar object between 4 and 12 months old. Only at 12 months old did the 
Cmah-/- mice spend less time in the target quadrant during the short-term 
Barnes maze assessment than control C57BL/10 mice. Additionally, at 12 
months old the Cmah-/- mice had a reduced D2 ratio compared to control 
C57BL/10 mice. Taken together these two findings are suggestive of a change 
in memory and learning capabilities of Cmah-/- mice at 12 months old where a 
decline in memory was observed.   
 
To the best of our knowledge, this is the first behavioural study to assess if 
cognitive impairment is progressive in the mdx mouse model of DMD. This 
study has highlighted a progressive cognitive deficit in the mdx mice using the 
Barnes maze test between 4 and 12 months old, with the highest impairment in 
long-term memory performance. Moreover, the NOR tasks outlined an increase 
in anxiety-related behaviour in mdx mice, with the highest levels of anxiety 
evident at 12 months old. Interestingly, no other genotype exhibited these 
anxiety and autistic-like traits. In this study we have identified an increased 
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latency to locate the target hole and a reduced success score for mdx mice 
during the Barnes maze test from 6 months old onwards. These two parameters 
could be used as outcome measures to non-invasively measure changes over 
time in relation to brain pathology in the mdx mice. However, the mice would 
need to be a certain age as we did not observe obvious cognitive dysfunction 
until mdx mice were 6 months old utilising the Barnes maze test.  
 
Additionally, this is the first study to employ behavioural assays in the Cmah-/-
mdx mice and given their unusual performance on the Barnes maze test and 
NOR tasks at 4 and 6 months old, further investigations and increased number 















Chapter 5. Alterations of blood-brain barrier permeability in 
dystrophin deficient mice  
5.1 Introduction  
5.1.1 The blood-brain barrier (BBB) formation 
The blood- brain barrier (BBB) development and differentiation is a gradual 
process that leads the embryonic vessels to acquire barrier properties, by 
selectively and progressively decreasing permeability and expression of specific 
endothelial transporters and antigens (Nico et al., 2005). Formed by specialised 
vascular endothelial cells, the BBB is tightly controlled by pericytes, embedded 
in the vascular basement membrane, perivascular microglial cells, astrocytes, 
and neurons; all of these elements contribute to the formation of the 
neurovascular unit (NVU) (Heye et al., 2014). A primary function of this 
specialised brain region is to regulate the ionic composition of the extracellular 
milieu by controlling local cerebral blood flow and transport across the BBB 
(Wilcock et al., 2009). BBB endothelial cells display a unique phenotype 
characterised by the presence of tight junctions (TJs) and the expression of 
specific polarised transport systems. TJs are composed of TJ proteins 
(occludin, claudins, zonula occludens (ZO)-1, ZO-2, ZO-3, cingulin, AF6, 7H6), 
adherent junctions (AJ) composed of cadherins, catenins, vinculin, and actinin, 
and junctional adhesion molecules (JAMs) (Abbott et al., 2010). Additionally, the 
BBB controls water transport, which has a pivotal role in the CNS physiology as 
it is involved in CSF production, fluid transport across the endothelium, and 
osmolarity compensation in potassium siphoning (Filippidis et al., 2017). The 
BBB allows the passage of water, various gases, and lipid-soluble molecules 
via passive diffusion, in addition to the selective transport of molecules such as 
glucose and amino acids, which are pivotal for correct neural functioning 
(Abbott et al., 2010). Disruption of the BBB is reported in numerous neurological 


























Figure 5.1: Pathophysiological outcomes by blood-brain barrier (BBB) 
disruption after damage. BBB disruption leads to several conditions 
including brain oedema, inflammatory damage, and haemorrhage. (Figure 
adapted from: (Michinaga and Koyama, 2017)). 
5.1.2 The role of AQP4 at the BBB 
Astrocytes control the neuronal microenvironment by direct or indirect regulation 
of the ionic flux occurring during neuronal activity (Iacovetta et al., 2012). In 
addition, astrocytes regulate the rate of water flow by means of a specific water 
channel, namely AQP4. AQP4 is considered to be an important marker for glial 
cells and is normally strongly expressed in perivascular processes, where it 
regulates both CSF production at the cerebral ventricle level and water 
permeability at the BBB (Iacovetta et al., 2012). Moreover, AQP4 proteins are 
associated with the DGC in the brain (Qiu et al., 2015). Syntrophins are 
members of the DGC and mice null for α-syntrophin show a mislocalisation of 
AQP4 on glial membranes, which suggests that proteins of the DGC are 
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necessary for correct localisation of AQP4 in the brain (Hoddevik et al., 2017). 
Vasogenic cerebral oedema occurs when the BBB is disrupted due to the 
breakdown of tight endothelial junctions and mainly affects the white matter 
through leakage from capillaries (Papadopoulos et al., 2004; Papadopoulos and 
Verkman, 2007). This is in contrast to cytotoxic cerebral oedema, where the 
BBB remains intact but the sodium and potassium pump in the glial cell 
membrane is impaired due to a disruption in cellular metabolism, causing 
cellular retention of sodium and water (Szu and Binder, 2016). Studies of 
cytotoxic oedema have shown that mice that are AQP4 deficient have 
protection against cellular swelling and improved neurological outcome 
(Verkman, 2005), whilst vasogenic oedema was worse in the absence of AQP4 
(Papadopoulos et al., 2004).  
5.1.3 Alterations of the BBB in mdx mice 
Dystrophin and other members of the DGC are expressed in brain microvessels 
(Lidov et al., 1995), and in astrocyte perivascular endfeet (Blake et al., 1999) 
where dystrophin proteins play a role in BBB functions. Dystrobrevin, a DGC- 
associated protein discovered by immunoelectron microscopy, was localised 
not only in the astrocytic endfeet around blood vessels and under the pia mater, 
but also in endothelial cells and plays a role in BBB functions as a component of 
the DGC complex (Ueda et al., 2000). Numerous members of the DGC are 
localised in the endothelial and glial cells, and are reduced in dystrophin 
deficiency (Nico et al., 2005).  
 
Ultrastructural alterations of the blood vessel wall have been reported in the 
mdx brain. The mdx mice endothelial cells demonstrated an increase in vesicles 
and vacuoles involved in transcellular transport in addition to a detachment of 
the TJ (Nico et al., 2005). Moreover, ZO-1 colocalises with α-actin in the wild 
type mouse brain and ZO-1 protein content was decreased and its expression 
pattern strongly modified in the mdx vessels (Nico et al., 2005). Using 
immunogold electron microscopy researchers found that α-actin was expressed 
in both pericytes and endothelial cells of the control vessels, where α-actin gold 
particles were concentrated along the cytoplasmatic face of the TJ in the form of 
an electron dense peripheral band. Conversely, in the mdx vessels α-actin 
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particles were scattered throughout the endothelial cytoplasm and not located at 
the inner aspect of the TJ, which appeared devoid of dense peripheral bands 
(Nico et al., 2005). The authors hypothesised that alteration of cytoskeletal 
actin, induced by dystrophin deficiency, caused alteration of ZO-1 anchoring to 
the TJ membranes (Nico et al., 2005), therefore impairing BBB integrity (Figure 
5.2).  
 
AQP4 is developmentally expressed during BBB differentiation. Its expression 
occurs in a polarised way at the perivascular glial processes facing the vessels 
(Nico et al., 2001). AQP4 glial expression is reduced in a damaged BBB 
(Filippidis et al., 2017). A reduction in AQP4 expression in the brains of mdx 
mice has been reported and is also associated with swollen astrocyte 
processes, suggesting that its function is related to the reabsorption of water 
from the extracellular fluid to the blood and CSF (Nico et al., 2010). Thus, a 
reduction of AQP4 expression in mdx mouse brain could cause a slower 
drainage of water out of the brain, astrocyte swelling, and cellular cerebral 
oedema (Nico et al., 2005). Another theory is that the reduction of AQP4 protein 
in the brain may be a consequence of an altered vascular permeability of the 













Figure 5.2: Schematic representation of endothelial junction plasma 
membrane. Mutations in the DMD gene lead to the dissociation of the 
relationship between cytoskeleton actin and the ZO-1 complex with cytoplasmic 
translocation of tight junction (TJs) proteins. (Figure adapted from:(Nico et al., 
2005)).  
5.1.4 Measuring BBB disruption  
A disruption in the BBB can enable the extravasation of low-molecular weight 
MRI contrast agents. This accumulation of contrast material in the extravascular 
extracellular space (EES) of affected tissues leads to an decreased longitudinal 
relaxation rate, and therefore increased signal intensity in T1-weighted MR 
images (Heye et al., 2014), which can evaluate and detect regions of BBB 
impairment. In the brain, MR signal changes caused by contrast agent 
extravasation are determined by several factors including tissue perfusion and 
capillary permeability (Heye et al., 2014).  
 
A more traditional method to assess BBB integrity is by Evans blue dye (EBD) 
extravasation. EBD binds to serum albumin which cannot cross the BBB 
therefore neural tissue remains unstained. However, when the BBB has been 
compromised serum-bound EBD can enter the CNS (Hawkins and Egleton, 
2006). However, this is an in vitro method and cannot be used for monitoring 




5.1.5 Measuring brain water content and environment 
Quantitative MRI acquisition and analysis techniques allow investigations 
beyond conventional qualitative interpretation and provide further insights into 
brain pathologies. Quantifying tissue specific characteristics enables the 
detection of reproducible parameters that mirror the underlying biological 
systems (Leppert et al., 2009). Relaxometry, for instance, combines acquisition 
and analysis techniques to generate MR relaxation time constants that directly 
reflect the local environment of water. Since the transverse relaxation time, T2, 
is a quantitative measure of a basic biophysical property, which leads to signal 
contrast on MRI, it can provide a quantitative monitoring tool in both healthy and 
disease states (Leppert et al., 2009).    
 
A more common technique to measure brain water content is the wet:dry brain 
method. This conventional method is easy to perform and widely used, but is 
associated with multiple limitations including: the requirement of large sample 
sizes, variations in oven temperature and drying times, and the heating process 
which changes tissue morphology (Sebastiani et al., 2017). Moreover, this 
method is an in vitro technique and cannot be used for monitoring brain water 














 To apply T2 relaxometry to control C57BL/10 mice and mutant mice 
brains to gain accurate data regarding brain water content and 
environment of numerous regions of interest and compare this in vivo 
method to the commonly used wet:dry brain ratio approach (in vitro). 
 To compare Evans blue dye extravasation in the brain between control 
C57BL/10 and mutant mice between 6 and 18 months old. 
 To quantify the effects of age on BBB disruption utilising a contrast 
enhanced T1 mapping approach in control C57BL/10 mice and mutant 


















5.2 Changes in brain water content 
Brain edema is a major pathological feature associated with neurological 
defects. Small percentage changes in brain water content can reflect much 
bigger changes in brain swelling. The characteristic pathophysiological 
conditions caused by BBB disruption are brain oedema resulting from an 
excessive increase of brain water content, inflammatory damage caused by 
infiltrating immune cells, and haemorrhage caused by the breakdown of 
microvessel structures (Michinaga and Koyama, 2017). We investigated the 
brain water content and environment of mutant mice by utilising quantitative 
MRI (T2 relaxometry) and the wet:dry brain method.  
5.2.1 T2 relaxation time at 7T 
We recorded the T2 relaxation times at 7T for numerous ROIs, including the 
cerebral cortex, corpus callosum, hippocampus, cerebellum and caudate 
putamen, in mutant and control C57BL/10 mouse brains at 6 and 18 months old 
(Figure 5.3). At 6 months old, no observation of change in T2 relaxation time 
was found in any ROI of either the control C57BL/10 or mutant mouse brains 
(F3, 60 = 1.11, p=0.35) (Figure 5.4). There was no significant main effect for any 
ROI within the genotype (F1, 24= 4.8, p=0.07).  
 
Remarkably, at 18 months old the Cmah-/-mdx mice had a substantially longer 
T2 relaxation time in all ROIs investigated compared to the control C57BL/10, 
mdx and Cmah-/- mice brains (Figure 5.5). There was a significant difference in 
the T2 relaxation rates between control C57BL/10 mice and Cmah-/- mice (F3, 24 
= 219, p<0.01). The largest difference in T2 relaxation time was observed in the 
hippocampus, with Cmah-/-mdx mice having a T2 relaxation time of 59±0.7 ms 
and control C57BL/10 mice displaying a T2 relaxation time of 51±0.3 ms 
(p<0.01). Interestingly, there was an elevation in T2 relaxation time of the 
caudate putamen in the mdx mice (50±0.5 ms) compared to control C57BL/10 
mice (48±0.7 ms) at 18 months old and this was the only ROI investigated 
where there was a difference in T2 relaxation times between mdx and control 




















Figure 5.3: Regions of interest (ROIs) for T2 measurements. A. 1. 
Hippocampus, 2. Cerebral Cortex and 3. Corpus Callosum, defined on a T2-
weighted coronal image. B. Corresponding coronal T2 map. C. ROI 4. Caudate 
Putamen, defined on a T2-weighted coronal image D. Corresponding coronal T2 
map E. ROI 5 in the cerebellum. F. Corresponding T2-weighted coronal image. 
































Figure 5.4: Comparison of T2 relaxation times of each region of interest 
(ROI) between control C57BL/10, mdx, Cmah-/-mdx mice, and Cmah-/- 
mice aged 6 months old. No difference in T2 relaxation rates was observed in 
any ROI between each genotype (n=4 mice/genotype). Data presented as 




























































Figure 5.5: Comparison of T2 relaxation times of each selected brain 
region between control C57BL/10, mdx, Cmah-/-mdx, and Cmah-/- mice 
aged 18 months old. The Cmah-/-mdx mice exhbited a higher T2 relaxation 
time in all regions of interest (ROI’s) compared to both control C57BL/10 and 
mdx mice (n=4 mice per genotype). The mdx mice exhbited similar T2 relaxtion 
rates to those of control C57BL/10 mice in all ROIs investigated. Data 
















































5.2.2 Wet:dry brain water content measurements  
The most common method used to measure brain water content is the wet:dry 
brain measurement. These measurements were performed in mice aged six 
months old and there was no main effect on genotype (F3, 24 = 1.89, p=0.16), 
indicating that there was no significant difference in the brain water content 
between control C57BL/10 mice (76.6 ±0.89 %), mdx mice (75.7±0.86 %), 
Cmah-/-mdx mice (78.2±0.84 %) and Cmah-/- mice (76.19±0.86 %) at 6 months 
old (Figure 5.6). There was a main effect for brain region (cortex and 
cerebellum) (F1, 24 = 4.8, p=0.03), demonstrating that the cortex (77.8±0.6 %) 
contained significantly more water than the cerebellum (75±0.5 %), which is 
expected given their differences in size. These findings are consistent with our 





















Figure 5.6: Brain wet:dry measurements. A. Outline of the method used for 
determining brain water content. B. Formula used for calculating brain water 
content. C. Bar graph showing the evaluation of brain water content in mice 
aged 4 months old. Data presented as mean ± SEM. No difference was 
observed in the brain water content between any genotype in either the whole 



































Brain separated into right 
hemisphere, left hemisphere 
and cerebellum and weighed 
to obtain wet weights 
Brains were dried at 100°C in 
an oven for 24 hours to 
obtain dry weights  
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5.3 Extravasation of Evans blue dye (EBD) 
To investigate the integrity of the BBB in the absence of full length dystrophin, 
we examined the extravasation of EBD from blood vessels following an 
intraperitoneal injection of a bolus of EBD into mice aged 6 months and 18 
months old. Successful uptake of EBD was considered when mice extremities 
appeared blue (Figure 5.7). There was a substantial leakage of EBD into the 
cerebrum of both mdx and Cmah-/-mdx mice at 6 months old as demonstrated 
in Figure 5.8. There were no vessels demonstrating EBD extravasation in 
control C57BL/10 mice and Cmah-/- mice brains at 6 months old. At 18 months 
old mdx and Cmah-/-mdx mice portrayed a significant leakage of EBD, more so 
than at the 6 months old time point (Figure 5.9) into the cerebrum but control 











Figure 5.7: Mouse 24 hours after intraperitoneal injection of Evans blue 














Figure 5.8: Representative images of Evans blue dye (EBD) fluorescence on coronal cyrosections of 6 month old frozen mouse 
brain (20 µm) (n=4 mice per genotype). The extravasation of EBD can be seen in the mdx and Cmah-/-mdx mice (white arrows). Scale 
bar = 20 µm at 20 x magnification and 50 µm at 40 x magnification. There were few vessels demonstrating EBD extravasation in either 


























Figure 5.9: Representative images of Evans Blue dye (EBD) fluorescence on coronal cyrosections of 18 month old frozen 
mouse brains (20 µm) (n=4 mice per genotype). The extravasation of EBD can be seen in the mdx and Cmah-/-mdx mice (white 
arrows). Tibialis anterior muscle served as a control tissue. Scale bar = 20 µm at 20 x magnification and 50 µm at 40 x magnification for 
brain images and 50 µm at 20 x magnification for muscle images. There were few vessels demonstrating EBD extravasation in either the 
control C57BL/10 or the Cmah-/- mouse brain at 18 months old.






























5.4 Western blot analysis of brain aquaporin’s  
Aquaporins are a family of proteins that function as water channels in the brain. 
There are two main aquaporins in the CNS: AQP1 and AQP4. AQP1 was found 
to be localised at the apical membrane of the choroid plexus, whereas AQP4 is 
located in the astrocyte foot processes that surround capillaries in the CNS in 
addition to its location at the basolateral membrane of the ventricular 
ependymal cells. AQP1 has previously been implicated in choroidal CSF 
secretion, driven mainly by carbonic anhydrase and Na+/K+ ATPase.  
5.4.1 Aquaporin-1  
Western blot analysis of whole brain tissue lysates from control C57BL/10, mdx, 
Cmah-/-mdx and Cmah-/- mice was performed at 1 month, 4 months and 12 
months old, and confirmed there was no difference in expression of the AQP1 
(~30 kDa) levels between either control or mutant brains (Figure 5.10). 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (~38 kDa) was used as 
a loading control. 
5.4.2 Aquaporin-4  
Western blot analysis of whole brain tissue lysates from control C57BL/10, mdx, 
Cmah-/-mdx and Cmah-/- mice was performed at 1 month, 4 months and 12 
months old, and demonstrated a progressive reduction of AQP4 in DMD mouse 
brains. Interestingly, there was also a reduced level of AQP4 present in the 
Cmah-/- mouse brain at 1 and 6 months old (Figure 5.11). However, by 12 
months old expression levels were comparable to that of control C57BL/10 













Figure 5.10: Representative western blot analyses of brain tissue from control C57BL/10, mdx, Cmah-/-mdx, and Cmah-/- mice 
at A. one month old, B. four months old and, C. twelve months old. There was no change in expression of AQP1 (30 kDa). Membranes 
were incubated with rabbit ployclonal AQP1 antibody (Abcam,ab15080) at a dilution of 1/500, GAPDH (Abcam, ab6276) was used as a 
loading control (1/1000), D. quantification of AQP1 expression at various time points where expression levels normalised to their 
corresponding GAPDH loading controls, E. example Ponceau stain to verify equal sample loading.  
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Figure 5.11: Representative western blot analyses of brain tissue from control C57BL/10, mdx, Cmah-/-mdx, and Cmah-/- mice  
at A. one month old, B. four months old and, C. twelve months old. There was a progressive reduction in the expression of both AQP4 
M1 and M23 isoforms (~30 kDa) in DMD mouse models with increasing age. Membranes were incubated with rabbit ployclonal AQP4 
antibody (Abcam,ab4182) at a dilution of 1/500. GAPDH (Abcam, ab6276) was used as a loading control (1/1000), D. quantification of 
AQP4 expression at various time points where expression levels normalised to their corresponding GAPDH loading controls, E. example 
Ponceau stain to verify equal sample loading.  
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5.4.3 T1- mapping with Gadolinium enhancement  
Loss of BBB integrity has previously been reported in mdx mice, yet no study to 
date has assessed BBB permeability in vivo in DMD mice. MRI offers the further 
possibility of monitoring the evolution of BBB modifications in the same animal. 
Gadolinium (Gd) is a paramagnetic MRI contrast agent used routinely for 
diagnosing BBB lesion in patients; the agent works by shortening tissue T1 after 
extravasation into brain parenchyma. Tissue infiltration of the tracer can be 
assessed using T1 mapping and T1-w images to assess contrast agent uptake 
overtime. We investigated five ROIs, including brain regions known to be rich in 
dystrophin, to determine the extent of potential BBB disruption throughout the 
brain including: cerebellum, hippocampus, ipsilateral (right) hemisphere, 
contralateral (left) hemisphere and the caudate putamen (Figure 5.12).  
 
 
Figure 5.12: Regions of interest (ROI) for T1 mapping measurements. 1. 
Hippocampus, 2. Caudate Putamen, 3. Ipsilateral Cortex, 4. Contralateral 
Cortex, and 5. Cerebellum, defined on T1-weighted coronal images.  
 
A temporal series of eight T1-w images were acquired for each mouse at 6 
(Figure 5.13) and 14 months old (Figure 5.14). The series of T1-w images were 
split into two parts: pre- and post-Gd administration, where two T1-w images 
were acquired pre-Gd administration and six T1-w images were acquired post-
Gd administration. Successful uptake of Gd, via a tail vein cannula, was 
confirmed when the vasculature appeared bright and the sagittal sinus lit up. It 
is important to confirm the uptake of the contrast agent as it is possible for a 
blood clot to form in the cannula, preventing the injection of contrast agent. 
Contrast enhancement of the temporalis muscle was also observed in some 









Figure 5.13: Representative T1-w images from control C57BL/10, mdx, 
Cmah-/-mdx and Cmah-/- mice at 6 months old pre-gadolinium (Gd) 
injection (0 minutes) and 14, 28, and 42 minutes post-Gd injection (n=6-8 
mice per genotype). Successful Gd injection was determined when the sagittal 
sinus and the vasculature (red arrow) appeared bright and was evident on post-
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Figure 5.14: Representative T1-w images from control C57BL/10, mdx, 
Cmah-/-mdx, and Cmah-/- mice at 14 months old pre-gadolinium (Gd) 
injection (0 minutes) and 14, 28, and 42 minutes post-Gd injection (n=6-7 
mice per genotype). Successful Gd injection was determined when the sagittal 
sinus and the vasculature (red arrow) appeared bright and was evident on post-
Gd injected images. Contrast uptake into temporal muscle tissue was observed 
in mdx mice (white arrows) where infiltration of Gd into muscle tissue appeared 
bright. Note also the change in head shape between genotypes as detailed in 
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Quantification of the concentration of Gd in brain tissue in vivo is possible using 
both the T1 mapped values and the following formula:  
 
 R1post = R1pre + r1[Gd] , where  r = 1/T1    
                        
Where R1post and R1pre are the relaxation rates of the tissue post- and pre- Gd 
injection, [Gd] is the concentration of contrast agent and r1 is the relaxivity of the 
contrast agent at 7T. (See Chapter 2 for further details regarding the methods 
used).   
  
The r1 relaxation rates before and after contrast enhancement were measured 
from the T1 maps in the brain, which in turn could be used to calculate the 
concentration of contrast agent in each ROI.  
 
The mdx mice displayed increased Gd uptake in the cerebellum at 6 months old 
compared to all other genotypes (Figure 5.15) at 42 minutes post-Gd injection 
(56 minutes of the scan protocol). The mdx mice had the highest concentration 
of Gd measured in the cerebellum at 12±1.4 µM compared to control C57BL/10 
mice at 1.8±2.7 µM. However, at 14 months old the concentration of Gd within 
the mdx cerebellum, at 42 minutes post-Gd injection, increased considerably up 
to 21.6±3.9 µM, whereas the concentration of Gd within the control C57BL/10 
mice cerebellum increased slightly to 11.4±1.4 µM (Figure 5.15). Additionally, at 
42 minutes post Gd injection, the concentration of Gd in the mdx cerebellum 
appeared to be rising still, whereas in the control C57BL/10 there was a decline 
in Gd concentration by this point. We expected to detect small levels of Gd in 
the brains of all mice since Gd is taken up into the vasculature and will 
contribute to a transient increase in T1 signal until it is cleared and excreted by 
the liver and kidneys. The 6 month old control C57BL/10 mice demonstrated 
this effect (Figure 5.15 and Figure 5.20). At 42 minutes post-Gd injection the 
level of Gd detected in the brain should be minimal unless Gd is ‘trapped’ due to 
decreased BBB integrity, which was clearly visible in numerous ROIs for mdx 




The Cmah-/-mdx mice displayed a similar concentration of Gd in the cerebellum 
at 6 months old compared to control C57BL/10 mice with 10.3±3.9 µM 
recorded, but by 14 months old the concentration of Gd within the cerebellum 
had increased similar to that of control C57BL/10 mice to 13.6±1.7 µM. 
Interestingly, the Cmah-/- mice showed little to no difference in Gd 
concentration in the cerebellum, 42 minutes post injection, between 6 and 14 
months old, with a detection level of 7.7±2.7 µM Gd and 5.8±2.4 µM Gd at 6 
and 14 months respectively.  
In the cortex, mdx mice showed similar levels of Gd uptake in both the 
ipsilateral and contralateral hemispheres, with 11.9±1.4 µM Gd and 10.6±0.9 
µM Gd recorded respectively at 6 months old 42 minutes post-Gd injection 
(Figure 5.16 and Figure 5.17). The control C57BL/10 mice had significantly less 
Gd in the ipsilateral and contralateral hemispheres (42 minutes post Gd 
injection) compared to mdx mice at 6 months old with concentrations of 
1.76±1.7 µM and 1.18±1.6 µM Gd recorded respectively. The Cmah-/-mdx mice 
displayed similar levels of Gd uptake in the ipsilateral and contralateral 
hemispheres to that of mdx mice at 6 months old, with a concentration of 
10.7±3.2 µM Gd and 10.2±2.4 µM Gd recorded. Again, the Cmah-/- mice had 
the lowest concentration of Gd detected with 6.7±2.3 µM and 7±1.4 µM Gd in 
the contralateral and ipsilateral hemispheres respectively at 42 minutes post-Gd 
injection. By 14 months old the concentration of Gd had increased in the mdx 
cortex (42 minutes post-Gd injection) to 21.8±4.1 µM Gd in the ipsilateral 
hemisphere and 17.1±2.7 µM Gd in the contralateral hemisphere. There was 
also a slight increase in the concentration of Gd detected in the control 
C57BL/10 mice cortex at 42 minutes post-Gd injection, but the increase was 
smaller than that observed in the mdx mice cortex at 14 months old, with 
12.7±4.1 µM Gd and 13.3±1.9 µM detected in the ipsilateral and contralateral 
hemisphere respectively. The Cmah-/-mdx and Cmah-/- mice displayed similar 
levels of Gd uptake in the cortex at 14 months to that detected at 6 months old 
at 42 minutes post-Gd injection.  
 
In the hippocampus at 6 months old all mice, regardless of genotype, displayed 
similar levels of Gd uptake at 42 minutes post-Gd injection (Figure 5.18). 
However, mdx mice did have the highest level of Gd in the hippocampus 
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recorded at 11.4±3.7 µM, whereas control C57BL/10 mice had a concentration 
of 2.8±1.4 µM, Cmah-/-mdx mice had a concentration of 3.0±0.5 µM, and 
Cmah-/- mice a concentration of 3.3±1.1 µM, by 42 minutes post-Gd injection. 
By 14 months old the concentration of Gd detected in the hippocampus had 
increased slightly for all genotypes at 42 minutes post-Gd injection except for 
the Cmah-/- mice, with 1±3.4 µM Gd recorded. The concentration of Gd in the 
mdx hippocampus at 14 months old was similar to that detected at 6 months 
old, with a concentration of 17.3±1.3 µM Gd recorded, as was the concentration 
of Gd in the hippocampus of control C57BL/10 and Cmah-/-mdx mice of 
13.3±1.9 µM Gd and 17.1±2 µM Gd detected respectively.  
 
Within the caudate putamen the mdx mice displayed the highest concentration 
of Gd at 6 months old, 42 minutes post-Gd injection, with a concentration of 
12.2 ±4.1µM Gd recorded, compared to control C57BL/10 mice with a 
concentration of 1.3±3.5 µM Gd (Figure 5.19). Focal areas within the mdx 
caudate putamen showed obvious signs of Gd uptake (Figure 5.21) The Cmah-
/-mdx mice had a similar level of Gd in the caudate putamen compared to that 
of control C57BL/10 mice, with a concentration of 9±3.8 µM detected. Again the 
Cmah-/- mice had the lowest levels of Gd detected at 42 minutes post injection, 
with a concentration of 3.3±1.9 µM Gd in the caudate putamen. At 14 months 
old there was an increase in Gd concentration in the caudate putamen of 
control C57BL/10, mdx, and Cmah-/-mdx mice, but the mdx mice still had the 
highest concentration of Gd detectable, 42 minutes post Gd-injection, at 
18.6±2.8 µM Gd, and the Cmah-/-mdx mice and control C57BL/10 mice had 
comparable levels to each other with 13.3±5.1 µM Gd and 13.6±0.8 µM Gd 
detected. The Cmah-/- mice displayed similar levels of Gd uptake in the 
caudate putamen at 14 months to that detected at 6 months old with a level of 
3.2±3.4 µM Gd with no focal areas of Gd uptake detected unlike that seen for 















Figure 5.15: Line graphs displaying the concentration of gadolinium (Gd) within the cerebellum. A. The concentration of Gd within 
the cerebellum at 6 months old (n=4 mice per genotype). The mdx mice displayed the highest concentration of Gd within the cerebellum, 
which persisted up to 42 mins post Gd injection. B. The concentration of Gd within the cerebellum at 14 months old (n=6-7 mice per 
genotype). The mdx mice again displayed the highest concentration of Gd within the cerebellum, which appeared to be increasing still 
beyond 42 mins post Gd injection. The concentration of Gd within the mdx cerebellum was higher at 14 months than at 6 months old 
whereas all other genotypes displayed a similar level of Gd within the cerebellum at 6 and 14 months old. Data presented as mean ± 








































































































Figure 5.16: Line graphs displaying the concentration of gadolinium (Gd) within the ipsilateral cortex. A. The concentration of Gd 
within the ipsilateral cortex at 6 months old (n=4 mice per genotype). The DMD mice displayed the highest concentration of Gd within the 
ipsilateral hemisphere, which persisted up to 42 mins post Gd injection. B. The concentration of Gd within the ipsilateral hemisphere at 
14 months old (n=6-7 mice per genotype). The mdx mice displayed the highest concentration of Gd within the ipsilateral hemisphere but 
there was also an increase in Gd concentration in the control C57BL/10 mice ipsilateral hemisphere. The Cmah-/- mice showed 















































































































Figure 5.17: Line graphs displaying the concentration of gadolinium (Gd) within the contralateral cortex. A. The concentration of 
Gd within the contralateral hemisphere at 6 months old (n=4 mice per genotype). At 6 months old all mice, regardless of genotype, 
displayed comparable amounts of Gd within the contralateral hemisphere, except the mdx mice at 42 minutes post-Gd injection where 
there appeared to be a sharp increase in Gd concentration. B. The concentration of Gd within the contralateral hemisphere at 14 months 
old (n=6-7 mice per genotype). The mdx mice displayed the highest concentration of Gd within the contralateral hemisphere, but there is 
also an increase in Gd concentration in the control C57BL/10 mice contralateral hemisphere. The Cmah-/-mdx and Cmah-/- mice showed 
















































































































Figure 5.18: Line graphs displaying the concentration of gadolinium (Gd) within the hippocampus. A. The concentration of Gd 
within the hippocampus at 6 months old (n=4 mice per genotype). At 6 months the mdx mice appeared to have a slight increase in the 
concentration of Gd within the hippocampus, all other genotypes display comparable amounts of Gd within the hippocampus. B. The 
concentration of Gd within the hippocampus at 14 months old (n=6-7 mice per genotype). The DMD mice displayed the highest 
concentration of Gd within the hippocampus at 14 months old, but there was also an increase in Gd concentration in the control 
C57BL/10 mice hippocampus. The Cmah-/- mice showed comparable levels of Gd within the hippocampus at 6 and 14 months old. Data 











































































































Figure 5.19: Line graphs displaying the concentration of gadolinium (Gd) within the caudate putamen. A. The concentration of Gd 
within the caudate putamen at 6 months old (n=4 mice per genotype). At 6 months the mdx mice appeared to have an increase in the 
concentration of Gd within the caudate putamen, all other genotypes displayed comparable amounts of Gd within the caudate putamen. 
B. The concentration of Gd within the caudate putamen at 14 months old (n=6-7 mice per genotype). The mdx showed a comparable 
level of Gd in the caudate putamen at 6 and 14 months old, except at 14 months old the concentration of Gd within the caudate putamen 
appeared to be increasing still beyond 42 mins post Gd injection There was an increase in Gd concentration in the control C57BL/10 
mice and Cmah-/-mdx mice caudate putamen between 6 and 14 months old. The Cmah-/- mice showed comparable levels of Gd within 












































































































Figure 5.20: Representative T1 maps for control C57BL/10 mice pre- and post-gadolinium (Gd) enhancement at 6 and 14 months 
old. Image 1 represents the cerebellar region, image 2 represents the hippocampus and caudate putamen, image 3 represents the brain 
ventricles and the caudate putamen, and image 4 represents the cortex. The intensity was measured between 0 and 3 seconds, where a 
darker red indicates areas of increased change in T1 signal (increased Gd detected) and therefore a shortening of tissue relaxation time. 
Red circle indicates focal areas of enhancement within the brain. At 6 months old there was little enhancement in any brain region but at 
























































Figure 5.21: Representative T1 maps for mdx mice pre- and post-gadolinium (Gd) enhancement at 6 and 14 months old. Image 1 
represents the cerebellar region, image 2 represents the hippocampus and caudate putamen, image 3 represents the brain ventricles, 
and the caudate putamen, and image 4 represents the cortex. The intensity was measured between 0 and 3 seconds, where a darker red 
indicates areas of increased change in T1 signal (increased Gd detected) and therefore a shortening of tissue relaxation time. Red circle 
indicates focal areas of enhancement within the brain. At 6 months old there was some enhancement in the caudate putamen and 
cerebellum but at 14 months old there was an increase in Gd detected in these regions. The ventricles were harder to distinguish in the 



























































Figure 5.22: Representative T1 maps for Cmah-/-mdx mice pre- and post-gadolinium (Gd) enhancement at 6 and 14 months old. 
Image 1 represents the cerebellar region, image 2 represents the hippocampus and caudate putamen, image 3 represents the brain 
ventricles and the caudate putamen, and image 4 represents the cortex. The intensity was measured between 0 and 3 seconds, where a 
darker red indicates areas of increased change in T1 signal (increased Gd detected) and therefore a shortening of tissue relaxation time. 
Red circle indicates focal areas of enhancement within the brain. At 6 months old there was some enhancement in the brain but at 14 























































Figure 5.23: Representative T1 maps for Cmah-/- mice pre- and post-gadolinium (Gd) enhancement at 6 and 14 months old. 
Image 1 represents the cerebellar region, image 2 represents the hippocampus and caudate putamen, image 3 represents the brain 
ventricles and the caudate putamen, and image 4 represents the cortex. The intensity was measured between 0 and 3 seconds, where a 
darker red indicates areas of increased change in T1 signal (increased Gd detected) and therefore a shortening of tissue relaxation time. 
Red circle indicates focal areas of enhancement within the brain. Between 6 and 14 months old there was little difference in contrast 
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During this study we identified additional brain abnormalities in both the control 
C57BL/10 and mdx mice. At the 14 months old time point one control C57BL/10 
and one mdx mice were identified with extreme hydrocephalus where the 
hydrocephalus was worse in the mdx than the control C57BL/10 brain (Figure 
5.24). This was only observed through MR imaging and the mice otherwise 
appeared healthy and did not display any abnormalities in head shape. As a 
consequence of this hydrocephalus the mice were not included in the analysis.  
 
Furthermore, it was interesting to observe and compare the control C57BL/10 
mice brains to the mutant mice brains following Gd administration, as the 
control C57BL/10 mice brain ventricles appeared bright, whereas the mutant 
mouse brain ventricles did not (Figure 5.25).  
 
 
Figure 5.24: Representative T1-w images and T1 maps from control 
C57BL/10 and mdx mice at 14 months old displaying normal brain 
structure vs. hydrocephalus. A. Representative T1-w coronal image and T1 
map from a control C57BL/10 mouse brain displaying the normal mouse brain 
structure, where the ventricles appeared bright on the T1 map and were small in 
volume. B. Representative T1-w coronal image and T1 map from a control 
C57BL/10 mouse brain displaying hydrocephalus. Note the larger size of the 
brain in the T1-w image. The T1 map image showed large ventricles which 
occupy the majority of brain tissue. C. Representative coronal T1-w image and 
T1 map from mdx mouse brain displaying hydrocephalus. The brain appeared 
even larger to that of control C57BL/10 mouse brain with hydrocephalus and the 































Figure 5.25: Representative T1-w coronal images from control C57BL/10, 
mdx, Cmah-/-mdx and Cmah-/- mice displaying brain ventricles and 
vasculature following administration of gadolinium (Gd) at 14 months old. 
Successful uptake of Gd was confirmed when the vasculature appeared bright 
(red arrows). In the control C57BL/10 mice the ventricles (lateral and third 
ventricles on image) appeared bright as well (yellow arrows). This effect was 
not observed in mutant mouse brains.   
C57BL/10 mdx 
Cmah-/-mdx Cmah-/- 
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5.5 Discussion 
The mdx mouse has previously been shown to exhibit dysfunction of the 
vascular compartment of the brain including brain oedema, alterations of the 
BBB, decreased levels of TJ - associated protein ZO-1, and reduced levels of 
AQP4, a glial protein (Frigeri et al., 2001; Laws and Hoey, 2004; Nico et al., 
2005; Tamma et al., 2013). AQP4 mediates the bidirectional transport of water 
molecules in brain tissue and is known to play a role in traumatic brain oedema 
(Iacovetta et al., 2012). Under normal conditions, water moves in a bidirectional 
manner across the BBB, obeying the rules of osmosis, into the CNS and away 
via the CSF and venous circulation. A reduction or loss of AQP4 expression in 
the brain is found after trauma, stroke, haemorrhage and tumours, resulting in 
oedema and impaired ability to maintain ionic balance between cells and 
interstitial fluid (ISF) (Badaut et al., 2014). Vasogenic brain oedema occurs 
when the BBB is disrupted due to the breakdown of tight endothelial junctions 
and mainly affects the white matter through leakage out of capillaries. Therefore 
we sought to determine the consequence of dystrophin deficiency on BBB 
function in vitro and in vivo in DMD mice, between the ages of 6 and 18 months 
old, to determine if this pathological aspect is progressive. 
5.5.1 Changes in brain water content 
As a non-invasive method, MRI has been used for evaluating brain oedema in 
patients and experimental animals. The in vivo T2 of brain tissue is related to 
the local water environment and free-to-bound water ratio, which may change in 
response to cellular and axonal loss or membrane breakdown. The Cmah-/-mdx 
mice showed higher brain water content, reflected by an increase in the T2 
relaxation time, at 18 months old compared to all other genotypes. The mdx 
mice only showed a slight elevation in the T2 relaxation times in the caudate 
putamen compared to control C57BL/10 mice but other ROIs investigated 
showed a comparable T2 relaxation time to that of control C57BL/10 mice. 
Additionally the Cmah-/- mice showed a reduced T2 relaxation time in the 
caudate putamen at both 6 months and 18 months old compared to all other 
genotypes.  
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The increase in T2 relaxation time in the Cmah-/-mdx mouse brain at 18 months 
old is particularly interesting, as this suggests that it is a combination of the loss 
of full length dystrophin and Neu5Gc from the brain, which causes changes in 
the brain water content associated with vasogenic brain oedema, potentially 
causing the cognitive dysfunction we observe. The T2 relaxation times in the 
Cmah-/-mdx mouse brain were comparable to that of the other genotypes at 6 
months old; at 6 months old we did not observe any cognitive impairment on the 
Barnes maze or NOR task (see Chapter 4 for details). However, by 12 months 
old we found a huge increase in the time it took the Cmah-/-mdx mice to locate 
the target hole, suggesting that hippocampal spatial learning and memory was 
impaired at this age, which is consistent with the development of vasogenic 
oedema at an older age.  
5.5.2 Evans blue dye (EBD) extravasation 
Traditional EBD confirmed an interruption at the BBB, in both the 6 and 18 
month old DMD mice with an increase in EBD extravasation observed at 18 
months old. BBB disruption in mdx mice due to reduced expression of tight 
junction proteins has been reported previously (Nico et al., 2001). We have also 
demonstrated a reduction in AQP4 expression by western blot analysis, in the 
DMD mice brains between 1 and 12 months old, where both the M1 and M23 
isoforms were reduced with increasing age.  
 
The lack of properly functioning AQP4 channels at the BBB in mdx mice may 
impair water clearance from the cerebrum and worsen cellular oedema. 
Consequently, the osmotic influx of water into the cell causes cellular oedema 
and a decrease in extracellular space. Alternatively, a leaky BBB may also lead 
to an increase of large molecules in the extracellular space in the mdx mouse 
brain and cause interruptions in the circulation. A recent study utilised EBD and 
a quantitative MRI technique to determine the extent of BBB impairment in mdx 
mice (aged 2-10 months old) (Goodnough et al., 2014). The authors 
hypothesised that the reduction in water diffusivity in the mdx mouse brain was 
likely due to an increase in cerebral oedema or the existence of large molecules 
in the extracellular space, from a leaky BBB. Since we did not detect any 
noticeable changes in T2 relaxation rates in any ROI of the mdx brain, we would 
suggest that a disruption of the BBB is likely causing an increase in large 
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molecules in the extracellular space and interruptions in the circulation, resulting 
in a cognitive defect.  
5.5.3 T1 mapping with gadolinium enhancement 
There was a huge amount of variation between each mouse within a given 
genotype regarding the concentration of Gd for a particular ROI. It is already 
well established that there is variation in the mdx mouse muscle tissues, 
particularly in the extent of sarcolemma damage (Straub et al., 1997). We saw 
the highest rate of variation between mice, regarding the concentration of Gd 
within a particular ROI, in the mdx mice, but the control C57BL/10 mice also 
demonstrated a large amount of variation. Another obscure finding was the 
apparent uptake of Gd into the control C57BL/10 mice brain ventricle system. In 
an intact BCSFB there should be no uptake of Gd into the brain ventricle 
system. These results therefore suggest that the control C57BL/10 mice have a 
compromised blood-cerebrospinal fluid barrier (BCSFB), but since we did not 
observe any reduction in AQP1 expression it is therefore likely that the small 
reduction in AQP4 expression observed between 1 and 12 months old is 
allowing Gd to enter the ventricles. Interestingly the Gd uptake in the control 
C57BL/10 mice brain ventricles was only evident at 14 months old. This effect 
could also be happening in DMD mouse brains, but since the reduction of AQP4 
is much greater we did not see the uptake of contrast agent into the brain 
ventricles, as it is already diffusing into brain parenchyma.  
 
The molecular weight of EBD is 961 g/mol whereas the molecular weight of 
gadolinium (Gadovist) is 604.7 g/mol therefore the Gd is smaller in size, which 
could account for why we did not see any extravasation of EBD in the control 
C57BL/10 brain parenchyma, but we did observe small amounts of Gd 
extravasation into various brain ROIs.  
 
The highest uptake of Gd in the mdx brain was observed in the cerebellum. The 
uptake of Gd into the mdx mouse cerebellum was higher at 6 months than at 14 
months old, which suggests the integrity of the BBB decreases with increasing 
age. It was also higher than that observed in the control C57BL/10 mice and in 
an ROI where dystrophin is enriched (Dp427p is lost from the mdx cerebellum).  
We also observed elevated levels of Gd in the mdx cortex (both ipsilateral and 
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contralateral hemispheres), which increased between 6 and 14 months old. 
Interestingly, the Gd concentration in the control C57BL/10 mice cortex also 
increased between these two time points, suggesting that this could be an age 
related effect rather than a pathological result in the mdx mice. In the caudate 
putamen we also observed elevated levels of Gd uptake in the mdx mice. At 6 
months old the mdx mice had the highest levels of Gd in the caudate putamen 
compared to all other genotypes. The levels of Gd remained consistent in the 
mdx mice caudate putamen at 14 months old, but increased in the Cmah-/-mdx 
mice between 6 and 14 months old. Other members of the brain DGC have 
been detected in the caudate putamen, β- and α-dystrobrevins were identified in 
subcortical structures of the caudate putamen (Blake et al., 1998), which 
suggests (alongside these findings) that the brain DGC has a function within the 
mouse caudate putamen.  
 
The Cmah-/- mice displayed the lowest uptake of Gd in any ROI investigated 
and the concentration of Gd detected did not increase between 6 and 14 
months old, which was the opposite to what was identified in the other 
genotypes. The loss of the effect of the Cmah gene from mice at the BBB has 
not previously been reported, but it suggests that the loss of Neu5Gc 
expression confers resistance to BBB degradation. Consistent with this theory is 
that the Cmah-/-mdx mice did not display a higher concentration of Gd in any 
ROI to that of the mdx mice. From existing studies it cannot be established 
whether traces of Neu5Gc expression, in the brain are confined to endothelial 
and blood cells, or extend across the BBB. It was unusual to detect a reduced 
expression of AQP4 in the Cmah-/- mouse brain, which was lower than that 
detected in control C57BL/10 mouse brain at corresponding time points. AQP4 
null mice have shown similar features to those observed in other studies of the 
Cmah-/- mice, including impaired hearing (Kwon et al., 2015) (Verkman, 2005).  
Additionally, we have demonstrated changes in brain ventricle volume in the 
Cmah-/- mice (see Chapter 3 for details) and it is therefore likely that the loss of 
Neu5Gc has an impact at the BCSFB too, but the mechanisms are yet to be 
defined.  Further investigations into brain aquaporins in mice lacking the Cmah 
gene are necessary to determine the effects of Neu5Gc loss on brain function. 
Future studies should focus upon the characterization of the BBB in Cmah-/- 
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mice, as evolutionarily this could be a mechanism which was beneficial for 
human survival.  
 
Interestingly, we also detected hydrocephalus in both the control C57BL/10 and 
mdx mice at 14 months old. The level of hydrocephalus appeared to be 
exacerbated in the mdx mouse compared to the control C57BL/10 mouse 
(larger brain and swollen brain ventricles). It is known that hydrocephalus 
occurs spontaneously in 1-3% of C57BL/10 mice, but it was still unusual for the 
hydrocephalus to go unnoticed until 14 months old. Therefore, the genetic 
background of these mice may influence the development of hydrocephalus and 
this may not be a pathogenic consequence of the loss of neural Dp427.  
5.5.3.1 Study limitations  
The highest uptake of Gd into the mdx brain was observed in the cerebellum. 
The cerebellum consists of grey and white matter, which have different T1 
relaxation rates. The ROI was placed into a region of the cerebellum which 
contained both grey and white matter, since the structure of the cerebellum and 
the quality of the images does not allow for accurate delineation of an 
independent grey or white matter region. There is thus a small possibility that 
the ROIs in the different genotypes contained different ratios of grey and white 
matter tissue, although this should not affect the results drastically, it should be 
taken into consideration.  
 
Unfortunately the caudate nucleus and putamen are not distinguishable in 
rodents. The myelinated fibres that penetrate the striatum to connect to the 
cerebral cortex and subcortical structures do not form an internal capsule, but 
are distributed throughout the striatum in the rodent brain. Thus, the rodent 
striatum is known as the ‘caudate putamen’ (Figure 5.26). Conversely, in 
humans it has two parts: the caudate nucleus and the putamen (Figure 5.26).  
The caudate nucleus encircles the putamen, separated from it by the internal 
capsule. Functionally the striatum co-ordinates multiple aspects of cognition in 
both rodents (Brovelli et al., 2011) and humans (Grahn et al., 2008). It is 
therefore possible that the differences in brain structure between mice and men 
give rise to the increased BBB permeability in the rodent caudate putamen.  
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Figure 5.26: The caudate putamen in mice and men. A. Coronal section of a 
human brain showing the cortex, the caudate, and the putamen separately that 
when combined make up the striatum in comparison to B. caudal section of a 
nissl stained mouse brain showing the striatum as one structure and the cortex. 
Figure adapted from (Evans et al., 2012) and (Paxinos, 2008).  
 
Given the large amount of variation we observed between mice within a 
genotype, it is difficult to come to a concrete conclusion as to whether the T1-
mapping with Gd enhancement is a sensitive enough qualitative biomarker to 
monitor BBB integrity over time. Future studies should aim to optimise this 
technique by increasing the scanning protocol time, since it was evident that at 
14 months old (and 6 months old for certain ROIs) the Gd had not completely 
been removed in the mdx mouse brain, as Gd concentrations were increasing 
at the last scan time (42 minutes post injection). The literature states that 
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minutes (Senanayake et al., 2017), which is why we opted to scan for 90 
minutes total. The Gd also appeared to persist in the control C57BL/10 mouse 
brains at 14 months old as the Gd concentration had not returned to baseline as 
it did in the 6 month old control C57BL/10 mice. This suggests that there is a 
decline in kidney and liver function in older control C57BL/10 mice, which is the 
clearance route of Gd, although we did not look specifically and kidney or liver 
function this would be interesting to address clearance rates in future studies.  
Increasing the number of mice studied would undoubtedly improve the findings, 
either by confirming that variation regarding Gd uptake is present in a larger 
sample of mice (including control mice), or by producing an overall effect in a 
genotype.  Additionally, monitoring the same mouse over time to detect BBB 
impairment on an individual basis would be the gold-standard method; this was 
not possible in our study due to scanning related problems.  
Overall, we have demonstrated a progressive decline in BBB integrity in DMD 
mice together with reduced AQP4 expression, increased EBD extravasation, 
and increased Gd concentration in various ROIs. A close relationship between 
AQP4 and the BBB integrity has been demonstrated, as AQP4 protein is 
developmentally expressed during BBB differentiation. Replacement of AQP4 at 
the BBB could be one potential target to ameliorate BBB dysfunction in DMD 
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Chapter 6. Proteomic profiling in the mdx mouse cerebellum 
6.1 Introduction 
Proteomics is a reliable, powerful and very sensitive state of the art technique, 
which has become an important tool in the field of neuromuscular disease 
research due to the unique ability to quantify thousands of proteins, in one 
approach, in an unbiased manner (Roos et al., 2016). Biomedical surveys 
established on mass spectrometry-based proteomics can provide a 
comprehensive overview of molecular changes that underlie paediatric 
disorders and identify novel proteomic biomarker candidates for improving 
predictive, diagnostic, prognostic and therapy-monitoring processes (Murphy et 
al., 2015). 
 
Numerous studies to date have argued that the cognitive abnormalities 
associated with DMD could be classified as a cerebellar disorder due to the 
absence of full-length dystrophin (Dp427-p) in the cerebellum (Cyrulnik and 
Hinton, 2008). The cerebellum contains four times more cells than the cerebral 
cortex and houses a staggering number of neurons (Andersen et al., 1992). 
These neurons are arranged uniformly in self-contained units consisting of a 
Purkinje cell (PCs) and the associated molecular and granular cell neurons. The 
PC is the primary output neuron of the cerebellum and it is thus likely that 
disruption of the PC structure will have a widespread impact on signalling 
efficiency (Elizabeth and Molliver, 2001).   
 
The cerebellum has a predominant role in controlling motor coordination (Snow 
et al., 2013) and more recently studies have confirmed the importance of the 
cerebellum in non-motor functions including cognitive processing (Yoshihara et 
al., 2003). The major anatomical subdivisions of the cerebellum include the 
flocculonodular lobe, which receives information on balance and equilibrium 
(Tokarz et al., 1998), and the lateral and vermal hemispheres. It has been 
widely documented that damage to the vermal hemisphere results in impaired 
motor behaviour, affecting equilibrium (Glickstein and Doron, 2008). Damage to 
the lateral hemisphere, which has received less attention, indicates this as 
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being the cerebellar region involved in cognition (Akshoomoff and Courchesne, 
1992). 
 
Dp427-p, the third full length dystrophin gene product, is expressed in the PCs, 
and in the wild type mouse dystrophin expression was found to be limited to the 
puncta on somatic and dendritic membranes of both the vermal and lateral 
cerebellum (Snow et al., 2013). Furthermore, the density of dystrophin 
expression was greatest in the lateral cerebellum, associated with cognitive 
ability, compared with vermal dystrophin expression (Snow et al., 2013). 
Dystrophin loss has also been associated with the dysfunction of signalling at 
the GABA synapses on PCs, potentially by destabilisation of GABAA receptor 
clusters (GABAA –R’s) (Snow et al., 2014). Intrinsic electrophysiological 
properties have recently been investigated and demonstrated that the 
membrane potential of PCs from the vermal region of wild type mice exhibited a 
significant hyperpolarisation, along with a concurrent reduction in the frequency 
of spontaneous action potentials compared with PCs from the lateral region 
(Snow et al., 2014). This regional hyperpolarisation and concurrent reduction in 
frequency was abolished in mdx mice, indicating a difference in 
electrophysiological properties in the absence of full length dystrophin (Snow et 
al., 2014). Furthermore, firing frequency in the lateral cerebellum was also 
reduced in PCs of mdx mice relative to wild type mice (Snow et al., 2014).  
 
Within the cerebellum, a decrease in the number of PCs has been reported in 
DMD patients at autopsy. In the only Golgi-staining study of dendritic 
morphology in DMD patients (Koenig et al., 1988) investigators noted 
decreased dendritic length and decreased dendritic branching in brains of all 
patients examined, although the visual cortex was the only region investigated 
(Jagadha and Becker, 1988). Moreover, the post-mortem studies are limited in 
number and often consist of a small number of cases of multiple myopathies 
that are not always restricted to DMD patients.  
 
The current literature highlights that cognitive impairments associated with DMD 
may be mediated by the loss of dystrophin predominantly associated with the 
lateral portion of the cerebellum.  Given the varied nature and occurrence of 
cognitive abnormalities seen within the DMD patient cohort, numerous 
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questions arise regarding the origin of the molecular and cellular pathogenesis 
of these brain abnormalities. Unbiased comparative proteome profiling has the 
potential to identify complex global changes within cellular systems compared to 
individual and hypothesis-driven biochemical, cell biological or physiological 
investigations. 
 
Previous systematic proteomic studies have demonstrated a number of 
changes in proteins involved in energy metabolism, cellular signalling, the 
extracellular matrix, cytoskeletal networks, and the cellular stress response in 
dystrophic skeletal and cardiac muscles (Holland et al., 2013). More recently, a 
label-free mass spectrometric analysis revealed complex changes in the brain 
proteome from the mdx4cv (transgenic mouse lacking any dystrophin isoforms) 
model of DMD. These included an increase in expression of glial fibrillary acidic 
protein (GFAP), the neuronal Ca2+ binding protein calretinin, annexin A5, 
vimentin, the neuron-specific enzyme ubiquitin carboxyl-terminal hydrolase 
isozyme L1, the dendritic spine protein drebrin, the cytomatrix protein bassoon 
of the nerve terminal active zone, and the synapse-associated protein SAP97 
(Murphy et al., 2015). Additionally, the mdx4cv serum reveals highly elevated 
levels of the inflammation-induced plasma marker haptoglobin, using a 
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6.1.1 Aims 
The aim of this chapter is to identify the molecular nature of pathophysiological 
processes caused by dystrophin deficiency in the cerebellum of mdx mice at 6 
months old using comparative proteomic techniques. Previous literature (Huard 
and Tremblay, 1992; Kueh et al., 2011; Snow et al., 2013; Snow et al., 2014) 
and results presented in chapters of this thesis have established changes in the 
cerebellum of mdx mice; hence we chose to investigate the mdx cerebellum at 
the biochemical level.  
 
Different therapeutic approaches for DMD not only target restoration of 
dystrophin expression, but also modulation of pathophysiological cellular 
cascades in order to antagonise the detrimental molecular effects caused by 
dystrophin deficiency. The principal goal of this chapter is to provide an 
understanding of the biochemical processes contributing to cognitive 
impairment in the genesis of DMD. This will not only provide a better 
understanding of the nature of cognitive impairment in DMD, but will potentially 
identify biomarkers in the brain which are suitable for therapeutic intervention.  
 
As membrane proteins are notoriously underrepresented in a normal shotgun 
proteomic approach, we aimed to further enrich membrane proteins via 
carbonate extraction and subjected these to protein profiling utilising mass 
spectrometry. This additional procedure helped to enable a more accurate and 
robust detection of direct targets of loss of Dp427 as a membrane associated 
protein. The differential expression patterns of identified proteins was confirmed 
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6.2 Identification of proteome wide changes in the CNS 
The workflow for global protein extraction and membrane enriched protein 
extraction is outlined in Figure 6.1. Within the CNS, dystrophin expression is 
highest in the cerebellum, where it is localized as discrete puncta along the 
somatic and dendritic membranes of PCs (Yoshida et al., 1994) in both mouse 
(Lidov et al., 1990) and human studies. The protein, visualised by immunogold 
electron microscopy, is predominantly expressed at postsynaptic sites (Lidov et 
al., 1990), including dendritic spines (Jancsik & Hajos, 1998). Dystrophin is 
extensively colocalised with a subset of GABAA-R’s clusters in the typical brain, 
including in the cerebral cortex, hippocampus, and cerebellum (Knuesel et al., 
1999), our preliminary data shows reduced abundance of membrane-resident 
AQP4 in DMD mouse brains (chapter 5), putting an increased emphasis on 
membrane proteins. However, it is well known that these proteins are 
underrepresented in protein lysates generated with common extraction 
methods. In order to overcome this problem, we used carbonate extraction 
methods to separate cytosolic and membrane proteins and analyse both 
fractions separately via liquid chromatography-mass spectrometry (LC-MS/MS). 
The “Tissue Omics” group of the Leibniz-Institute of Analytical Science (ISAS 
e.V.) in which the proteomic investigations were performed, has substantial 
experience in the application of the strategy (Labisch et al., 2017). Assays for 
protein content and plasma membrane markers allow calculation of the yield 
and extent of plasma membrane enrichment by 70%. This parallel investigation 
of membrane and cytosolic proteins combined with faithful pathway analyses 
has enabled this study to better assess the question of how loss of dystrophin 
affects both, membrane and cytosolic/cytoskeletal proteins, and how these 






  259 
 
 
Figure 6.1: Proteomic studies on mdx and control (C57BL/10) mouse 
cerebella. A. Workflow for global proteome profiling. B. Workflow to enrich 
membrane proteins followed by subsequent liquid chromatography – mass 
spectrometry (LC-MS/MS). C. Volcano plot of proteomic findings obtained from 
global protein extracts derived from mdx and control C57BL/10 mice cerebella. 
D. Volcano plot of proteomic findings obtained in protein extracts enriched for 
membrane proteins derived from mdx and control C57BL/10 mice cerebella. In 
both volcano plots, proteins with decreased abundances are represented as red 
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6.2.1 Cerebellar global protein extraction 
Cerebellar proteins identified with an increased concentration, with two or more 
unique peptides, in the mdx mouse included: thrompospondin-1 (TSP-1), 
fibrinogen α and β chains, Ig kappa chain C region, acetyl-coenzyme 
thioesterase, peptidyl-prolyl cis-trans isomerase FKBP3, aspartoacylase, and 
NADH dehydrogenase 1 beta subcomplex subunit 3, 9 and 10 (Table 6.1). 
Proteins with an identified statistically significant decreased abundance in the 
mdx cerebellum included: the 60S acidic ribosomal protein P1, Rho GTPase-
activating protein 21, and histone deacetylase 6 (Table 6.1).  
 
Cerebellar proteins with an increased concentration, with one unique peptide, in 
the mdx mice included: SH3 and multiple ankyrin repeat domains protein 3, and 
synaptoporin (Table 6.2). Whereas proteins with a decreased abundance in the 
mdx cerebellum, identified with one unique peptide, included: bifunctional 3'-
phosphoadenosine 5'-phosphosulfate synthase 1, U6 snRNA-associated Sm-
like protein LSm8, and coiled-coil domain-containing protein 58 (Table 6.2). 
. 
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Global protein extraction 
Accession 
number 
Protein name Peptide 
count 






E9PV24 Fibrinogen alpha 
chain 
11 0.03 1.25 Secreted Cleaved by the protease thrombin to yield monomers which, 
together with fibrinogen beta (FGB) and fibrinogen gamma 
(FGG), polymerize to form an insoluble fibrin matrix. May also 
facilitate the immune response via both innate and T-cell 
mediated pathways. 
P01837 Ig kappa chain C 
region 
4 0.04 1.71 Membrane  Antigen activates B Cell Receptor (BCR) leading to generation of 
second messengers. 




Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix 
interactions. 
P47955 60S acidic ribosomal 
protein P1 
6 0.02 -0.63 Cytoplasm Plays an important role in the elongation step of protein 
synthesis. 
Q3UUI3 Acyl-coenzyme A 
thioesterase THEM4 
2 0.00 1.72 Cytosol, 
mitochondrion  
Inhibits AKT1 phosphorylation and activity. Interacts with AKT1. 
Expressed predominantly in skeletal muscle, testis, uterus, brain 
and kidney. Down-regulated in glioblastoma or glioma compared 




3 0.04 0.64 Cytoplasm, 
nucleus 
Constitutes a family of receptors for the two immunosuppressants 
which inhibit T-cell proliferation by arresting two distinct 
cytoplasmic signal transmission pathways.  
Q6DFV3 Rho GTPase-
activating protein 21 








Functions as a GTPase-activating protein (GAP) for RHOA and 
CDC42. Downstream partner of ARF1 which may control Golgi 
apparatus structure and function.  
Q8K0E8 Fibrinogen beta chain 6 0.02 0.82 Secreted Cleaved by the protease thrombin to yield monomers which, 
together with fibrinogen alpha (FGA) and fibrinogen gamma 
(FGG), polymerize to form an insoluble fibrin matrix. May also 
facilitate the immune response via both innate and T-cell 
mediated pathways. 
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Table 6.1: Proteins altered in abundance in mdx cerebellar tissue as revealed by label-free liquid chromatography – mass 
spectrometry (LC–MS/MS) analysis following global protein extraction identified with two or more unique peptides. Proteins in 
green were elevated in the mdx (n=4) cerebellum compared to control C57BL/10 (n=4) cerebellum at 6 months old. Red proteins had 
decreased abundance in mdx cerebellum compared to control cerebellum. Information regarding protein function was obtained from 
UniPort (Pundir et al., 2017).  
 
 
Q8R3P0 Aspartoacylase 5 0.04 0.64 Cytoplasm, 
nucleus 
Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to 
produce acetate and L-aspartate. NAA occurs in high 
concentration in brain and its hydrolysis NAA plays a significant 
part in the maintenance of intact white matter. 
Q9CQJ8 NADH dehydrogenase 
1 beta subcomplex 
subunit 9 
4 0.04 1.66 Mitochondrion 
inner membrane 
Accessory subunit of the mitochondrial membrane respiratory 
chain NADH dehydrogenase (Complex I), that is believed to be 
not involved in catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain.  
Q9CQZ6 NADH dehydrogenase 
1 beta subcomplex 
subunit 3 
2 0.04 1.85 Mitochondrion 
inner membrane 
Accessory subunit of the mitochondrial membrane respiratory 
chain NADH dehydrogenase (Complex I), that is believed to be 
not involved in catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain. 
Q9DCL9 Multifunctional protein 
ADE2 







This protein is involved in step 1 of the subpathway that 
synthesizes 5-amino-1-(5-phospho-D-ribosyl) imidazole-4-
carboxamide from 5-amino-1-(5-phospho-D-ribosyl) imidazole-4-
carboxylate. 
Q9DCS9 NADH dehydrogenase 
1 beta subcomplex 
subunit 10 
6 0.03 1.43 Mitochondrion 
inner membrane 
Accessory subunit of the mitochondrial membrane respiratory 
chain NADH dehydrogenase (Complex I), that is believed to be 
not involved in catalysis. Complex I functions in the transfer of 
electrons from NADH to the respiratory chain. 
Q9Z2V5 Histone deacetylase 6 2 0.01 -0.78 Nucleus, 
cytoplasm, 
perikaryon 
Responsible for the deacetylation of lysine residues on the N-
terminal part of the core histones. 
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Table 6.2: Proteins altered in abundance in mdx cerebellar tissue as revealed by label-free LC–MS/MS analysis following global 
protein extraction identified with one unique peptide. Proteins in green were elevated in the mdx (n=4) cerebellum compared to 
control C57BL/10 (n=4) cerebellum at 6 months old. Red proteins had decreased abundance in the mdx cerebellum compared to control 
C57BL/10 cerebellum. Information regarding protein function was obtained from UniPort (Pundir et al., 2017). 
Global protein extraction 
Accession 
number 









Protein function  
Q4ACU6 SH3 and multiple 
ankyrin repeat 
domains protein 3 











Major scaffold postsynaptic density protein which interacts with 
multiple proteins and complexes to orchestrate the dendritic 
spine and synapse formation, maturation and maintenance. 
Interconnects receptors of the postsynaptic membrane including 
NMDA-type and metabotropic glutamate receptors. Plays a role 
in the structural and functional organization of the dendritic spine 
and synaptic junction. May be required at an early stage of 






1 0.02 -1.36  Bifunctional enzyme with both ATP sulfurylase and APS kinase 





1 0.03 -0.94 Nucleus  Binds specifically to the 3'-terminal U-tract of U6 snRNA and is 
probably a component of the spliceosome. 





Intrinsic membrane protein of small synaptic vesicles. Probable 
vesicular channel protein. 
Q8R3Q6 Coiled-coil domain-
containing protein 58 
1 0.05 -1.02 Mitochondrion  
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6.2.2 Cerebellar membrane enriched protein extraction 
Following carbonate extraction methods, in order to enrich membrane proteins, 
numerous proteins were detected with increased abundance in the mdx 
cerebellum compared to control C57BL/10 mice at 6 months old. Proteins with 
an increase concentration, identified with two or more unique peptides, in the 
mdx cerebellum included: syntaxin-1A, protein IMPACT, cytochrome c oxidase 
subunit 3, gelsolin, sodium- and chloride-dependent GABA transporter 3, 
Purkinje cell protein 4-like protein 1, uncharacterised protein C19orf52 homolog, 
brain acid soluble protein 1, and cadherin-13 (Table 6.3). In contrast, only one 
protein was identified with a reduced abundance in the mdx mice cerebellum 
compared to control C57BL/10 mice cerebellum at 6 months old; CDGSH iron-
sulfur domain-containing protein 2 (Table 6.3). 
 
Cerebellar membrane enriched tissue-associated proteins with an increased 
concentration, with one unique peptide, in the mdx mice included: fibrinogen β 
chain, alpha-1-antitrypsin 1-5, peripherin, ubiquitin-like modifier-activating 
enzyme 5, poly(rC)-binding protein 2, guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-4, membralin, aggrecan core protein, actin-
related protein 10, gap junction gamma-2 protein, cystatin-C, receptor-type 
tyrosine-protein phosphatase S, and Ras-related protein Rab-31 (Table 6.4). In 
contrast, proteins with a decreased abundance (one unique peptide) in the mdx 
cerebellum following membrane protein enrichment included three proteins: 
catechol O-methyltransferase, protein FAM134C, and diacylglycerol kinase 
epsilon (Table 6.4). 
 
  265 
Cerebellar membrane enrichment 
Accession 
number 















Plays a role in hormone and neurotransmitter 
exocytosis (By similarity). Potentially involved in 
docking of synaptic vesicles at presynaptic active 
zones. 
O55091 Protein IMPACT 2 0.01 0.74 Cytoplasm Translational regulator that ensures constant high 
levels of translation upon a variety of stress 
conditions, such as amino acid starvation, UV-C 
irradiation, proteasome inhibitor treatment and 
glucose deprivation. May be required to regulate 
translation in specific neuronal cells under amino 
acid starvation conditions by preventing GCN2 
activation and therefore ATF4 synthesis Through 
its inhibitory action on EIF2AK4/GCN2, plays a 
role in differentiation of neuronal cells by 
stimulating neurite outgrowth. 
P00416 Cytochrome c oxidase 
subunit 3 
2 0.0001 0.79 Mitochondrion 
inner membrane 
Subunits I, II and III form the functional core of the 
enzyme complex. 
P13020 Gelsolin 7 0.01 0.63 Cytoplasm, 
cytoskeleton 
Calcium-regulated, actin-modulating protein that 
binds to the plus (or barbed) ends of actin 
monomers or filaments, preventing monomer 
exchange (end-blocking or capping). It can 
promote the assembly of monomers into filaments 
(nucleation) as well as sever filaments already 
formed.  
P31650 Sodium- and chloride-
dependent GABA 
transporter 3 
4 0.03 0.60 Membrane Terminates the action of GABA by its high affinity 
sodium-dependent reuptake into presynaptic 
terminals. Can also transport beta-alanine and 
taurine. 
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Q6W8Q3 Purkinje cell protein 4-like 
protein 1 
2 0.053 0.61 Expressed in 
laminar and 
nuclear structures 
of the CNS 
Expressed at early stages of development in the 
isthmus and in metencephalic and mesencephalic 
roof plates. At later stages of development, it is 
expressed in structures corresponding to 
circumventricular organs which in adult control the 
production of the cerebrospinal fluid. 
Q8BGX2 Uncharacterised protein 
C19orf52 homolog 
2 0.02 0.72 Mitochondrion 
inner membrane 
Component of the TIM22 complex, a complex that 
mediates the import and insertion of multi-pass 
transmembrane proteins into the mitochondrial 
inner membrane.  
Q91XV3 Brain acid soluble protein 
1 
10 0.003 0.83 Cell membrane  
Q9CQB5 CDGSH iron-sulfur 
domain-containing protein 
2 
2 0.02 -0.67 Endoplasmic 
reticulum 
membrane 
Regulator of autophagy that contributes to 
antagonize BECN1-mediated cellular autophagy 
at the endoplasmic reticulum. Participates in the 
interaction of BCL2 with BECN1 and is required 
for BCL2-mediated depression of endoplasmic 
reticulum Ca(2+) stores during autophagy. 
Contributes to BIK-initiated autophagy, while it is 
not involved in BIK-dependent activation of 
caspases.  
Q9WTR5 Cadherin-13 2 0.02 0.64 Cell membrane Cadherins are calcium-dependent cell adhesion 
proteins. They preferentially interact with 
themselves in a homophilic manner in connecting 
cells; cadherins may thus contribute to the sorting 
of heterogeneous cell types. May act as a 
negative regulator of neural cell growth. 
 
Table 6.3: Proteins altered in abundance in mdx cerebellar tissue as revealed by label-free LC–MS/MS analysis following 
membrane enriched extraction identified with two or more unique peptides. Proteins in green were elevated in the mdx mouse 
(n=5) cerebellum compared to control C57BL/10 mouse (n=4) cerebellum at 6 months old. Red proteins had decreased abundance in 
mdx cerebellum compared to control C57BL/10 cerebellum. Information regarding protein function was obtained from UniPort (Pundir et 
al., 2017).  
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Cerebellar membrane enrichment 
Accession 
number 










Q8K0E8 Fibrinogen beta chain 1 0.008 2.54  Cleaved by the protease thrombin to yield monomers which, 
together with fibrinogen alpha (FGA) and fibrinogen gamma 
(FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a 
major function in hemostasis as one of the primary components of 
blood clots. May also facilitate the immune response via both 
innate and T-cell mediated pathways.  
Q00898 Alpha-1-antitrypsin 1-5 1 0.002 
 
2.21 Secreted  Does not inhibit elastase or chymotrypsin. No target protease has 
been identified to date. 
P15331 Peripherin 1 0.04 1.55  Class-III neuronal intermediate filament protein. 
Q8VE47 Ubiquitin-like modifier-
activating enzyme 5 
1 0.002 1.40 Cytoplasm, 
nucleus 
E1-like enzyme which activates UFM1 and SUMO2. 
Q61990 Poly(rC)-binding 
protein 2 
1 0.001 1.08  Single-stranded nucleic acid binding protein that binds 
preferentially to oligo dC. Major cellular poly(rC)-binding protein. 
Binds also poly(rU). Negatively regulates cellular antiviral 





1 0.03 1.07 Cell membrane Guanine nucleotide-binding proteins (G proteins) are involved as a 
modulator or transducer in various transmembrane signaling 
systems. The beta and gamma chains are required for the GTPase 
activity, for replacement of GDP by GTP, and for G protein-effector 
interaction. 
Q8CIV2 Membralin 1 0.01 0.93 Endoplasmic 
reticulum 
membrane 
May have a role in the ERAD pathway required for clearance of 
misfolded proteins in the endoplasmic reticulum (ER). Promotes 
survival of motor neurons, probably by protecting against ER 
stress. 
Q61282 Aggrecan core protein 1 0.02 0.81 Secreted, 
extracellular space, 
extracellular matrix 
This proteoglycan is a major component of extracellular matrix of 
cartilagenous tissues. A major function of this protein is to resist 
compression in cartilage. It binds avidly to hyaluronic acid via an 
N-terminal globular region.  
Q9QZB7 Actin-related protein 10 1 0.01 0.76   
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Table 6.4: Proteins altered in abundance in mdx cerebellar tissue as revealed by label-free LC–MS/MS analysis following 
membrane enriched extraction identified with one unique peptide. Proteins in green were elevated in the mdx (n=5) cerebellum 
compared to control C57BL/10 cerebellum (n=4) at 6 months old. Red proteins had decreased abundance in mdx cerebellum compared 
to control C57BL/10 cerebellum. Information regarding protein function was obtained from UniPort (Pundir et al., 2017).  
Q8BQU6 Gap junction gamma-2 
protein 
1 0.01 0.67 Cell membrane One gap junction consists of a cluster of closely packed pairs of 
transmembrane channels, the connexons, through which materials 
of low MW diffuse from one cell to a neighboring cell. May play a 
role in myelination in central and peripheral nervous systems.  
P21460 Cystatin-C 1 0.01 0.64 Secreted As an inhibitor of cysteine proteinases, this protein is thought to 





1 0.02 0.64 Membrane Interacts with LAR-interacting protein LIP.1. 
Q921E2 Ras-related protein 
Rab-31 
1 0.02 0.63 Early endosome, 
Golgi apparatus 
The small GTPases Rab are key regulators of intracellular 
membrane trafficking, from the formation of transport vesicles to 
their fusion with membranes. Rabs cycle between an inactive 
GDP-bound form and an active GTP-bound form that is able to 
recruit to membranes different set of downstream effectors directly 
responsible for vesicle formation, movement, tethering and fusion. 
Required for the integrity and for normal function of the Golgi 
apparatus and the trans-Golgi network. Plays a role in the 
internalization of EGFR from the cell membrane into endosomes. 
O88587 Catechol O-
methyltransferase 





Catalyzes the O-methylation, and thereby the inactivation, of 
catecholamine neurotransmitters and catechol hormones.  
Q9CQV4 Protein FAM134C 1 0.04 -1.06 Membrane  Mediates NRF1-enhanced neurite outgrowth. 
Q9R1C6 Diacylglycerol kinase 
epsilon 
1 0.002 -1.08 Membrane, 
cytoplasm 
Highly selective for arachidonate-containing species of 
diacylglycerol (DAG). May terminate signals transmitted through 
arachidonoyl-DAG or may contribute to the synthesis of 
phospholipids with defined fatty acid composition 
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6.3 Confirmation of proteins identified following cerebellar proteomic 
profiling   
NLD-Progenesis software, which was used for label-free comparison, generated 
3D-montages, to provide a visual representation of the increases in the unique 
tryptic peptide for the protein of interest.  Following ionisation and detection by 
MS, a tryptic peptide is blotted in an ion chromatogram by Progenesis software 
based on its mass/charge (m/z) and its retention time (RT). The numbers of 
each detected peptide, following normalisation with all the samples, was 
converted into sizes and represented by a big or small peak/s (Figure 6.2).  
 
Following both investigation of global and membrane enriched protein fractions, 
we identified changes in the abundance of six proteins, which we determined 
had the greatest relevance to brain function (based on the current literature) 

























Figure 6.2: Screenshot of the NLD-Progenesis software. The NLD-Progenesis software was used to produce the 3D-montages of the 
unique tryptic peptide of a protein and provided a visual representation of the output following mass spectrometry (MS).  
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6.3.1  Elevated levels of thrombospondin-1 in the mdx mouse 
cerebellum 
Astrocytes are the prominent glial cell population in the CNS, they are also the 
first cells of the brain parenchyma to encounter foreign molecules crossing the 
BBB (Chen et al., 2011). In the developing CNS, soluble factors derived from 
astrocytes regulate synapse formation and neuronal survival (Chen et al., 
2011). Thrombospondins (TSPs) belong to the multimeric extracellular matrix 
glycoprotein (450 kDa) families, which are involved in the regulation of cell 
growth, motility, and differentiation (Risher and Eroglu, 2012). Astrocytes 
secrete TSP-1 and thrombospondin-2 (TSP-2), which have roles in promoting 
neurite outgrowth and synaptogenesis (Christopherson et al., 2005). 
 
TSP-1 was found to be elevated in the mdx cerebellum following global protein 
analysis (Figure 6.3). This increase in TSP-1 expression was confirmed via 
western blot analysis (Figure 6.3) and IF staining (Figure 6.3). In contrast, no 
difference in the expression levels of TSP-2 was detected in the mdx 
cerebellum at 6 months old following global protein profiling.  
 
We performed immunoblotting analyses on cerebellar lysates from control 
C57BL/10 (n=3) and mdx (n=3) brain tissue. Expression of TSP-1 in the 
cerebellum was examined by western botting using a polyclonal antibody 
against TSP-1. Results confirmed the overexpression of TSP-1 in the 
cerebellum of mdx compared to the control C57BL/10 mice at 6 months old 
(Figure 6.3). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (~38 kDa) 
was used as a loading control. 
 
Additional confirmation of TSP-1 overexpression in the cerebellum of mdx mice 
was achieved using IF staining. We performed IF staining at two time points, 6 
and 18 months old mice, to detect if TSP-1 overexpression was persistent. 
GFAP (mouse monoclonal antibody) was used as an accurate marker for 
astrocytes. The IF staining results demonstrated an increased expression of 
TSP-1 in the mdx cerebellum at 6 months old compared to age matched control 
C57BL/10 mice (Figure 6.4 and Figure 6.5). Moreover, there was no difference 
in the expression levels of GFAP between mdx and control C57BL/10 mice at 6 
months old. An increased concentration of GFAP is an established indicator of 
  272 
glial scar formation in the field of neuropathology (Kristjansdottir et al., 2001). 
Increased expression of GFAP has previously been identified in mdx4cv mouse 
brain (Murphy et al., 2015), suggesting that loss of Dp427 does not affect GFAP 
expression levels in the mdx mouse cerebellum (Murphy et al., 2015). 
Additionally, a reduced level of GFAP was found in the brains from embryonic 
and 30 day old mdx mice via western blot analysis, however this study 
measured levels of GFAP in the telencephalon (cerebrum) and did not provide 
results pertaining to the levels of GFAP in the cerebellum (Nico et al., 2004). It 
could therefore be possible that GFAP is expressed developmentally in the mdx 

































Figure 6.3: Western blot analysis of TSP-1 expression at various time 
points. A. Western blot analysis for TSP-1(125 kDa) at 6 months old on 
cerebellar lysates from control C57BL/10 and mdx mice. B. Repeated TSP-1 
western blot at 6 months old on cerebellar samples 2. C. Western blot analysis 
for TSP-1 at 1 month and 18 months old. All blots show TSP-1 overexpression 
in mdx mice cerebellum. D. Modified screenshot image of a profile plot 
demonstrating how band intensity was quantified using ImageJ gel analysis, 
calculated from area under the curve. E. Quantification of TSP-1 expression 
compared to loading control. In all blots GAPDH (38 kDa) was used as a 
loading control (mouse monoclonal, ab8245, at 1/10000). TSP-1 (rabbit 
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Figure 6.4: Immunofluorescence labelling of thrombospondin-1 (TSP-1) at 
40x magnification. Double immunofluorescently labelled cryosections (10 µm) 
of control C57BL/10 and mdx mouse cerebellum at 40x magnification, stained 
with (TSP-1) (red), the astrocytic marker glial fibrillary acidic protein (GFAP) 
(green) and DAPI (blue) used to locate cell nuclei. Overexpression of TSP-1, 
identified following proteomic analysis, is evident in the mdx mice cerebellum 
compared to aged matched control C57BL/10 mice (6 months old). No 
difference in GFAP expression was observed. Scale bar= 20 µm. GFAP (mouse 










































Figure 6.5: Immunofluorescence labelling of thrombospondin-1 (TSP-1) at 
20x magnification. Double immunofluorescently labelled cryosections (10 µm) 
of control C57BL/10 and mdx mouse cerebellum at 20x magnification, stained 
with TSP-1(red), the astrocytic marker GFAP (green) and DAPI (blue) used to 
locate cell nuclei. Overexpression of TSP-1, identified following proteomic 
analysis, was evident in the mdx mice cerebellum compared to aged matched 
control C57BL/10 mice (6 months old). No difference in GFAP expression was 
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6.3.2 Elevation of gelsolin expression in the mdx cerebellum 
Actin and its associated binding proteins play a critical role in cellular signalling 
(Basu et al., 2008). Actin responds to extracellular signalling by converting from 
soluble to polymerised actin, under the control of gelsolin. Gelsolin is present 
intracellularly, in all cell types, and in the plasma/CSF as a secreted protein (Ji 
et al., 2009). Intracellularly, gelsolin is a major actin-binding protein that caps 
the actin filaments growing end, stimulates its nucleation, and severs the actin 
filaments (Ji et al., 2009). Both plasma/CSF and intracellular gelsolin originate 
from the alternative splicing of a single gene (Kwiatkowski et al., 1988). Not only 
does gelsolin facilitate in controlling the formation of cytoplasmic actin filaments, 
but it also plays important roles in both apoptosis and amyloidosis (Antequera et 
al., 2009).  
 
Gelsolin levels were found to be elevated in the mdx cerebellum at 6 months old 
following the membrane protein enrichment extraction method (Table 6.3). We 
confirmed the increase of gelsolin via western blot analysis (Figure 6.6).  
 
We performed immunoblotting analyses on cerebellar lysates from control 
C57BL/10 (n=3) and mdx (n=3) brain tissue, using a polyclonal antibody against 
gelsolin. Results confirmed the overexpression of gelsolin in the cerebellum of 
mdx mice compared to the control C57BL/10 mice at 6 months old (Figure 6.6). 
Multiple bands were possibly a consequence of posttranslational modification 
events. GAPDH (~38 kDa) was used as a loading control. 
  277 
 
 
Figure 6.6: Immunoblot analysis showing relative expression levels of Gelsolin in mdx and aged match control C57BL/10 
mouse cerebellar lysates. A. Three separate blots using three independent cerebellar lysates from different mice per genotype 
represented by blots one, two and three. GAPDH was used as a loading control (1/1000). B. Graph showing relative Gelsolin expression 
calculated based on the results from the three blots. Gelsolin (rabbit polyclonal, ab74420, 1/1000). Data represented as ± SEM, p*<0.05, 
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6.3.3 Detection of changes in GABA expression in mdx cerebellum  
GABA is an inhibitory neurotransmitter in the CNS. The binding of GABA to 
specific transmembrane receptors in the plasma membrane, of both pre- and 
postsynaptic neuronal processes results in the opening of ion channels, 
allowing the flow of either negatively charged chloride ions into the cell or 
positively charged potassium ions out of the cell (Macdonald and Olsen, 1994). 
The result of this mechanism is a negative change in the transmembrane 
potential, usually causing hyperpolarisation. GABAA receptors are part of a 
ligand-gated ion channel complex, whereas GABAB metabotropic receptors are 
G-protein coupled receptors, which open or close ion channels via 
intermediates (Macdonald and Olsen, 1994; Borden, 1996).  
 
It has previously been reported that there is a significant decrease in the 
number and size of GABAA receptor clusters immunoreactive for α1 and α2 
subunits in the cerebellum and hippocampus of the mdx mouse (Knuesel et al., 
1999).  The GABAA α1 and α2 subunit-containing receptors have also been 
implicated to have critical roles in working memory and cognition (Hashimoto et 
al., 2009). Normally GABAA receptor subunit clusters are colocalised with 
dystrophin at the post-synaptic densities of cerebellar PCs and more recent 
reports suggest that there is no difference in expression of the gene for the 
GABAA receptor α1 subunit in the cerebellum of young (3–4 month 
old) mdx mice compared to aged matched controls (Wallis et al., 2004). 
Moreover, the latest reports hypothesise that the absence of dystrophin, from 
mdx Purkinje cells, reduces the number of post-synaptic GABAA–R’s and as a 
consequence causes an increase in extrasynaptic receptors. (Kueh et al., 
2011). 
 
Following proteomic analysis in the mdx cerebellar membrane protein enriched 
fraction, GABA transporter type 3 (GAT3) was found to be elevated compared 
to age matched control C57BL/10 mice. GAT1 and GAT3 are the two main 
subtypes of GATs responsible for the regulation of extracellular GABA levels in 
the CNS (Borden, 1996). GAT3 is highly expressed in the deep cerebellar 
nuclei and widely expressed in glial elements throughout the brain. Following 
the release of GABA from the pre-synaptic terminals it is rapidly removed from 
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the extracellular space by GATs, a regulatory mechanism that terminates 
inhibitory synaptic transmission maintaining GABA homeostasis to prevent 
excessive tonic activation of synaptic and extrasynaptic GABA-R’s (Borden, 
1996).  It has recently been suggested that GATs modulation could play a 
critical role in maintaining homeostasis of GABAergic transmission (Jin et al., 
2012).  
 
Firstly, we performed a western blot analysis for the GABAA receptor α2 subunit 
to address potential changes in the expression levels of this protein with 
increasing age in mdx mice. Our findings demonstrate that GABAA receptor α2 
subunit protein levels remain unchanged in the mdx mice cerebellum between 6 
and 12 months old (Figure 6.7). The western blots were carried out with the 
same antibody (rabbit polyclonal from Alomone labs) at the same concentration 
(1/500) but with two separate aliquots. The first aliquot only produced a band 
detectable at 30 kDa, whereas the second antibody aliquot produced a band at 
the correct 50 kDa position (Figure 6.7). GAPDH (~38 kDa) was used as a 
loading control. For further confirmation of these findings, the western blots 
should be performed with an additional antibody obtained from a different 
source.  
 
A successful western blot was achieved and confirms overexpression of GAT3 
in the mdx mice cerebellum (Table 6.3), but further investigations are necessary 
to gain a better understanding of how the GABAegic system in the cerebellum is 
affected in mdx mice (Figure 6.8). Nevertheless, these findings suggest a 
dysfunction in the GABAergic system in the cerebellum of mdx mice, due to the 
loss of Dp427. 
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Figure 6.7: Western blot analysis for GABAA α2 protein at 4 and 6 months old using mdx and control C57BL/10 cerebellar 
lysates.  A. Western blot performed with first aliquot of antibody at 6 and 12 months old. B. Quantification of GABAA α2 protein at 4 and 6 
months old. C. Western blot performed with a second aliquot of antibody at 4 and 6 months old. D. Repeated western blot at 12 months 
old with the second aliquot of antibody. E. Quantification of GABAA α2 protein at 4 and 6 months old. Glyceraldehyde 3-phosphate 
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Figure 6.8: Western blot analysis for GAT-3 in mdx and control C57BL/10 
mouse cerebellum.  A. Overexpression of GAT3 is detectable in mdx 
cerebellar protein lysate compared to control C57BL/10 at 6 months old. 
Glyceraldehyde 3-phosphate dehydrogenase. B. Quantification of GAT3 
expression in the cerebellum. Data presented as mean ± SEM, p<0.05 vs 
control C57BL/10 mice. (GAPDH) (~38 kDa) was used as a loading control. 
GAT3 (rabbit polyclonal, AGT-003, at 1/500).
6.3.4 Changes in mitochondrial proteins in the mdx cerebellum  
Given the crucial roles for mitochondria in ATP energy supply, Ca2+ handling, 
and cell death, mitochondrial dysfunction has long been suspected to be an 
important pathogenic feature in DMD. In muscle, mdx mice have displayed 
significant uncoupling of oxidative phosphorylation and a reduction in maximal 
ATP synthesis capacity, which together resulted in decreased intramuscular 
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ATP levels (Percival et al., 2013). The mitochondrial bioenergetic dysfunction in 
mdx skeletal muscle has been well document and its contributions to disease 
pathogenesis in dystrophin-deficient skeletal muscle investigated. However, 
changes in mitochondrial function in mdx mouse cerebellum as a consequence 
of Dp427 loss remain unknown.  
 
Following both investigation of global and membrane enriched protein fractions, 
mitochondrial proteins were found to be elevated in the mdx cerebellum 
compared to control C57BL/10 mice cerebellum at 6 months old (Table 6.1 and 
Table 6.3). NADH dehydrogenase was the most highly elevated mitochondrial 
protein in the mdx cerebellum (Figure 6.9). Prompted by this finding we 
performed a western blot analysis using the Oxphos 5 antibody (total OXPHOS 
rodent WB cocktail), which recognises all five mitochondrial complexes, and 
determined that complex III and complex II were significantly elevated in the 
mdx cerebellum compared to age matched control C57BL/10 mice.  
Cytochrome C reductase (complex III) was found to be elevated following 
membrane enriched protein extraction methods and along with complex II form 
the functional core of the enzyme complex (Figure 6.10). The voltage-
dependent anion channel (VDAC/Porin) (31 kDa) was used as a loading control.  
 
Additionally, we sought to determine if the increased abundance of 
mitochondrial enzymes had an impact on the structural integrity of the 
mitochondria. Thus we performed electron microscopy of cerebellar sections 
derived from 6 and 12 month old mice, which revealed no ultrastructural 
changes in the mitochondria at either time point in the mdx cerebellum 
compared to age matched control C57BL/10 mice (Figure 6.11).   
  


















Figure 6.9: Representative 3D montages generated from NLD-Progenesis 
software following label free comparison. Each peak represents a unique 
tryptic peptide of the respective protein. A. 3D montage for NDUB3 protein from 
control and mdx cerebellar lystates. B. 3D montage for NDUB9 protein from 
control and mdx cerebellar lystates. C. 3D montage for NDUBA_mouse protein 
from control and mdx cerebellar lystates. D. 3D montage for NDUB5 protein 
from control and mdx cerebellar lystates. Green box indicates a tryptic peptide 
with a charge state of +3. Red box indicates a tryptic peptide with a charge 




















































































































































































































































Figure 6.10: Western blot analysis for oxphos 5 antibody in control C57BL/10 and mdx cerebellar protein lysates at 6 months 
old. A. Three blots with independent samples displaying overexpression of mitochondrial proteins in the mdx cerebellum. VDAC/Porin 
was used as a loading control. B. The Coomassie protein stain served as confirmation of equal protein loading. C. Ponceau stain to 
confirm western blot transfer and equal protein loading. D. Quantification of oxphos 5 levels in control C57BL/10 and mdx cerebellar 
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Figure 6.11: Representative Transmission electron micrographs (TEM) of 
control C57BL/10 and mdx mouse cerebellum. Mitochondria were 
abundantly present at 6 and 12 months old in both genotypes. The mitochondria 
(blue arrow) appeared ultrastructurally normal with no abnormalities in 
membrane (inner and outer) integrity or cristae architecture and showed 
extensive surrounding by endoplasmic reticulum (ER) (mitochondria-ER-
membrane sites) (red arrow). (n=2 mice/genotype at each time point). Images 
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6.3.5 Elevated levels of fibrinogen in the mdx cerebellum  
Fibrinogen is a 340 kDa plasma glycoprotein that is converted by thrombin into 
fibrin during blood clot formation. Thrombin then converts the soluble fibrinogen 
into insoluble fibrin strands (Ryu et al., 2015). These strands are then cross-
linked by factor XIII to form a blood clot. Blood proteins such as fibrinogen, 
plasminogen and thrombin are therefore critical for the functional maintenance 
of integral vasculature homeostatic processes, which involve blood clotting 
(Palta et al., 2014). However, rupture of the vasculature, due to pathological 
conditions and weakening of the BBB allows the entry of blood proteins into the 
brain and precedes subsequent oedema formation and neuronal damage 
(Abbott et al., 2010). Recent studies have demonstrated fibrin deposition and 
damaged vasculature in transgenic mouse models of Alzheimer’s disease (AD) 
(Paul et al., 2007). It has been further identified that infiltration of fibrinogen into 
parenchymal regions acts to amplify and sustain chronic inflammatory 
microenvironments, which are proposed as toxic to bystander neurons (Ryu and 
McLarnon, 2009). 
 
Following the proteomic analysis of global protein extracts and membrane 
enriched protein fractions, elevated levels of fibrinogen were detected in the 
mdx mouse cerebellum compared to control C57BL/10 mouse cerebellum at 6 
months old (Table 6.1 and Table 6.4). More specifically, the α and β fibrinogen 
chains were found to be overexpressed in the mdx cerebellum. We confirmed 
the increased abundance of fibrinogen using immunological techniques (Figure 
6.12). Western blot analysis was performed on mdx and control C57BL/10 
mouse cerebellar lysates using a polyclonal antibody which detected fibrinogen-
α chain at 95 kDa and confirmed the overexpression in the mdx cerebellar 
protein extracts (Figure 6.12). GAPDH (~38 kDa) was used as a loading control. 
For further confirmation of fibrinogen overexpression we also performed IF 
staining on cryosections of control C57BL/10 and mdx mouse cerebellum 
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Figure 6.12: Analysis of fibrinogen expression. A. Western blot analysis for 
fibrinogen-α chain in the mdx and control C57BL/10 cerebellar protein lysates at 
6 months old. B. The Coomassie stained protein gel served as a verification of 
correct protein loading. C. Quantification of fibrinogen overexpression in the 
mdx cerebellum at 6 months old. GAPDH (~38 kDa) was used as a loading 






















































































































Figure 6.13: Immunofluorescently labelled cryosections (10 µm) of control 
C57BL/10 and mdx mouse cerebellum at 20x and 40x magnification, 
stained with an antibody raised against the fibrinogen α chain. There 
appeared to be overexpression of fibrinogen in the mdx cerebellum compared 
to control C57BL10 cerebellum at 6 months old. The white arrows indicate 
extensive areas of diffuse fibrinogen deposition. Scale bar= 50 µm at 20x and 
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6.3.6 Further protein analysis 
Enhanced proteins were analysed for enriched gene ontology (GO) terms using 
STRING (https://string-db.org/) software, which detected functional protein 
association networks from the proteins identified by both global and membrane 
enriched protein extraction methods. STRING highlighted two protein networks 
of interest (Figure 6.14). The first protein network highlighted was the known 
association between TSP-1, fibrinogen and the integrin beta-2 precursor, which 
are all proteins involved in an inflammatory response. The second protein 
network highlighted a link (co-expression) between NADH dehydrogenase and 
peptidyl-prolyl cis-trans isomerase (Figure 6.14). Panther (http://pantherdb.org/) 
bioinformatics software was also used to identify the protein class and 
molecular function of proteins which were found to have an increased 
abundance in the mdx cerebellum at 6 months old (Figure 6.15). Interestingly, 
the highest proportion of proteins identified were found to be functional binding 
proteins (50%) (Figure 6.15). The largest proportion of proteins identified with 
an increased abundance in the mdx cerebellum were either structural, 
cytoskeletal, or membrane trafficking proteins.   
 
Figure 6.14: Analysis of protein interaction networks using STRING. 
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Figure 6.15: Protein class and molecular function identified with Panther 
software. A. Summary of increased protein classes in the mdx cerebellum 
following global protein extraction and membrane enrichment protein extraction 
compared to control C57BL/10 mouse cerebellum. The bioinformatics software 
programme PANTHER was employed to establish the clustering of protein 
classes based on liquid chromatography- mass spectrometry (LC-MS/MS) 
analysis. B. Pie chart summarising the molecular function of proteins which 
were elevated in the mdx mouse cerebellum following LC-MS/MS analysis.  
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6.4 Discussion 
Within the rodent cerebellum dystrophin (Dp427) is present in the molecular cell 
layer (MCL), the Purkinje cell layer (PCL) and the granular cell layer (GCL) 
(Hendriksen et al., 2016b).  Morphologically, dystrophin appears to be present 
around PCs, in astrocytes of both the MCL and GCL, and in blood vessels 
across all three cerebellar layers (Snow et al., 2013; Hendriksen et al., 2016b). 
Therefore, we sought to identify how the loss of full length dystrophin affected 
the mdx cerebellum utilising an unbiased proteomic profiling approach.  
6.4.1 Elevated levels of thrombospondin-1 in the mdx mouse 
cerebellum 
Elevated levels of TSP-1 were detected in the mdx cerebellum at 6 months old 
and this was confirmed using both western blot analysis and IF staining. 
Astrocytes are known to provide signals to guide synapse formation and neurite 
development, critical in both the developing and mature brain (Risher and 
Eroglu, 2012). Factors secreted by astrocytes are involved in the regulation of 
the stability, dynamics, and maturation of dendritic spines (Cheng et al., 2016). 
Changes in TSP expression can have direct impact on synapse function and 
development.  
 
TSP’s have also been implicated in the inflammatory response of the CNS. 
Nearly all neurological disorders are hallmarked by inflammation, characterised 
by the induction of microglia, monocytes, cytokines, and other mediators of 
injury (Wee Yong, 2010). In the immune system, TSP-1 modulates the adhesion 
and aggregation of monocytes/macrophages via interaction with CD36 and 
CD47 (Yamauchi et al., 2002b). Cytokines have recently been identified as 
having roles in synaptic plasticity and neurogenesis. For example IL-6 has been 
shown to modulate long-term potentiation (LTP) in vitro in the rat hippocampus 
(Yamauchi et al., 2002a). On the other hand TSP-1 can also suppress IL-10 
release via interactions with latent TGF-β1 (Schultz-Cherry et al., 1994). TSP-1 
and TGF-β1 may therefore play a role in cortical injury given their significant up 
regulation following brain injury (Schultz-Cherry et al., 1994). In the peripheral 
nervous system (PNS), TGF-β1 is linked to multiple aspects of plasticity and 
synapse formation, particularly in Schwann cells (the major glial cell of the 
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PNS), where its release promotes synapse formation at the neuromuscular 
junction (Feng and Ko, 2008).  
 
Previous studies in the skeletal muscles of mdx mice have also identified TSP-1 
as a pathogenic biomarker. TSP-1 acts as a potent mediator of angiotensin-II-
induced TGF-β via angiotensin-2. Control mice did not express significant 
amounts of TSP-1 in skeletal muscle but strong sarcolemma expression of 
TSP-1 was observed in the diaphragm (and other muscles) of mdx mice (Cohn 
et al., 2007). Treatment with Lorstan, an angiotensin-II type 1 inhibitor, 
attenuated disease progression and reduced TSP-1 expression in the muscles 
of treated mdx mice.  
6.4.1.1 Changes in thrombospondin-1 expression in other neurological 
disorders 
TSP’s have been identified as key disease regulators in numerous neurological 
diseases, for example, Fragile X-syndrome (FXS) is the most common form of 
intellectual disability and is a leading cause of ASD (Cheng et al., 2016). Both in 
vitro and in vivo studies have demonstrated the capacity of TSP’s to increase 
synapse number, promote the localisation of synaptic molecules, and refine the 
pre- and post-synaptic alignment. For example hippocampal astrocytes were 
cultured from a FSX mouse model (Fmr1 KO) and displayed a significant 
decrease in TSP-1 expression compared to controls. Fmr1 hippocampal 
neurons also exhibited morphological dendritic spine deficits and altered long-
term excitatory synapse formation (Cheng et al., 2016). Following the 
application of exogenous TSP-1, to the cultured astrocytes, spine and synaptic 
abnormalities were abolished. This work demonstrated an integral role of 
astrocyte-secreted signals in the establishment of neuronal communication. 
 
Down’s Syndrome (DS), a common form of genetic mental retardation, has 
recently been linked to decreased TSP-1 expression characterised by altered 
spine morphology and reduced synaptic density in DS astrocytes (Garcia et al., 
2010). Additionally, in the progressive neurodegenerative disorder AD initial 
cognitive decline is characterised by a huge synaptic loss and TSP-1 
expression is markedly decreased in vulnerable populations in AD patient 
brains, impairing correct repair of synapses (Terry et al., 1991; Buee et al., 
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1992). Following stroke, TSP-1 and TSP-2 expression is drastically elevated 
where their upregulation is primarily driven by purinergic signalling in astrocytes 
(Tran and Neary, 2006).   
 
Epilepsy is also characterised by synaptic disorganisation. Aberrant 
synaptogenesis following a seizure may influence hyper- excitability and worsen 
epileptic discharges. The ‘matrix response’ is a mechanism by which seizure 
activity induces widespread alteration in the localisation and synthesis of ECM 
molecules (Risher and Eroglu, 2012a). Gabapentin, the anticonvulsant drug, 
inhibits TSP induced synaptogenesis and could thus have direct implications on 
the drugs mechanism of action suggesting that the prevention of aberrant 
synaptic remodelling may be therapeutic (Eroglu et al., 2009). Interestingly, a 
higher incidence of epilepsy is reported in DMD patients (6.3%) compared to 
the normal population (1%) (Pane et al., 2013).  
 
It is therefore likely that elevation in TSP-1 in the cerebellum of mdx mice may 
be pathogenic, either by causing an increased inflammatory environment, or by 
altering synaptogenesis. Further investigations into TSP-1 overexpression in the 
cerebellum of mdx mice are required to confirm these findings. 
6.4.1 Elevation of gelsolin expression in the mdx cerebellum 
Elevated levels of gelsolin were detected in the mdx cerebellum at 6 months old 
and this was confirmed using western blot analysis. Gelsolin, a Ca2+ dependent 
actin-regulatory protein, which has been shown to modulate actin assembly and 
disassembly, is believed to regulate cell motility through modulation of the actin 
network (Basu et al., 2008). Gelsolin contains six homologous domains (G1-6), 
each of which has a discrete function.  More precisely, G1 binds to actin 
monomers in a Ca2+- independent manner, and the complex is capable of 
capping actin fragments. G2 contains a Ca2+-independent actin polymer binding 
site and is capable of binding to actin filaments (Kamada et al., 1998). The N-
terminal fragment with G1-3 carries F-actin-cutting activity, and the C-terminal 
fragment with G4-6 carries a Ca2+-dependent actin monomer binding activity 
(Kamada et al., 1998).  
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Studies have also suggested an important role of gelsolin in apoptosis signal 
transduction. Human gelsolin has been shown to inhibit apoptosis by preventing 
cytochrome C release from mitochondria resulting in the lack of activation of 
caspase-3, -8, and -9 (Ohtsu et al., 1997). An important role of mitochondria in 
apoptotic signalling is the translocation of cytochrome C from the mitochondrial 
intermembrane compartment into the cytosol (Kusano et al., 2000). Once 
released, cytochrome C binds to apoptotic protease activating factor 1 (APAF-1) 
in the presence of ATP or dATP and forms a complex that processes and 
activates pro-caspase-9, which in turn cleaves and activates the executioner 
caspases, such as caspase-3 and -7 (Green and Reed, 1998). But this was not 
the same for mouse gelsolin, which is suspected to be as a result of differences 
in sequence homology of the G5 domain of the C-terminal of the gelsolin 
protein. The manner in which gelsolin may inhibit apoptosis in mouse cells has 
yet to be elucidated. Nevertheless, elevation of gelsolin levels in mdx mouse 
cerebellum is suggestive of increased levels of apoptosis. 
6.4.1.1 Changes in gelsolin expression in other neurological disorders 
Overexpression of gelsolin has been detected in the brain of patients with Down 
Syndrome (DS). The authors theorised that gelsolin may have a number of 
roles:  it binds to actin and regulates actin polymerisation, binds to beta-amyloid 
and regulates its clearance, and it responds to oxidative stress by increasing its 
expression (Ji et al., 2009). 
 
Taken together these findings suggest that gelsolin plays a critical role in the 
mdx cerebellum and that its overexpression may be as a consequence of 
increased cell death. However, it is not possible to derive conclusive evidence 
that gelsolin overexpression in the mdx cerebellum has a positive or negative 
impact and further studies are required to confirm this. 
6.4.1 Changes in mitochondrial proteins in mdx cerebellum  
Overexpression of mitochondrial proteins was detected following both global 
and membrane enriched protein extraction methods and was confirmed by 
western blot analysis. Interestingly we did not detect any ultrastructural 
malformations in the mitochondria from mdx mice cerebellum at either 6 or 12 
months old, which was expected considering the majority of DMD patients only 
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exhibit mild cognitive impairment. Additionally, we did not detect elevated levels 
of Porin/VDAC (outer membrane channel) in either proteomic profiling or 
western blot analysis of the cerebellum, which confirms our electron microscopy 
findings and further suggests that mitochondrial numbers were comparable 
between control C57BL/10 and mdx cerebellum. We also did not find any 
abnormalities in cristae packing density between control C57BL/10 and mdx 
cerebellum which suggests that the size of the inner membrane was 
comparable between both genotypes and consequently an increase in inner 
membrane proteins was not likely to result from this. These findings suggest 
that the mitochondrial inner membrane proteins were overexpressed in a 
compensatory manner to account for increasing energy demands of the mdx 
cerebellum, possibly due to increased amounts of stress or increased apoptosis 
occurring in the mdx cerebellum.   
 
The primary function of the mitochondrial electron transport chain (ETC) is to 
synthesize ATP. The ETC, present in the inner mitochondrial membrane, is 
comprised of multiple polypeptide components which are grouped into four 
enzyme complexes. The polypeptides that constitute complexes I (NADH 
ubiquinone reductase), III (ubiquinol cytochrome c reductase), and IV 
(cytochrome C oxidase) are coded for by both nuclear and mitochondrial DNA, 
whilst complex II (succinate ubiquinone reductase) is exclusively coded for by 
nuclear DNA (DiMauro, 1996). Briefly, transfer of reducing equivalents from 
NADH or FADH2 to molecular oxygen is coupled to the pumping of protons 
across the inner mitochondrial membrane resulting in the formation of a proton 
gradient (Heales et al., 1999). Dissipation of this proton gradient through the 
membrane sector of the mitochondrial ATP synthase (complex V) induces a 
conformational change in the active site of this enzyme, which favours ADP 
phosphorylation and hence ATP synthesis (Heales et al., 1999). 
 
The defects in energy production, as a consequence of mitochondrial 
dysfunction, have been documented in neurodegenerative diseases such as 
dementia, Alzheimer’s disease (AD), and Parkinson’s diseases, all of which 
ultimately result in some level of cognitive impairment (Johri and Beal, 2012). 
High energy demanding tissues, such as the brain, contain a large number of 
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mitochondria and therefore have increased susceptibility to the effects of 
changes in aerobic energy metabolism.   
 
The bioenergetics abnormalities reported in the DMD brain have also been 
documented in the mdx mouse, with an increased inorganic phosphate-to-
phosphocreatine ratio, increased intracellular brain pH, and alteration in 
metabolism of glucose (Tracey et al., 1996; Rae et al., 2002). We have 
demonstrated altered abundance of mitochondrial proteins in the mdx mouse 
cerebellum. In this regard, changes in mitochondrial enzymes may affect the 
production of ATP, causing changes in energy metabolism in the mdx 
cerebellum. A previous report identified changes in the mitochondrial enzymes 
in the mdx mouse brain by monitoring creatinine kinase (CK) levels and 
mitochondrial enzyme activity levels (Tuon et al., 2010). The report highlighted 
an increase in CK activity and theorised that this could be causing a protective 
effect against cellular damage, since it functions as a buffering system for 
cellular ATP levels. Additionally, the report identified changes in mitochondrial 
enzymes in various brain structures: complex I activity was decreased in the 
hippocampus, prefrontal cortex, cortex, striatum and cerebellum (Tuon et al., 
2010). Complex II remained unchanged in all the aforementioned brain 
structures. Complex IV was only elevated in the striatum and prefrontal cortex 
(Tuon et al., 2010). Although the finding regarding complex II and complex III 
activity differ to those found in this current study, this could be as a result of 
different experimental techniques used to determine mitochondrial complex 
activities. Moreover, different ages of mice were studied.  
6.4.2 Changes in mitochondrial function in other neurological 
disorders  
There is strong evidence emerging suggesting mitochondrial dysfunction in the 
pathogenesis of numerous neurodegenerative diseases. Alzheimer’s disease 
(AD) has strong association with mitochondrial dysfunction, which may be as a 
consequence of β-amyloid peptide accumulation within the mitochondria 
themselves (Johri and Beal, 2012). Additionally, a decrease in complex IV 
activity has been reported in the cerebral cortex of individuals who died with AD, 
where this complex is particularly susceptible to oxidative damage (Johri and 
Beal, 2012). In Parkinson’s disease, the second most common 
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neurodegenerative disorder, a decreased complex I activity has been reported 
in the substantia nigra of post mortem samples obtained from patients (Beal, 
2007). 
 
Our study is the pioneer study in showing altered abundance in mitochondrial 
proteins in the cerebellum of the mdx mouse, as a consequence of full length 
dystrophin loss. Further studies are needed to better elucidate the 
neurobiological alterations in the mdx mouse cerebellum, investigations into 
mitochondrial copy number (to detect DNA damage) or level of fission and 
fusion proteins (to detect mitochondrial development) could be studied to 
provide a better understanding of mitochondrial dysfunction in the mdx 
cerebellum. 
6.4.3 Elevation of fibrinogen expression in the mdx cerebellum  
Following both global and membrane enriched protein extraction methods, 
fibrinogen was found to be elevated in the mdx cerebellum, which we confirmed 
with both western blot analysis and immunofluorescent staining. We have 
established a progressive disruption of the BBB in mdx mice between 6 and 14 
months old using EBD extravasation and T1- mapping with contrast 
enhancement (Chapter 5). Elevated levels of fibrinogen have been documented 
in AD and recent studies demonstrated that as a consequence of BBB 
impairment the extravasation of the glycoprotein fibrinogen can be found in 
brain parenchyma. This effect is similar to that seen in the mdx cerebellum and 
this is the first time that this has been documented in dystrophin deficiency.    
 
Infiltration of fibrinogen into parenchymal regions acts to amplify and sustain 
chronic inflammatory microenvironments, which are proposed as toxic to 
bystander neurons. Both thrombospondin-1 (TSP-1) and fibrinogen are 
released following tissue injury and exogenous TSP-1 enhances thrombin-
stimulated aggregation.  
 
Given the increased levels of TSP-1, indicating a potential increase in the 
inflammatory response in mdx mouse cerebellum, we can speculate that 
insoluble fibrin deposits, following extravasation of fibrinogen through a leaky 
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BBB, causes a toxic environment for neurons and thus impacts upon normal 
cognitive functioning. 
 
To the best of our knowledge this is the first time that a substantial change in 
the cerebellar microenvironment of mdx mice had been reported. Investigations 
into the combined effect of enhanced fibrinogen and TSP-1 levels in the mdx 
cerebellum need to be performed, but recently there has been evidence that 
they have opposite effects at inhibitory synapses in vitro via the mediation and 
inhibition of neurite outgrowth, respectively (Charrier et al., 2010).  
6.4.4 Elevated levels of GABA Transporter 3 in the mdx cerebellum  
GABA is a predominant neurotransmitter, mediating fast inhibitory synaptic 
transmission and regulating the excitatory activity of neurons (Macdonald and 
Olsen, 1994). GABAergic neurons control the onset of large-scale network 
oscillations at various frequency ranges during development and in the mature 
brain, and their dysfunction is implicated with the onset of disease states like 
epilepsy, schizophrenia, and autism (Le Magueresse and Monyer, 2013).  In the 
cerebellar cortex, four of the five types of neurons, Purkinje, satellite, basket, 
and Golgi cells release GABA as a neurotransmitter (Takayama and Inoue, 
2005). The stellate cell axons make many GABAergic synaptic contacts with the 
dendritic shafts of PCs in the molecular layer (ML). Whereas, the basket cell 
axons form GABAergic synapses with PC bodies and the initial segment of the 
PC axons in the PCL (Takayama and Inoue, 2005). Additionally, Golgi cell 
axons form inhibitory synapses with granule cell dendrites at the peripheral part 
of the synaptic glomeruli in the granular layer (GL). GABAergic inputs regulate 
the neuronal activity of Purkinje and granule cells, which organise the major 
stream of neural circuitry in the cerebellar cortex. 
 
Physiological and biochemical studies have demonstrated that the non-
vesicular form of GABA is released via the plasma membrane by the reverse 
transporter action of plasma membrane GABA transporters (GATs) (Varju et al., 
2001). GATs mediate the GABA-uptake from the synaptic cleft by exchanging 
Na+ and Cl− ions in the mature brain (Gadea and Lopez-Colome, 2001). GAT-1 
and GAT-3 have been found to be widely localised in neural and glial cells in 
the rodent cerebellum (Itouji et al., 1996; Rosina et al., 1999). Recent studies 
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have found that GABA might be extra synaptically released only by exocytosis 
from GABAergic axons in the developing mouse cerebellar cortex (Takayama 
and Inoue, 2005). During formation of GABAergic synapses, GABA could be re-
uptaken, firstly into the presynaptic terminals via GAT-1, and subsequently into 
both presynaptic terminals via GAT-1 and astrocyte processes via GAT-3 
(Takayama and Inoue, 2005). 
 
The overexpression of GAT-3 detected in the mdx cerebellum indicates 
abnormalities in the GABAergic system. It is hypothesised that altered spatial 
localization of GABAA receptors due to Dp427 loss is a pathological mechanism 
associated with brain dysfunction in DMD, and researchers suggest that 
targeting extra synaptic GABAA receptors could provide useful therapeutic 
targets (Vaillend and Chaussenot, 2017). In this study we found no difference in 
the expression levels of GABAA α2 receptor in the mdx cerebellum but we did 
not look at the spatial distribution of this receptor. It is necessary to perfectly 
time GABA release from pre-synaptic terminals with GABA receptors activation 
in pre- and post-synaptic membranes, and GABA clearance from the 
extracellular space, in order to coordinate normal neuronal functioning. 
Overexpressing GABA transporter (GAT) alters the rate of uptake of GABA from 
the extracellular space and has direct impact upon excitatory and inhibitory 
events in the cerebellum. It remains unclear whether GABA transporters can 
shape the GABA concentration profile inside the synaptic cleft, given what is 
currently known about their expression, binding kinetics, and transport efficiency 
(Le Magueresse and Monyer, 2013). 
 
Interestingly depolarizing events that induce activation of voltage-gated 
Ca2+ channels increase the recycling rate of GABA transporters (Deken et al., 
2003); proteins of the SNARE complex that mediate neurotransmitter vesicle 
release, like syntaxin-1A, interact with GABA transporters and increase their 
surface expression (Deken et al., 2000). We also identified elevated levels of 
syntaxin-1A in the mdx cerebellum (Table 6.3), although we did not confirm this 
finding, and future studies should focus on how, if at all, syntaxin-1A and GAT3 
overexpression affects neuronal excitability in the mdx cerebellum. There is little 
information regarding the functioning of Dp40, the shortest dystrophin brain 
isoform, which contains only the β-dystrogylcan binding portion of the protein 
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and is produced via alternative splicing of the Dp71 transcript (the most 
abundant dystrophin isoform in the brain). Recently Dp40 has been identified to 
interact with syntaxin-1A and synaptosomal-associated protein 25 (SNAP25) 
(Tozawa et al., 2012), which is theorised to form a novel protein complex and 
play a crucial role in presynaptic function. Future experiments could investigate 
GABA expression in the cerebellum other mdx mouse models (e.g. mdx4cv) to 
elucidate which dystrophin isoforms are involved in GABA dysfunction other 
than Dp427.  
 
Overall, our findings demonstrate numerous and complex biochemical changes 
occurring in the CNS due to the loss of Dp427. We speculate that some of the 
changes in the mdx cerebellar proteome, in comparison to control mice, serve 
as compensatory mechanisms whilst others may contribute directly to cognitive 
dysfunction in DMD. Additionally, candidate proteins identified could be 
evaluated for their suitability as proteomic biomarkers for monitoring treatment 
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Chapter 7. General discussion and future direction 
7.1 Discussion 
The overall aim of this thesis was to use non-invasive methods to develop 
outcome measures to monitor CNS pathology longitudinally in DMD mice. The 
mdx mouse is used for preclinical drug development studies and there is urgent 
need to develop reliable, reproducible, and robust outcome measures, as there 
is an increasing focus upon understanding and treating cognitive dysfunction in 
DMD patients. Additionally, we sought to determine if the Cmah-/-mdx mouse 
model was a more superior mouse model to that of the mdx for studying CNS 
pathology associated with dystrophin deficiency. 
The majority of studies have examined intellectual function in young DMD boys 
(Anderson et al., 1988; Hinton et al., 2007; Doorenweerd et al., 2014) and 
cognitive symptoms in DMD adults have received less attention (Ueda et al., 
2017). As treatment options, life expectancy, and the prognosis of DMD patients 
has dramatically improved (Passamano et al., 2012) over the past few decades, 
more attention needs to be paid to the natural history of cognitive deficits in 
DMD to improve overall quality of life. Historically, the majority of research 
regarding the pathophysiology of DMD was focused upon the study of muscular 
impairment. To date, the understanding of the psychocognitive manifestations in 
DMD and its aetiopathogenic basis is yet to be defined.   
There is no concrete genotype-phenotype relationship between the position of a 
mutation in the DMD gene and the subsequent risk of cognitive impairment. It 
has been postulated that differences in the neuropsychological profiles 
observed in DMD patients are related to the number and isoforms of CNS–
expressed dystrophin (Taylor et al., 2010). It is hypothesised that mutations in 
the distal portion of the DMD gene are more commonly associated with an 
increased risk of mental retardation in comparison to more proximal gene 
mutations (Muntoni et al., 2003). However, there is reported evidence of various 
patients whose mutation does not correlate with this hypothesis (Erturk et al., 
2010). Additionally, many structures in the brain express full-length dystrophin 
(cerebellum, hippocampus, amygdala, prefrontal cortex) and understanding the 
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implications of the loss of full-length dystrophin in the CNS is vital to better 
understand how cognition is affected in DMD.  
A recent study examining the cognitive profiles and characteristics of adults with 
DMD (n=15 and an average age of 30.4 years) found a significant deficit in 
scores for picture completion, arithmetic, matrix reasoning, symbol search, 
letter-number sequencing, and digit span of the Wechsler Adult Intelligence 
Scale III (WAIS-III) (Ueda et al., 2017). Logical memory and delayed logical 
memory, measured using Clinical Assessment for Attention (CAT), were also 
impaired in DMD adult patients (Ueda et al., 2017). However, the study found 
that cognitive ability that does not require sequential processing was not 
impaired in DMD adults. These findings were consistent with previous studies 
(Cotton et al., 2005), indicating that VIQ improved with age. Moreover, a recent 
study investigating cognitive dysfunction in 14 DMD patients (age range 18-37 
years) identified GABAA-R clustering to be functionally abnormal, utilising 123 I-
MZ Single-photon emission computed tomography (SPECT) imaging, and 
demonstrated that there was progressive GABAA-R functional abnormality in the 
prefrontal cortex of DMD patients (Suzuki et al., 2017). Remarkably, the 
progressive reduction of GABAA-R correlated with worsening 
neuropsychological performance with increasing age. These studies highlight 
the importance of studying cognitive abilities with increasing age in DMD 
patients and support to the premise that intellectual functioning in the DMD 
patients changes with age (Suzuki et al., 2017; Ueda et al., 2017).  
To the best of our knowledge this is the first study to investigate if cognitive 
dysfunction is progressive in mdx mice. Additionally, this is the first study to 
characterise the Cmah-/-mdx mouse brain phenotype. The work presented in 
this thesis established a progressive decline in cognitive ability in the mdx 
mouse, due to the loss of full length dystrophin only, with increasing age. 
Additionally, we report numerous changes in the brains of DMD mouse models, 
which are exacerbated with age, including: an increased total brain volume, 
increased lateral ventricular volume, changes in brain fluid handling, reduced 
AQP4 expression, and reduced integrity of the BBB. We further identified 
potential molecular pathways in the mdx cerebellum which are altered in 
response to Dp427 deficiency. We speculated that some of the changes in 
comparison to control mice serve as compensatory mechanisms, such as 
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mitochondrial changes, whilst others may contribute directly to the cognitive 
dysfunction observed in DMD.  
7.1.1 Identification of progressive cognitive dysfunction in mdx mice 
The mdx mouse was studied between 4 and 12 months old with the Barnes 
maze test and the NOR task and we identified an effect of ageing on the 
behavioural responses of these mice. At 4 months old the mdx mice had a 
comparable performance to that of control C57BL/10 mice during the Barnes 
maze test, and only showed a slight increase in their acquisition times to learn 
where the target hole was located (primary latency). However, by 12 months old 
we identified profound memory impairments in the mdx mice, particularly with 
respect to long-term memory ability, and mdx mice primary latencies differed 
considerably to that of the control C57BL/10 mice. This study reinforced the 
importance of measuring cognitive abilities longitudinally in mdx mice in order to 
assess how the loss of full-length dystrophin affects learning abilities with age. 
Mice are not men and although we have identified a progressive cognitive 
dysfunction in the mdx mouse model of DMD, the literature highlights a 
particular deficit in VIQ in DMD patients, a cognitive aspect not measurable in 
mice. However, there are now an increasing number of studies focusing upon 
understanding the molecular and biological aetiology of this cognitive 
dysfunction and it is envisaged that future studies will have an increasing 
emphasis upon monitoring cognitive impairment progressively in both DMD 
patients and mdx mice, which will be vital for therapy development.  
7.1.2 The study of the effect of Neu5Gc expression in the brain 
Although mice are widely used in research, questions remain about their 
reliability as a model for human diseases. Indeed, 99% of mouse genes have 
an equivalent in humans, making mice a valuable model for studying the 
function of human genes both in healthy and disease states (Vandamme, 2014). 
The CMAH gene is one of the genes that differ between mice and men 
(Okerblom and Varki, 2017).  
 
The evolution of modern humans from the great apes coincided with a series of 
genetic changes that caused alterations in the composition of sialic acids on the 
surface of human cells, in addition to changes in the properties of sialic acid-
  304 
binding proteins. In mouse brain, Neu5Gc is most highly expressed in 
endothelial cells, although not all blood vessels have strong expression and 
some microglia/macrophages show no expression (Naito-Matsui et al., 2017). 
Moreover, no species (rat, chimpanzees, rabbits, xenopus and whitefish) 
demonstrate clear staining of Neu5Gc in neural cells or neutrophils. There are 
theorised advantages to this change in sialyation capacity, for example 
diminishing infections by lethal pathogens such as malaria (Okerblom and 
Varki, 2017). However, we have demonstrated an increasing similarity in brain 
aging between Cmah-/- mice and humans (brain atrophy with age) which may 
or may not be considered advantageous.  
This current study has established that the loss of the Cmah gene has a 
profound impact on the CNS of mice. We have demonstrated enlarged TBV in 
Cmah-/-mdx between 4 and 18 months old, abnormal ventricular structures, and 
changes in cognitive abilities between 4 and 12 months old. Conversely we 
found a reduced TBV in Cmah-/- mice between 4 and 18 months old, significant 
reduction in lateral ventricular volume, and focal brain atrophy at 18 months old. 
This is the first time that MR brain imaging has been applied to mice lacking the 
Cmah gene, allowing us to study the same cohort of mice longitudinally. Given 
the results presented in this thesis it is likely that this gene has an essential 
function in the brain and suggests a direct role of sialic acids (Neu5Ac and 
Neu5Gc) for modifications in brain development, although their exact role is yet 
to be fully elucidated.  
Interestingly, the initial paper detailing the muscle pathology of the Cmah-/-mdx 
mice (Chandrasekharan et al., 2010) indicated that these mice better mimic the 
dystrophic characteristics observed in DMD patients. Cmah-/-mdx mice had 
accelerated onset of loss of ambulation, cardiac and respiratory muscle 
weakness, and a reduction in lifespan, compared to the mdx mice, which are all 
major phenotypes contributing to DMD morbidity and mortality 
(Chandrasekharan et al., 2010). Surprisingly, in our study we did not detect any 
shortening of lifespan in the Cmah-/-mdx mice. In fact, we had a higher 
frequency of mortality in the mdx mouse colony due to the development of an 
increased frequency of rhabdomyosarcoma in this genotype (Chamberlain et 
al., 2007). Cardiac studies in our lab suggested that the cardiac function of 
Cmah-/-mdx mice is not significantly different from mdx mice at baseline, 
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although Cmah-/-mdx mice performed worse under dobutamine stress 
conditions (Blain et al. 2017, under review). However, further characterisation of 
this mouse model, in terms of the cumulative loss of both dystrophin and 
Neu5Gc expression in muscle and in brain is necessary to determine if this 
mouse model is a relevant model to study either the cognitive dysfunction or the 
muscle pathophysiological aspects of DMD. 
The mdx mouse remains the gold standard and best characterised mouse 
model for DMD (Bulfield et al., 1984). Although the mdx mouse model has a 
relatively mild muscle phenotype compared to that of DMD patients and the 
lifespan is not significantly reduced, these differences in the severity of 
phenotype between humans and mice are usually anticipated by the 
investigator, and subsequently overcome by critical evaluation of the 
experimental design (TREAT-NMD protocols (Willmann et al., 2012)). For 
example using older mdx mice where the muscle pathology is more severe and 
exacerbating the phenotype by exercise. Difficulties arise in trying to establish a 
mouse model that might better mimic the human disease phenotype given that 
advancements may have already been made in pre-existing models. Indeed, 
the Cmah-/-mdx is a better phenocopy of DMD than the mdx mouse and some 
suggest that Cmah-deficient mdx mice represent a new small animal model for 
DMD that better approximates the human glycome and its contributions to 
muscular dystrophy (Chandrasekharan et al., 2010). However, limited studies 
utilising this model make it difficult to translate and interpret findings and given 
the abnormalities we have detected in the Cmah-/- mouse we believe that the 
mdx mouse still remains the best model for studying the cognitive dysfunction in 
DMD.  
7.1.3 Phenotypes observed in wild type mice 
Selection of an appropriate animal model is a crucial first step in many research 
investigations. Throughout this study we used control C57BL/10 mice which are 
a popular inbred strain used as ‘wild type’ and all mice in this study were bred 
onto a C57BL/10 background. In this model hydrocephalus is known to occur 
spontaneously in approximately 3% of pups. Throughout this present study we 
identified changes in this mouse model, which are important when considering 
the changes observed in our mutant mice. We observed an increased TBV with 
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increasing age, increased impairment of the BBB with increasing age, and 
reduced spatial learning and memory with increasing age. As well as revealing 
some interesting observations with regards to the effect of ageing on the normal 
mouse brain, this current study highlights the importance of breeding mice onto 
the same genetic background in order to deduce which characteristics are 
simply inherent and which are pathogenic in mutant mice. The C57BL/10 strain 
has previously demonstrated behavioural characteristics which are not present 
in the C57BL/6 strain, despite the high genetic similarity between these two 
mouse strains. In cognitive tests, female C57BL/10 mice showed marked 
deficits in spatial working memory, but not in reference memory, whether spatial 
or non-spatial and impaired coordination and balance, compared to C57BL/10 
mice (Deacon et al., 2007). Nonetheless, this is an important consideration 
when comparing cognitive behaviour in mdx mice, given that differences exist in 
innate behavioural characteristics between background mouse strains, and it is 
therefore not advisable to utilise these strains interchangeably.  
7.1.4 Complex changes identified in the mdx mouse cerebellar proteome  
We analysed the cerebellar proteome from control C57BL/10 mice and mdx 
mice at 6 months old using an LC-MS approach, and identified major 
differences in the expression levels of numerous proteins between the two 
genotypes. The study was the first investigation for evaluating the proteomic 
profile of the cerebellum due to the loss of full-length dystrophin and we 
identified numerous elevated proteins which we hypothesise occur in a 
compensatory manner. Increased mitochondrial proteins in the mdx cerebellum 
may be expressed to cope with elevated demands for ATP suggesting the mdx 
cerebellum requires a higher output to function normally due to full-length 
dystrophin loss.  
GAT3 was also elevated in the mdx cerebellum and it has long been 
hypothesised that dystrophin loss affects the brain GABAergic system 
(Anderson et al., 2002; Sekiguchi et al., 2009; Suzuki et al., 2017). The 
GABAergic system is one of the key modulators of neuronal plasticity, and 
plays an important role in the control of “critical periods” during brain 
development (Varju et al., 2001). This study indicates that in the absence of 
dystrophin, there is an abnormality of the molecular machinery which underlies 
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the precise GABAergic synaptic transmission in the cerebellum due to 
overexpression of GABA transporters (GAT3). Further studies are necessary to 
determine the mechanisms behind GAT3 overexpression in the mdx cerebellum 
and how this impacts on both motor and cognitive function.  
The identification of elevated levels of fibrinogen in the mdx cerebellum at 6 
months old reinforced our findings of BBB defects as elevated fibrinogen 
deposits are suggestive of weakened BBB. Interestingly, in AD it has been 
reported that vascular perturbations manifest in a leaky BBB and extravasation 
of fibrinogen (Ryu and McLarnon, 2009). Taken together, elevated fibrinogen 
deposits with elevated TSP-1 levels suggest an increased inflammatory 
environment for neurons within the mdx cerebellum, which could be detrimental 
to their survival.  
7.1.5 Difference in brain morphology and function between the mdx and 
Cmah-/-mdx mouse models of DMD 
The behavioural testing performed in this study has demonstrated that the mdx 
and Cmah-/-mdx mice behave differently in terms of spatial learning and 
memory and object recognition memory. The Cmah-/-mdx mice out performed 
even the control C57BL/10 and Cmah-/- mice on the Barnes maze test between 
6 and 12 months old, whereas the mdx mice performed worse with increasing 
age. Additionally during the NOR task the Cmah-/-mdx mice had a preference 
for the novel object rather than the familiar object compared to mdx mice, who 
showed a significant preference for the familiar object. The Cmah-/-mdx mice 
displayed little anxiety related behaviour (repetitive jumping, freezing, etc.). The 
Cmah-/-mdx also had a larger total brain volume (at all time points), increased 
T2 relaxation times at 18 months old (in all ROIs compared between the two 
genotypes), additional brain ventricle abnormalities (CSP), and reduced BBB 
impairment in the cortex, cerebellum, and caudate putamen at 6 months old 
(identified via Gd uptake).  
The Cmah-/-mdx mice did however display numerous comparable brain 
characteristics to that of the mdx mice including: reduced AQP4 expression with 
increasing age, similar levels of EBD extravasation between 6 and 18 months 
old in the cerebrum, enlarged lateral ventricle volume (enlargement increasing 
with increasing age), reduced long-term spatial learning and memory at 12 
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months old on the Barnes maze test and similar skeletal abnormalities (skull 
widening, kyphosis and scoliosis).  
It is therefore possible that the loss of the Cmah gene in conjunction with the 
loss of full length dystrophin confers some resistance to the loss of full length 
dystrophin alone. It is difficult to come to a precise conclusion given that the 
loss of the Cmah gene on brain function and structure, in both humans and 
mice, is yet to be elucidated and this is the first study to investigate the brain in 
Cmah-/-mdx mice. Our studies have found that the Cmah-/- mouse differs 
considerable to the control C57BL/10 mice with regards to brain structure and 
function, therefore our finding in the Cmah-/-mdx mice are confounded by the 
fact that the Cmah-/- mice have a brain phenotype. We have identified 
numerous quantifiable changes in the CNS pathology of mdx mice, therefore 
this model is relevant for studying full-length dystrophin loss on brain function 
longitudinally.  
7.1.6 Dystrophin loss in other neurological disorders 
Dystrophin has a function in many other neurological diseases, often as a 
secondary effect. It has been shown that AQP4 deficiency increases the 
propensity for seizures (Badaut et al., 2014) and in human mesial temporal lobe 
epilepsy (TLE), associated with hippocampal degeneration and sclerosis, there 
is a loss of the DGC and AQP4 expression. In patients with TLE the loss of 
Kir4.1 expression was associated with loss of dystrophin and α-syntrophin, but 
not with loss of β-dystroglycan, suggesting partial disruption of the DGC which 
likely interferes with K+ homeostasis and may contribute to the epileptogenicity 
of the sclerotic hippocampus (Heuser et al., 2012). Conversely, other studies 
have found that hippocampal full-length dystrophin (Dp427b) levels are 
upregulated in human TLE (Hendriksen et al., 2016b). Taken together these 
findings suggest that changes in hippocampal dystrophin expression may 
contribute to the underlying pathology of TLE. Furthermore, DMD patients have 
an increased susceptibility to seizures (Pane et al., 2013). 
 
Moreover, dystrophin deficiency is associated with neurodegenerative disorders. 
We only identified an obvious cognitive decline in old mdx mice (~6 months) 
and mdx mice have a normal lifespan. Therefore, if the life expectancy of DMD 
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patients increases further, due to better treatment options, a decline in cognitive 
function could be detrimental to overall quality of life. For example, in 
Alzheimer’s disease (AD), a reduction and even loss of Dp71 and AQP4 have 
been reported where a reduction of these proteins was associated with 
increased vascular amyloid deposits (cerebral amyloid angiopathy) similar 
effects have been demonstrated in AD mice and autopsied AD patient brains 
(Wilcock et al., 2009).  
  
Recent reports propose that altered AQP4 and Dp71 complex contribute to the 
sub-ischemia prevalent in the brain tissue of idiopathic pressure hydrocephalus 
(iNPH). iNPH is associated with clinical triad gait disturbance, cognitive 
impairment (dementia), and enlarged cerebral ventricles, affecting patients >65 
years old (Eide and Hansson, 2017). It has been shown that iNPH patients have 
prominent astrogliosis and reduced expression of AQP4 and Dp71 
immunoreactivities in the astrocytic perivascular endfeet, where higher levels of 
astrogliosis correlated with a lower levels of AQP4 and Dp71 at astrocytic 
endfeet (Eide and Hansson, 2017). 
  
Dystrophin is involved in the pathology of various neurological disorders, this 
reinforces the importance of rare disease research, where advances in the 
understanding of the physiology and pathophysiology related to cognitive 
dysfunction in DMD can have a positive impact on much wider fields of study. 
Therefore, fully elucidating the function of neuronal dystrophin may also help to 
ameliorate symptoms in other neurological disorders. 
7.1.7 Study limitations 
The number of mice used in this study was limited to only 8 mice per genotype 
for each time point. Although this study demonstrated numerous significant 
findings across all genotypes, increasing the number of mice studied will 
ultimately provide further reinforcement of the findings already established. 
Increasing the number of mice will help reduce the variability and allow for the 
identification of a more robust phenotype. 
Another limitation of this study, which may have an impact on the Cmah null 
mouse phenotype, is the diet the mice are fed. Normal mouse chow contains 
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exogenous Neu5Gc. It is theorised that exogenous dietary sources of Neu5Gc 
(red meats, milk, cheese etc.) can enter human cells via micropinocytosis to 
reach the endosomal/lysosomal system (Bardor et al., 2005). There it can be 
transported into the cytosolic compartment and get activated to Neu5Gc, which 
would eventually enter the Golgi apparatus, where sialyltransferases can 
catalyse transfer of Neu5Gc to newly synthesised glycoconjugates. It has also 
been shown that humans absorb a portion of ingested Neu5Gc, excrete it into 
the urine, and incorporate a small amount into newly synthesised 
glycoconjugates (Tangvoranuntakul et al., 2003). Providing the mice with a diet 
containing Neu5Gc should therefore not be a fundamental issue impacting upon 
the brain changes observed during this study. Additionally, all mice, regardless 
of genotype, had free access to the same diet. However, absorption of Neu5Gc 
from the gut into the blood-stream could be considerably different between 
species and was not studied here. Nevertheless, it is an interesting question to 
address in future studies.  
We identified that hippocampal spatial learning and memory declines in mdx 
mice with age utilising the Barnes maze test. Additionally, we identified a 
reduced recognition memory in mdx mice and behavioural changes 
characterised by elevated levels of anxiety related behaviour at 12 months old, 
evident using the NOR task. However, unfortunately the Barnes maze test and 
NOR tasks detailed in this project are not standardised procedures and many 
modifications to already established protocols can be made easily i.e. changing 
the number of habituation days, the length of time the mouse had to search, the 
number of days between short and long-term memory tasks etc. Additionally, 
many factors can influence a behavioural test in rodents including: test 
environment (noise, light etc.), previous exposure to testing equipment, 
laboratory housing conditions, the investigator/s, and complexity of tasks. It is 
important to acknowledge that there is a large amount of inherent variation with 
behavioural assays in rodents and the findings in this study pertain to the 
outlined procedures for the Barnes maze test and NOR task detailed in the 
material and methods (chapter 2).  
7.1.8 Outcome measures to monitor cognitive dysfunction in DMD mouse 
models  
As therapy development for DMD is rapidly increasing and the life expectancy 
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of DMD patients is likely to increase further, there is urgent need for reliable 
biomarkers in the brain to monitor both disease progression but also provide 
potential therapeutic targets. It is evident from both this study and the current 
literature that the loss of full-length dystrophin from the mdx brain has numerous 
and complex implications in a variety of brain regions. The multifunctional 
actions that dystrophin appears to play within in the brain could provide a 
possible explanation for the heterogeneous cognitive phenotype observed in 
DMD patients. We have demonstrated that the average primary latency of mdx 
mice to find the target hole during Barnes maze testing increased with 
increasing age (spatial memory is progressively worse with age in mdx mice). 
Additionally, we have found that the extravasation of contrast agents into the 
mdx mouse brain parenchyma increased significantly with increasing age 
(similar effect seen for both EBD and Gd). Targeting the integrity of the BBB, by 
restoring dystrophin expression, could help improve the cognitive dysfunction 
observed in DMD. Additionally, the increase in average latency to locate the 
target hole observed in mdx mice during the Barnes maze test could be a useful 
outcome measure for monitoring treatment efficacy. 
Ultimately, the long-term goal is the discovery of therapeutic strategies for the 
treatment of both the muscle and brain involvement in DMD and it is hoped that 
the identification of possible roles for brain dystrophin and potential outcome 
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7.2 Future direction  
7.2.1 Further validation of proteomic studies and elucidation of protein 
function  
The characterisation of the pathways involved in the CNS pathology due to 
dystrophin loss will be instrumental for the identification of novel therapeutic 
targets, which may be useful in the treatment of cognitive dysfunction 
associated with DMD. It is therefore important to perform studies to determine 
the functional significance of regulated proteins that we identified using 
proteomic profiling studies in the cerebellum. Other interesting proteins 
identified with increased abundance following proteomic profiling in the mdx 
cerebellum, which were not verified in this study, but are interesting candidates 
with function roles in the CNS, include:  
 Aspartoacylase: catalyses the deacetylation of N-acetylaspartic acid 
(NAA) to produce acetate and L-aspartate. NAA occurs in high 
concentration in brain and its hydrolysis NAA plays a significant part in 
the maintenance of intact white matter (Pundir et al., 2017). Changes in 
NAA concentration have been reported in the brains of both mdx mice 
(Tracey et al., 1996) and DMD patients (Rae et al., 1998). 
 Syntaxin-1A: plays a role in hormone and neurotransmitter exocytosis. It 
is potentially involved in the docking of synaptic vesicles at presynaptic 
active zones (Pundir et al., 2017). Furthermore, syntaxin-1A has been 
reported to interact with the shortest dystrophin isoform-Dp40 (Tozawa et 
al., 2012) in the brain. 
 Purkinje cell protein 4-like protein 1: expressed at early stages of 
development in metencephalic and mesencephalic roof plates (Pundir et 
al., 2017). At later stages of development, it is expressed in structures 
corresponding to circumventricular organs which in adults control the 
production of the CSF (Bulfone et al., 2004). Purkinje cell protein 4-like 
protein 1 has been demonstrated to positively regulate nitrite outgrowth 
and neurotransmitter release (Harashima et al., 2011). We identified 
increased lateral ventricles in the mdx mouse brain with age. Given that 
Purkinje cell protein 4-like protein 1 has a functional role in controlling 
CSF production it would be interesting to determine if this protein is 
responsible for the ventricular abnormalities we observe, potentially due 
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to increasing the CSF circulating in the brain ventricles.  
  
Additionally performing proteomic profiling on other brain regions known to be 
dystrophin-rich, such as the hippocampus where Dp427b is expressed 
abundantly in pyramidal neurons, could provide additional insights into how 
specific brain structures are affected at the protein level due to full-length 
dystrophin loss.  
7.2.2 Imaging techniques to further monitor dystrophin deficiency on 
mouse brain structure and function with age 
Magnetic resonance spectroscopy (MRS) is a non-invasive method that could 
be used to measure the concentration of brain metabolites including NAA, 
Creatine, Choline, Myo-inositol, Total Glutamate + Glutamine (as standards), 
within a predefined voxel in ROIs of the brain. This could be used to additionally 
confirm aspartoacylase overexpression in the mdx mouse cerebellum (by 
confirming increased NAA concentrations) and provide further information 
regarding the functional integrity of specific brain regions paramount to a normal 
cognitive functioning. Furthermore, this technique would provide evidence of 
specific neurometabolites that indicate biochemical changes in the brain that 
are thought to underpin abnormalities in cognitive performance. There have 
been previous reports of decreased NAA to Cho ratio in the mdx mouse 
cerebral cortex (Tracey et al., 1996). Interestingly, there are conflicting reports 
regarding changes in the metabolic composition in the cerebellum, frontal and 
temporo-parietal cortex in DMD patients. A reduction in glutamate, an elevation 
and reduction in choline containing compounds, and an increase in NAA have 
been identified via MRS (Rae et al., 1998; Kreis et al., 2011). However, most 
recently an MRS study in DMD patients indicated preservation in cerebral 
biochemical composition (Doorenweerd et al., 2017b). Discrepancies regarding 
the cerebral biochemical composition in DMD patients could be attributed to 
differences in field strength, smaller cohorts, and differences in statistical 
analyses. Nevertheless, this is an interesting parameter to focus on in future 
investigations both in animal and human studies. 
Diffusion tensor imaging (DTI) has been reported in one study in the mdx 
mouse brain. DTI is predominantly used to measure brain white matter 
structural integrity by taking advantage of the natural phenomenon of diffusion: 
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the random movement of molecules. Without restriction this movement is 
isotropic (equal in all direction). However, in the brain, due to differing cell 
shapes and size, movement is restricted (i.e. molecules cannot cross 
membranes), making the diffusion anisotropic. Fractional Anisotropy (FA) is 
given a value between 0 and 1, where 0 is isotropic and 1 is very anisotropic. In 
mdx mice there is evidence of elevations in diffusion diffusivities in the 
prefrontal cortex and a reduction of fractional anisotropy in the hippocampus. 
There was no change reported in the DTI measurements from either the grey or 
white matter of the mdx cerebellum (Xu et al., 2015). This paper did not show 
the cerebellar results making it hard to deduce if the finding signified very little 
change between control and mdx mice or a larger change which just precluded 
significance. Moreover, this study (Xu et al., 2015) used a relatively small 
sample size (7-8 male mice) and only investigated one time point (9 months 
old), so it would therefore be interesting to employ DTI to a larger sample size 
at different ages to determine if DTI was a valuable in vivo tool for monitoring 
changes in the mdx brain (including the cerebellum) over time.  
7.2.3 Further confirmation of a progressive cognitive dysfunction in mdx 
mice 
Prospective studies could also include further behavioural analysis of both mdx 
and Cmah-/-mdx mice. Preforming additional cognitive tests which measure 
different aspects of learning and memory from that of the Barnes maze test and 
NOR task may help to understand if the cognitive impairment observed 
currently in the mdx mice is globally progressive or is restricted to certain 
aspects of cognition. For example, the Y maze spontaneous alteration test 
assesses the rodents’ willingness to explore new environments, and relies 
heavily of proper functioning of the hippocampus, septum, basal forebrain, and 
prefrontal cortex (Sarnyai et al., 2000; Wolf et al., 2016). It would also be 
interesting to perform the reversal Barnes memory approach as (Remmelink et 
al., 2016) previously demonstrated where mdx mice showed inflexibility to learn 
the reversal task, given that cognitive inflexibility remains a paradoxical question 
in autistic patients (Geurts et al., 2009), and further distinguish if this element of 
learning worsens with increasing age.  
There is increasing evidence in the literature that the majority of patients with 
mutations affecting Dp71 are intellectually disabled (Daoud et al., 2009). 
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Additionally, studies in DMD patients have identified that mild mental retardation 
is significantly more frequent with mutations affecting Dp140 (Doorenweerd et 
al., 2014). Therefore, it would be interesting to perform a longitudinal MR 
imaging and behavioural analysis, similar to this study, in the mdx4cv mouse 
model of DMD, where a nonsense point mutation in exon 53 leads to premature 
translation termination (Im et al., 1996), and consequently does not express the 
brain Dp427, Dp140, and Dp71 dystrophin isoforms. This model has already 
been studied briefly, utilising a comparative proteomic whole brain analysis 
identifying protein changes which differ to those observed in the mdx mouse 
(Murphy et al., 2015), but no longitudinal characterisation of cognitive 
dysfunction has been performed. 
7.2.4 Histological investigations  
Additional histological investigations are vital to provide an insight into how 
dystrophin deficiency affects brain structure at a cellular level. Basic staining 
could provide information on how the brain ventricle system is changed due to 
loss of full length dystrophin, for example if damage or rearrangement of the 
ependymal cell layer could impact CSF production and cause alterations in the 
brain ventricular volumes. Staining for dystrophin in various brain regions is also 
essential to provide further information regarding isoform specific expression 
within defined brain regions. This study identified for the first time that 
dystrophin could be expressed in the mdx mouse caudate putamen, given that 
this is the brain region which demonstrated increased T2 relaxation rate and 
enhanced Gd extravasation, therefore it would be interesting to stain for 







































Genotyping mdx mice 
Representative PCR on genomic DNA extracted from ear clips showing 
amplified fragments of ~134 bp for wild type allele and 117 bp for mutant allele. 
All bands are measured against a 100 bp DNA ladder. Water lane is a negative 










Genotyping Cmah-/-mdx mice  
Representative PCR on genomic DNA extracted from ear clips showing 
amplified fragments of ~297 bp for wild type allele and 400 bp for mutant allele. 
All bands are measured against a 1 kb DNA ladder. Water lane is a negative 
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